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ABSTRACT

The purpose of the dissertation was to characterize the adaptive changes in 5HT 1A receptors induced by repeated injections of 5-HT uptake inhibitors. Hormones
released in response to 5-HT 1A agonists were used as markers to determine the function
of hypothalamic 5-HT 1A receptors. The density of 5-HT1A receptors, their coupling to
G proteins and the levels of Gi and G0 proteins were examined. Daily injections of 5-

HT uptake inhibitor fluoxetine for three weeks significantly reduced the ACTH,
corticosterone and oxytocin responses to the 5-HT 1A agonists 8-0H-DPAT and
ipsapirone. In contrast, daily injections of desipramine or acute injection of fluoxetine
did not alter the hormone responses to 5-HT1A agonists. Fluoxetine injections did not
reduce the affinity or density of 5-HT1A receptors in the hypothalamus. An examination
of the time-course of the effect of fluoxetine and paroxetine revealed that both drugs
produce a gradual reduction in the ACTH, corticosterone and oxytocin responses to 80H-DPAT. The reduction in hormone responses to 8-0H-DPAT appeared after three
days and reached a maximum after seven to fourteen daily of injections.

No change

was observed in the density of 5-HT1A receptors and in their G protein coupling in the
hypothalamus or in other brain regions after daily injections of fluoxetine or paroxetine.
The time course of both drugs in reducing the hypothalamic level of Gi3 proteins was
similar and parallel to the time course of the decrease in the hormone responses to 8-

xv

OH-DPAT. This similarity suggests that the reduction in the level of Gi3 proteins may
be involved in the desensitization of hypothalamic 5-HT 1A receptors. In conclusion, our
results suggest that prolonged blockade of 5-HT uptake sites, but not of norepinephrine
uptake sites, produces a delayed and gradual desensitization of hypothalamic 5-HT 1A
receptors. This desensitization may be mediated by alterations in signal transduction
mechanisms of 5-HT 1A receptors in the hypothalamus.

xvi

CHAPTER I
INTRODUCTION

Selective serotonin (5-HT) reuptake inhibitors (SSRI's), such as fluoxetine
(Prozac®), fluvoxamine (Luvox®), paroxetine (Paxil®), sertraline (Zoloft®) and
citalopram are widely used to treat affective disorders, including depression,
premenstrual disorder, obsessive compulsive disorder, bulimia/anorexia nervosa and
anxiety (Advokat and Kutlesic, 1995; Wong et al.1995; Lam et al.1995; Tollefson et
al.1994; Lecrubier, 1993; Sternlicht, 1993). Serotonin reuptake is the principal process
responsible for terminating the action of 5-HT at post-synaptic receptors. By inhibiting
the uptake of 5-HT into the nerve terminals, SSRI's act to increase the 5-HT
concentration in the synaptic cleft. However, since there is a delay of about 14-21 days
in clinical improvement after the initiation of SSRI administration, the therapeutic
effects of these drugs may be mediated by adaptive changes in serotonergic
neurotransmission, initiated by the inhibition of 5-HT uptake sites (Blier and de
Montigny, 1994; Montgomery, 1994; Briley and Moret, 1993; Richelson, 1991). It has
been suggested that dysfunction of 5-HT 1A receptor systems may contribute to the
etiology of affective disorders (Lesch et al.1992c; Lesch et al.1991b; Lesch, 1991).
Furthermore, it has been hypothesized that somatodendritic 5-HT 1A receptors are
involved in the delay of the onset of clinical improvement after treatment with SSRI's
(Gardier et al.1996; Briley and Moret, 1993). Therefore, studying the effect of 5-HT
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uptake inhibitors on the 5-HT1Areceptor system can contribute to the understanding and
improvement of the therapeutic effects of 5-HT uptake inhibitors.
5-HT IA receptors can be classified into somatodendritic 5-HT IA receptors
(autoreceptors) and postsynaptic 5-HT1A receptors.

Somatodendritic 5-HT1A

autoreceptors are located on serotonergic perikarya in the dorsal and median raphe
nuclei in the midbrain (Le Poul et al.1995; Kreiss and Lucki, 1992). These 5-HT1A
autoreceptors function as a negative feedback mechanism.

Activation of 5-HT1A

autoreceptors in the raphe decreases the firing rate of 5-HT neurons and, subsequently,
reduces 5-HT release from their nerve terminals in the forebrain (Kreiss and Lucki,
1995; Kreiss and Lucki, 1992). Postsynaptic 5-HT1A receptors are widely distributed
in the brain and are located on neurons that are innervated by serotonergic pathways
(Khawaja, 1995; Kung et al.1995; Wright et al.1995). The function of postsynaptic 5HT1A receptors is related to the function of target cells. For example, activation of 5HT1A receptors in the hypothalamus increases the secretion of ACTH, corticosterone
and oxytocin (Fletcher et al.1996; Critchley et al.1994a; Van de Kar and Brownfield,
1993; Gilbert et al.1988a; Bagdy and Makara, 1994; Bagdy and Kalogeras, 1993).
Therefore, hormone responses to 5-HT1A agonists can be used as a peripheral marker
of the functional status of hypothalamic 5-HT1A receptor systems. Somatodendritic 5HT1A receptors are more sensitive to 5-HT 1A agonists than the postsynaptic 5-HT1A
receptors.

The doses of 5-HT1A agonists (such as 8-0H-DPAT, ipsapirone or

buspirone) that activate somato-dendritic autoreceptors to suppress the firing rate of
dorsal raphe neurons are about 10-fold lower (Hjorth and Magnusson, 1988; Sprouse
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and Aghajanian, 1988; Aghajanian et al.1990), than the doses that activate post-synaptic
hypothalamic 5-HT1Areceptors and increase the secretion of hormones such as ACTH
(Pan and Gilbert, 1992) or oxytocin (Bagdy and Kalogeras, 1993).
Several investigators have hypothesized that long-term exposure to 5-HT uptake
inhibitors will first desensitize somatodendritic 5-HT1A autoreceptors, leading to
increase release of 5-HT in the forebrain, and subsequently desensitize postsynaptic 5HT1A receptors (Le Poul et al.1995; Bel and Artigas, 1992; Blier and Bergeron, 1995;
Blier and de Montigny, 1994). Inhibition of 5-HT uptake sites results in an increase
of concentration of 5-HT in the synaptic cleft, thereby activating 5-HT1A receptors.
Since 5-HT1A autoreceptors are more sensitive to the increase of 5-HT concentration
than postsynaptic 5-HT1A receptors, the 5-HT1A autoreceptors are predominantly
activated after administration of 5-HT uptake inhibitors. The activation of 5-HT1A
autoreceptors will decrease the firing rate of 5-HT neurons and subsequently reduce the
release of 5-HT from serotonergic nerve terminals (Arborelius et al.1995; Gartside et
al.1995). Therefore, although forebrain 5-HT uptake sites are still blocked during this
period, the concentration of 5-HT in forebrain synaptic clefts would not be increased.
Following repeated administration of SSRI's, somatodendritic 5-HT1A receptors are
desensitized by consistent increase of 5-HT concentration in the presynaptic cleft of 5HT neurons.

The desensitization of somatodendritic 5-HT 1A autoreceptors would

eventually free 5-HT neurons; firing would be resumed and 5-HT release would return
to normal.

Since forebrain 5-HT uptake sites are still inhibited by 5-HT uptake

inhibitors, the concentration of 5-HT in the postsynaptic cleft would increase and induce
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desensitization of postsynaptic 5-HT 1A receptors, such as hypothalamic 5-HT 1A
receptors. If this hypothesis is correct, then repeated injections of fluoxetine would
produce a delayed and gradual reduction in the function of hypothalamic 5-HT 1A
receptors. Several investigators have provided evidence that 5-HT uptake inhibitors
first produce inhibition of the firing rate of 5-HT neurons and decrease the release of
5-HT in the forebrain, followed by desensitization of somatodendritic 5-HT1A
autoreceptors in the dorsal raphe nucleus as early as 3 days after administration of 5-HT
uptake inhibitors (Le Poul et al.1995). However, very little is known regarding the
onset of desensitization of postsynaptic 5-HT1A receptors after repeated injections of 5HT uptake inhibitors.
5-HT 1A receptors are coupled to G0 and/or Gi proteins (Raymond et al.1993;
Fargin et al.1991; Sprouse and Aghajanian, 1988; Emerit et al.1990). Somatodendritic
5-HT 1A autoreceptors in the raphe nuclei are coupled to G0 proteins, which increase the
opening of K+ channels (Sprouse and Aghajanian, 1988).

Activation of 5-HT1A

receptors that are coupled to Gi proteins inhibits the activity of adenylyl cyclase and
consequently decrease the intracellular concentration of cAMP (cyclic adenosine
monophosphate) (Varrault et al.1994).

5-HT lA receptors have high affinity for Gi

proteins with the rank order of affinity being Gi3 > Gil > Gi2 > G0 proteins (Raymond
et al.1993). Most of the studies having investigated the coupling of 5-HT 1A receptors
to G proteins, however, were conducted in cells in culture transfected with expressing
cloned 5-HT 1A receptors and G proteins. Little is known about specific G proteins that
are involved in specific 5-HT 1A receptor-mediated functions in vivo. For example, it
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is still unclear which G proteins mediate 5-HT1A receptor-induced increases of ACTH
and oxytocin secretion and 5-HT1A receptor-inducted hypothermia.
The purpose of the present project was to investigate adaptive changes in the
hypothalamic 5-HT1A receptor systems induced by daily injections of 5-HT uptake
inhibitors. The hypothesis was that daily injections of 5-HT uptake inhibitors produce
a delayed and gradual desensitization of the hypothalamic 5-HT1A receptors.

This

desensitization may be mediated by alterations in the signal transduction of 5-HT1A
receptors.

Three specific aims were designed to address the hypothesis.

First, to

examine whether long-term fluoxetine and desipramine influence 5-HT1A receptor
systems.

Fluoxetine is a widely used SSRI, while desipramine is a norepinephrine

uptake inhibitor and a tricyclic antidepressant. Comparing the effect of fluoxetine with
desipramine on 5-HT1A receptors allowed us to understand whether the effects of
fluoxetine are unique to SSRI's. In addition, the effects of acute fluoxetine on the 5HT lA receptors were examined in order to determine whether the effects of fluoxetine
are mediated by the long-term administration. Secondly, the time-course of the effects
of fluoxetine on 5-HT1Areceptor systems was determined. If 5-HT1Aautoreceptors play
a role in the delay of therapeutic effects of SSRI's, daily injections of 5-HT uptake
inhibitors should produce a delayed, gradual alteration in postsynaptic 5-HT1Areceptors
in the hypothalamus. Finally, I determined whether the effects of fluoxetine on the 5HT1A receptors are mediated by the blockade of 5-HT uptake sites by examining the
time-course of effects of paroxetine on the hypothalamic 5-HT1A receptors and
comparing these effects with those observed in the fluoxetine study.

Paroxetine is
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another 5-HT uptake inhibitor with a different chemical structure from fluoxetine. It
has a higher affinity for 5-HT uptake sites, shorter half-life than fluoxetine, and no
active metabolites (Nemeroff, 1993). Therefore, if the effects of paroxetine on the 5HT1A receptors are similar to those induced by fluoxetine, one can conclude that the
alterations in the 5-HT1A receptors induced by daily injections of fluoxetine or
paroxetine are mediated by the sustained blockade of 5-HT uptake sites. The following
biochemical and functional parameters of 5-HT1A receptors examined to achieve these
aims. 1) Hormone responses to 5-HT1A agonists were used as functional markers of 5HT1A receptors. 2) The density of 5-HT1A receptors and their coupling to G proteins
in the rat brain were measured using homogenate or autoradiographic analysis of 3H-80H-DPAT binding. 3) Gil, Gi2 , Gi3 and G0 proteins, which are coupled to 5-HT1A
receptors, were examined by immunoblots.

CHAPTER II
REVIEW OF RELATED LITERATURE

Serotoner1:ic Systems
General review of serotonergic systems
Serotonergic pathways are important neurotransmitter systems in the central
nervous system. Serotonin neurons, projecting their axons to the forebrain, are located
in the dorsal and median raphe nuclei and in the ventrolateral B9 cell group in the brain
stem. The distribution of serotonergic projections from the dorsal and median raphe
are different. For example, the striatum mainly receives projections from the dorsal
raphe, while the hippocampus receives projections from the median raphe (Bonvento
et al.1992; Kreiss and Lucki, 1994). The serotonin neurons in both median and dorsal
raphe nuclei project to the hypothalamus, cortex and amygdala (Van de Kar and
Lorens, 1979; Sawchenko et al.1983; Petrov et al.1992). On the other hand, 5-HT
neurons in the raphe nuclei receive 5-HT input from 5-HT axon collaterals or dendrodendritic junctions, which is related to feedback regulation of 5-HT release (Wang and
Aghajanian, 1978; Wang and Aghajanian, 1977).
Serotonin neurons synthesize serotonin from tryptophan, an essential amino acid.
The key enzyme for the synthesis of 5-HT is tryptophan hydroxylase, which converts
tryptophan to 5-hydroxytryptophan (5-HTP). 5-HTP is decarboxylated to 5-HT by
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aromatic L-amino acid decarboxylase. Serotonin is then transported to serotonergic
terminals through axons and stored in vesicles in the nerve terminals. When 5-HT
neurons are activated, the firing rate of the neurons is increased, resulting in 5-HT
release from nerve terminals to the synaptic cleft. In the synaptic cleft, 5-HT can bind
to and stimulate 5-HT receptors, resulting in physiological responses. 5-HT, in the
synaptic cleft, can also be taken back into the nerve terminal via 5-HT uptake sites (i.e.
5-HT transporters), which are located on the membrane of nerve terminals. In the
nerve terminals, 5-HT can be restored in the vesicles or metabolized in the
mitochondria to 5-HIAA (5-hydroxyindole acetic acid) by monoamine oxidase (MAO).
5-HT receptors are located on pre- or postsynaptic membranes. To date at least
fifteen types of 5-HT receptors have been found by receptor-cloning studies (Hoyer et
al.1994). The 5-HT receptors are classified into 5-HT 1, 5-HT2, 5-HT3 , 5-HT4 , 5-HT5 ,
5-HT6 and 5-HT7 receptors (Saxena, 1995; Hoyer et al.1994). Among them, 5-HT 1
receptors are subclassified to 5-HT 1A, 5-HTrn, 5-HT 10 , 5-HTrn, and 5-HT 1F receptors.
5-HT2 receptors are subclassified to 5-HT2A, 5-HT28 and 5-HT2c receptors. 5-HT2A
(previously 5-HT2) receptors and 5-HT2c (previously 5-HT1c) receptors have similar
structures and few agonists or antagonists can distinguish between them. However, 5HT2c receptors have a higher affinity for 5-HT than 5-HT2A receptors. Also, 5-HT2c
receptors are abundant in the choroid plexus.
autoreceptors.

5-HTrn and 5-HT10 receptors are

They are located in the nerve terminals and function as feedback

regulators of 5-HT release. 5-HTrn receptors are found in rodent species, such as rats
and mice, while 5-HT10 receptors are located in non-rodent mammalian species, such
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as guinea pig, pig, calf, rabbit, dog, monkey and human. The distribution of 5-HTrn
and 5-HTrn receptors in the brain is similar. Therefore, it is believed that 5-HTrn and
5-HT 10 receptors play the same role in the different species.

Except for 5-HT3

receptors which are cation channel-ligand gated receptors, all other 5-HT receptors are
G protein-coupled receptors. 5-HT 1 receptors have a high affinity for 5-HT and are
coupled to Gi proteins, which inhibit adenylyl cyclase. Beside Gi proteins, 5-HT1A
receptors also couple to G0 proteins that increase opening of potassium channel and
inhibit the opening of Ca2 + channel. Except for 5-HT2c receptors, 5-HT2 receptors
have relative lower affinity for 5-HT. Stimulation of 5-HT2 receptors will activate
phospholipase C and, consequently increase the hydrolysis of inositol phospholipid to
inositol triphosphate (IP3) and diacylglycerol (DAG). DAG induces Ca2 + mobilization,
which in tum activates protein kinase C, while IP3 activates calmodulin-dependent
protein kinase.

5-HT4 , 5-HT6 and 5-HT7 receptors are positively linked to adenylyl

cyclase. The signal transduction system of 5-HT5 is still unknown. Except for 5-HTrn
and 5-HT 10 receptors that are located presynaptically, all other 5-HT receptors are
located on postsynaptic membranes. Thus, their physiological functions are related to
the function of the target cells. Physiological functions of 5-HTrn, 5-HT1p, 5-HT5 , 5HT6 and 5-HT7 receptors remain unknown. These 5-HT receptors were identified from
cloned cDNA. Due to the lack of selective agonists and antagonists, few studies have
been reported regarding their distribution and functions in the tissue of intact animals
or humans.
In conclusion, serotonergic systems are involved in many regulatory processes
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and play important roles in maintaining normal life. On the other hand, serotonergic
systems are very complicated systems and very little is known about the systems. The
present dissertation is focused on the effects of SSRI's on 5-HT1A receptors. In the
following review, I will expand the discussion on the 5-HT1A receptor systems.

5-HT iA receptor systems
Structure and function

5-HT 1A receptors belong to the G protein-coupled receptor family. Like other
receptors in this family, 5-HT1A receptors contain seven hydrophobic transmembrane
domains, which are highly conserved with other G protein-coupled receptors, such as
B2 adrenergic receptors (Raymond et al.1992).

The connections of these seven

membrane-spanning domains form three extracellular loops (ol-o3) and three
intracellular loops (il-i3). The N-terminal of 5-HT1A receptors faces the membrane
surface and the C-terminal is in the cytoplasm. The intracellular features of 5-HT1A
receptors are similar to other cloned receptors which couple to Gi proteins, such as a
long i3 loop and a short C terminal tail. These features are different from the receptors
coupled to Gs or Gq proteins, such as the B2 and 5-HT2A 12c receptors, suggesting that the
i3 loop and C terminus may be involved in the coupling of 5-HT1A receptors to their
G proteins. Few studies on the function of 5-HT 1A receptor domains in term of ligand
binding and G protein coupling have been reported. Aspartate at positions 82 and 116
(Asp86 and Asp 116), asparagine at position 396 (Asn396) and serine at position 393 (Ser393)
may be important for ligand binding (Chanda et al.1993; Raymond et al.1992). Asp86
and Asp 116 are located in transmembrane domain II and III respectively and Asn396 and
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Ser393 are in transmembrane region VII. Except for these residues, the transmembrane
IV domain may also play a role in the binding of ligands to 5-HT1A receptors (Chanda
et al.1993). It is interesting that about 70% of amino acids in transmembrane VI of 5HT1A receptors are identical to those in B receptors, suggesting that this domain may
be related to the binding property of B antagonists to 5-HT1A receptors. Although 5HT1A receptors do not contain the sequence for phosphorylation by protein kinase A,
at least 3 potential phosphorylation sites for protein kinase C have been found in the 5HT1A receptor. They are located in the i2 and i3 loops. These sequences may be the
target for protein kinase C and induce a phosphorylation of 5-HT1A receptors, which
would consequently produce a desensitization of 5-HT1Areceptors (Nebigil et al.1995;
Raymond and Olsen, 1994; van Huizen et al.1993; Raymond, 1991). Furthermore, two
cysteine residues in the C terminus of 5-HT1A receptors may be palmitoylated, which
is one of the post-translational modifications that may modify the coupling of receptors
to their G proteins (Raymond et al.1992).
5-HT1A receptors have been classified into somatodendritic and postsynaptic
receptors (Hoyer and Boddeke, 1993; Blier et al.1993a; Blier et al.1993b).

The

somatodendritic 5-HT1A receptors (5-HT 1A autoreceptors) are located on serotonin
neurons in the dorsal and median raphe nuclei and receive serotonergic input from
recurrent collaterals or from other raphe neurons (Wang and Aghajanian, 1978; Wang
and Aghajanian, 1977; Sotelo et al.1990).

The somatodendritic 5-HT 1A receptors

function as feedback regulators of 5-HT release from nerve terminals. When 5-HT
neurons are activated, the firing rate of the neurons is increased, resulting in an
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increase of 5-HT release from nerve terminals and recurrent collaterals. The increased
concentration of 5-HT in the synaptic cleft of serotonin neurons activates
somatodendritic 5-HT lA receptors. Consequently, the activation of somatodendritic 5HT 1A receptors inhibits the firing rate of 5-HT neurons and reduces 5-HT release from
serotonergic nerve terminals (Hjorth and Sharp, 1991; Hjorth and Magnusson, 1988;
Bonvento et al.1992). Furthermore, activation of somatodendritic 5-HT1A receptors
inhibits 5-HT synthesis in 5-HT neurons (Hjorth and Magnusson, 1988; Sharp et
al.1993).
Postsynaptic 5-HT 1A receptors are located on target cells in most forebrain
regions. The functions of postsynaptic 5-HT 1A receptors are related to the target cells.
For example, 5-HT lA receptors in the ventromedial nucleus of the hypothalamus (VMN)
may be involved in sexual behavior (Uphouse et al.1994a; Uphouse et al.1994b;
Mendelson and Gorzalka, 1986), and 5-HT 1A receptors in the hippocampus may play
a role in the feedback regulation of corticosteroid secretion (Burnet et al.1992; Lopez
et al.1993; Zhong and Ciaranello, 1995; Chalmers et al.1993). As will be discussed
later, 5-HT 1A receptors in the paraventricular nucleus of the hypothalamus may be
involved in the regulation of ACTH, corticosterone and oxytocin secretion (Bagdy,
1995; Bagdy and Makara, 1994).
The density of 5-HT 1A receptors varies among brain regions. The distribution
of 5-HT1A receptors in the brain has been studied using autoradiographic analysis of
radioligand binding (Gozlan et al.1995; Khawaja, 1995; Le Poul et al.1995; Frankfurt
et al.1994; Radja et al.1992; Dillon et al.1991; Hensler et al.1991; Marlier et al.1991;
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Sijbesma et al.1991; Welner et al.1989; Palacios et al.1987) and immunocytochemistry
(Kia et al.1996).

The hippocampus, septum and dorsal raphe contain the highest

density of 5-HT1A receptors, while the caudate putamen contains few 5-HT1A receptors.
Most of the studies on the autoradiography of 5-HT1A receptors have focused on the
hippocampus and raphe nuclei. Very little is known regarding the distribution of 5HT lA receptors in the hypothalamus. A few investigators (Hensler et al .1991 ; Palacios
et al.1987; Sijbesma et al.1991) have examined the density of 5-HT lA receptors in the
hypothalamus, but only within a few nuclei, such as the ventromedial nucleus,
dorsomedial nucleus and lateral hypothalamus.

So far, the distribution of 5-HT1A

receptors in subdivisions of nuclei in the hypothalamus and amygdala has not been
reported.
Several studies have compared the map of 5-HT 1A receptors and the encoding
mRNA of 5-HT1A receptors (Miquel et al.1991; Chalmers and Watson, 1991;
Pompeiano et al.1992; Wright et al.1995; Raghupathi et al.1996).

Generally, the

distribution of 5-HT1A receptors is consistent with their mRNA expression. A recent
study (Raghupathi et al.1996) showed that inactivation of 5-HT 1A receptors by a high
dose (10 mg/kg), but not by low doses (0.1and1 mg/kg) of EEDQ (N-ethoxycarbonyl1,2-ethoxydihydroquinoline) induced an increase of 5-HT 1A receptor mRNA within 12
hours after injection.

mRNA levels returned to normal, when the density of the

receptors recovered. However, the magnitude of the increase of mRN A varied between
brain regions, whereas reduction of the density of 5-HT 1A receptors was similar among
brain regions. Also, less than 503 inactivation of 5-HT1A receptors did not alter the
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level of 5-HT1A receptor mRNA.

These results suggest that changes in the 5-HT1A

receptor mRNA may not be an exclusive mechanism of regulation of the density of 5HT1A receptors, especially when a modest change in the density of 5-HT1A receptors
occurs.

Signal transduction of 5-HT iA receptors
5-HT1A receptors are G protein-coupled receptors.

According to the model

proposed by Lefkowitz et al. (1976), G protein-coupled receptors exist in high
(coupled) and low (uncoupled) affinity states with respect to agonists. Agonists only
bind to receptors in high affinity states, while antagonists bind to both high and low
affinity state receptors. The coupled receptor-G protein configuration only exists while
GDP (Guanosine diphosphate) is bound to the a-subunit of the G protein. When an
agonist binds to receptors, the GDP on the G proteins coupled to the receptors will be
exchanged with GTP (Guanosine triphosphate) due to changes in the conformation of
the receptors.

The replacement of GDP with GTP on the a-subunit of G proteins

results in a dissociation of the G proteins from the receptors, which consequently
switches the receptors from a high affinity-state to a low affinity-state. The dissociated
G proteins are then further dissociated into a and B'Y subunits. The a subunits activate
a second messenger system, such as adenylyl cyclase and phospholipase C, which in
turn activates the effectors and produces a physiological response. The a subunits are
then inactivated by hydrolysis of the GTP into GDP via its intrinsic GTPase.

The

GDP-bound a subunits will finally reassociate with the fJ'Y subunits and couple to
receptors.
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To date, about 20 G proteins have been identified and have been divided into 4
classes (Hamm and Gilchrist, 1996) based on their a subunit, Gs, Gi, Gq and G12 • Gs
proteins include Gs and G01 f proteins.

They activate adenylyl cyclase.

Gi proteins

include Gil• Gi2 , Gi3 , G01 , G02 , Gz, Ggust and Gr proteins. Some of them (Gil• Gi2, Gi3
and Gz) inhibit adenylyl cyclase.

G0 proteins increase the opening of potassium

channels and decrease the opening of calcium (Ca2 +) channels. Except for Gz proteins,
all Gi proteins are pertussis toxin-sensitive, i.e pertussis toxin inactivates the Gi proteins
via ADP-ribosylation. Most of the Gq proteins (Gq, G11 , G 14 and G 15 ) stimulate
phospholipase C and increase the intracellular concentration of inositol triphosphate and
diacylglycerol.
Stimulation of hippocampal 5-HT1A receptors with 5-HT agonists inhibits
forskolin-stimulated adenylyl cyclase activity (Yocca and Maayani, 1990; De Vivo and
Maayani, 1986). This inhibitory effect of 5-HT1A receptors can be blunted by pertussis
toxin, which selectively inactivates Gi and G0 proteins by ADP-ribosylation (Clarke et
al.1987). These results suggest that hippocampal 5-HT 1A receptors are coupled to Gi
proteins. On the other hand, activation of 5-HT1A autoreceptors in the dorsal raphe
does not inhibit forskolin-stimulated adenylyl cyclase activity (Yocca and Maayani,
1990; Clarke et al. 1990; Clarke et al. 1996), but does increase the opening of potassium
channels, resulting in a hyperpolarization of 5-HT neurons (Sprouse and Aghajanian,
1988). This inhibitory effect of 5-HT1A agonists on cell firing and 5-HT release can
also be blocked by pertussis toxin (Innis and Aghajanian, 1987; Innis et al.1988;
Romero et al.1994). These results suggest that 5-HT 1A autoreceptors in the raphe are
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coupled to G0 proteins. From these results, it is believed that 5-HT 1A receptors are
coupled to Gi or G 0 proteins. However, it is still unclear which particular Gi or G 0
proteins are coupled to 5-HT1Areceptors in specific cells, since at least three Gi and two
G0 proteins have been identified (Bimbaumer, 1993). Also, it cannot be ruled out that
other G proteins, such as Gz or Gq proteins could couple to 5-HT1A receptors, since 5HT1A receptors are located on different cells and are involved in different functions.
However, it is difficult to study these questions in intact animals, since living cells are
very complex and contain several different G proteins. Thus, most molecular biologic
studies on the G protein-coupling of 5-HT1A receptors are performed using the
expressional cloned 5-HT1Areceptors in a receptor-free cell line that does not naturally
contain the 5-HT1A receptors.
Using co-expressed human 5-HT1A receptors and G proteins in Hela and CHOKl cells, Raymond et al. (1993; 1994) found that 5-HT1Areceptors have a high affinity
for Gi and G 0 proteins. The rank order of the affinity for 5-HT1A receptors is Gi3 >
Gi 1 > Gi2

>

G0 proteins (Raymond et al.1993; Mulheron et al.1994; Bertin et al.1992).

Gs proteins do not seem to couple to 5-HT1A receptors (Raymond et al.1993; Bertin et
al.1992; Butkerait et al.1995).

These findings are consistent with biochemical and

electrophysiological results that 5-HT1A receptors are coupled to Gi and/or G 0 proteins.
However, in reconstituted cells, Gz protein, a pertussis toxin-insensitive member of the
Gi protein family, also strongly increases

3

H-8-0H-DPAT binding (Butkerait et

al.1995), suggesting that Gz proteins may be coupled to 5-HT1A receptors. In addition,
in different receptor-negative cell lines, transfected 5-HT1A receptors express different
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functions. For example, 5-HT1A receptors transfected into pituitary GH4 cells inhibit
the activity of adenylyl cyclase, increasing the opening of potassium channels and
closing calcium channels, but having no effect on phospholipase C. However, in Ltk
fibroblast cells (L cells), transfected 5-HT1A receptors not only inhibit adenylyl cyclase,
but also stimulate phospholipase C and increase phosphoinositide turnover (Albert et
al.1996; Liu and Albert, 1991). Since all responses to 5-HT1A agonists in both cell
lines can be blocked by pertussis toxin, it is unlikely that 5-HT 1A receptors in L cells
are coupled to Gq proteins. These results suggest that the functions of 5-HT 1A receptors
may vary in different cell environments. However, it should be noted that conditions
in the cell lines are different from those in living cells. It is still a puzzle how G
proteins link to 5-HT1A receptors in vivo, since the natural cells are much more
complicated than cell lines. It is possible that the coupling of 5-HT1A receptors is not
only dependent on their affinity for G proteins, but also dependent on the relative
amount of each G protein in the cells (Raymond et al.1993).

5-HT tA agonists and antagonists

Several 5-HT 1A agonists have been discovered such as 8-0H-DPAT, ipsapirone,
flesinoxan, gepirone and buspirone (Hoyer et al.1994; Van Wijngaarden et al.1990).
Among them, 8-0H-DPAT has been considered to be the most selective 5-HT 1A agonist
and is a full agonist for most 5-HT 1A receptor-mediated responses.

3

H-8-0H-DPAT is

the most widely used radioactive ligand for examination of 5-HT 1A receptors.
However, several studies have shown that 3H-8-0H-DPAT may bind to both high and
low affinity 5-HT 1A receptors (Butkerait et al.1995). This could be due to the small
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difference in affinity for 8-0H-DPAT between the high and low affinity-states of 5HT1A receptors (Kd=0.7nM vs. Kd=17nM) (Chamberlain et al.1993). Although
ipsapirone and buspirone are partial 5-HT1A agonists, they have been frequently used
in research since they can be administered to humans.
Few 5-HT1Aantagonists are available. Most 5-HT1Aantagonists, such as NAN190 and WAY-100135, also behave as partial agonists (Escandon et al.1994; Cliffe et
al.1993; Fletcher et al.1993; Gobert et al.1995; Greuel and Glaser, 1992; Claustre et
al.1991b). Pindolol is a 5-HT1A antagonist and can be used in humans. However, it
also is a B adrenergic antagonist. So far, the only silent 5-HT lA antagonist is WAY100635 (Forster et al.1995; Khawaja et al.1995; Routledge, 1995; Craven et al.1994).
Recently, several 5-HT1Aagonists and antagonists have been discovered, such as 8-0HPIPAT (5-HT 1A agonist) (Zhuang et al.1993) and p-MPPI (5-HT 1A antagonist) (Kung
et al.1994).

However, further studies on their pharmacologic profiles are still

necessary.
5-HT1A agonists and antagonists bind to both somatodendritic and postsynaptic
5-HT 1A receptors.

However, some of them have a higher affinity for the

somatodendritic 5-HT1Areceptors than for postsynaptic 5-HT1A receptors (Matheson et
al.1994). For example, the ED50 of azapirones (such as ipsapirone and buspirone) for
inhibiting the firing rate of 5-HT neurons is much lower than the ED50 for stimulation
of postsynaptic 5-HT1A receptors (Matheson et al.1994). This may be due to a larger
receptor reserve for 5-HT1A autoreceptors in the raphe than for postsynaptic 5-HT1A
receptors in the forebrain (Cox et al.1993; Bohmaker et al.1992).
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5-HT iA receptor-mediated neuroendocrine responses
Several 5-HT receptors are involved in the regulation of hormone secretion
(Tuomisto and Mannisto, 1985; Van de Kar et al.1995b; Van de Kar and Brownfield,
1993; Van de Kar, 1991 ; Yatham and Steiner, 1993; Murphy et al.1991 ; Fuller, 1992;
Fuller, 1990). For example, the secretion of ACTH, corticosterone and oxytocin can
be stimulated by 5-HT1A agonists (Van de Kar and Brownfield, 1993; Van de Kar,
1991).

Stimulation of 5-HT2A;zc receptors will increase plasma levels of ACTH,

corticosterone, renin, prolactin, oxytocin and vasopressin in a dose-dependent manner
(Rittenhouse et al.1994; Li et al.1993a; Rittenhouse et al.1993; Van de Kar and
Brownfield, 1993; Li et al.1992). Also, 5-HT18 and 5-HT3 receptors may be involved
in the regulation of prolactin secretion (Levy et al.1995).

5-HT1A agonists do not

stimulate renin and vasopressin secretion under normal conditions.

In the present

review, the effect of 5-HT1A receptors on the regulation of hormone secretion will be
discussed.
Most evidence has shown that hormonal regulatory effects are mediated by
postsynaptic 5-HT lA receptors in the hypothalamus (Przegalinski et al.1989; Gilbert et
al.1988b).

However, the signal transduction pathway of 5-HT 1A receptor-mediated

hormone secretion is still unknown.

For example, which G proteins and second

messengers are involved in 5-HT1A receptor-mediated hormone secretion? How do
changes in second messengers trigger hormone release? Since 5-HT1A receptors may
be coupled to Gi or G0 proteins, it is possible that the hormone responses to 5-HT1A
agonists are inversely related to the activity of adenylyl cyclase.
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5-HT1A receptor-mediated ACTH and corticosterone secretion
The secretion of ACTH and corticosterone is regulated by the hypothalamicpituitary-adrenocortical axis (HPA axis).

The paraventricular nucleus of the

hypothalamus (PVN) contains parvocellular cells that secrete corticotropin-releasing
hormone (CRH or CRF). When the parvocellular cells are activated, CRH is released
into the pituitary portal vessels and travels into the anterior lobe of the pituitary gland
through the

superior hypophyseal artery.

In the

anterior pituitary

(i.e

adenohypophysis), CRH stimulates adrenocorticotropin (ACTH) release from ACTH
containing cells (corticotrophs). ACTH then travels to the adrenal gland through the
circulation, where ACTH stimulates adrenal cortical cells resulting in release of
corticosterone in rats or cortisol in humans. The HPA axis includes both neurons and
endocrine cells and spans from the central nervous system to the peripheral adrenal
gland. It can be expected that the HPA axis will be regulated by both central and
peripheral factors.
Several neurotransmitter systems mediate the regulation of ACTH and
corticosterone release. For example, activation of adrenergic a 1 receptors increases the
secretion of ACTH and corticosterone (Al-Damluji and Francis, 1993; Levy et al.1994;
Feldman et al.1995; Radant et al.1992).

In addition, stimulation of dopamine D2

receptors and µ opiate receptors also increases ACTH and corticosterone release (Levy
et al.1994; Boesgaard et al.1990; Borowsky and Kuhn, 1992). It is worth noting that
D2 andµ receptors couple to Gi proteins, just as 5-HT1A receptors do. Therefore, it is
possible that these receptors share common G proteins, and hence, they can interact

21
with each other. Parvocellular cells (CRH cells) receive serotonergic input from dorsal
and median raphe nuclei (Petrov et al.1992; Liposits et al.1987). Activation of several
5-HT receptors, such as 5-HT1A, 5-HTrn, 5-HT2Aizc and 5-HT3 receptors, increases
CRH, ACTH and corticosterone secretion (Fuller, 1995; Fuller, 1992; Fuller, 1990;
Fuller, 1981; Van de Kar and Brownfield, 1993; Van de Kar, 1991; Chaouloff, 1993).
Activation of 5-HT 1A receptors by 5-HT1A agonists, such as 8-0H-DPAT,
ipsapirone, buspirone and gepirone, increases plasma ACTH and corticosterone
concentrations (Cowen et al.1990; Fuller, 1992; Gilbert et al.1988a; Koenig et
al.1988).

The hormone responses to 5-HT 1A agonists can be inhibited by 5-HT 1A

antagonists, such as pindolol, spiperone, NAN-190, UH-301, WAY-100135 and WAY100635 (Cowen et al.1990; Lejeune et al.1993; Pan and Gilbert, 1992; Critchley et
al.1994b; Przegalinski et al.1989; Kelder and Ross, 1992; Vicentic et al.1996), but not
by 5-HTrn, 5-HT2 , 5-HT3 and adrenoceptor antagonists (Przegalinski et al.1989).
Several laboratories (Przegalinski et al.1989; Gilbert et al.1988b) and our preliminary
data have shown that destruction of 5-HT neurons using 5,7-dihydroxytryptamine (5,7DHT) or depletion of 5-HT storage by p-chlorophenylalanine (PCPA) does not reduce
the ACTH and corticosterone responses to 5-HT1A agonists. These results suggest that
the ACTH and corticosterone responses to 5-HT 1A agonists are exclusively mediated by
activation of postsynaptic 5-HT1A receptors.

However, a study by Bluet Pajot et

al.(1995) showed that infusing 8-0H-DPAT into the dorsal raphe nucleus slightly
increases ACTH secretion. Also, in that study, repeated injections of PCPA decreased
ACTH responses to 8-0H-DPAT.

These results suggest that presynaptic 5-HT1A
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receptors may also be involved in the ACTH response to 8-0H-DPAT. However, no
other data support these results so far and further confirmation is necessary.
Hypothalamic 5-HT 1A receptors, especially those in the paraventricular nucleus,
might be involved in the regulation of ACTH secretion (Bagdy and Makara, 1994;
Bagdy, 1994; Calogero et al.1989). Infusion of 8-0H-DPAT into the PVN significantly
increases ACTH secretion (Bluet Pajot et al.1995).

A lesion in the hypothalamic

paraventricular nucleus blocks the effect of the 5-HT1A agonist ipsapirone on plasma
corticosterone concentration (Bagdy and Makara, 1994; Bagdy, 1994). Taken together,
these results suggest that the ACTH and corticosterone responses to 5-HT 1A agonists are
mediated by postsynaptic 5-HT1A receptors in the hypothalamus.
A receptor-reserve has been demonstrated for the 5-HT 1A receptor-mediated
increase of plasma ACTH and corticosterone concentrations (Meller and Bohmaker,
1994; Pinto et al.1994). Irreversible inactivation of 5-HT IA receptors by EEDQ (Nethoxycarbonyl-1,2-ethoxydihydroquinoline) shifts the 8-0H-DPAT dose-response
curves for plasma ACTH and corticosterone to the right.

A low dose of EEDQ

(lmg/kg, sc) (Pinto et al.1994) reduced the density of 5-HT 1A receptors by 53%, but
did not change the hormone responses to 8-0H-DPAT. A high dose of EEDQ (6
mg/kg, sc) decreased both the potency and efficacy of ACTH and corticosterone
responses to 8-0H-DPAT (Meller and Bohmaker, 1994). The fractional occupancy of
5-HT 1A receptors required to reach 50% maximal response of ACTH or corticosterone
is 25% or 5.5% respectively (Meller and Bohmaker, 1994). The effect of EEDQ on
the hormone responses to 8-0H-DPAT can be prevented by pretreatment with the 5-
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HT 1A antagonist pindolol, suggesting that the effect of EEDQ on the ACTH and
corticosterone responses to 8-0H-DPAT is mediated by 5-HT1A receptors (Meller and
Bohmaker, 1994). The apparent receptor-reserve for 5-HT 1A receptor-mediated ACTH
and corticosterone may be due to the cascade of the HPA axis. When a hypothalamic
5-HT 1A receptor is stimulated, the signals travel through the HPA axis from the
hypothalamus, pituitary and adrenal cortical cells. The signals are amplified in each
step along the pathway, and thus, the response to the 5-HT1A agonist becomes
amplified. This is consistent with data showing that the corticosterone response has
more receptor reserve than the ACTH response.

5-HT1A receptor-mediated oxytocin secretion
Oxytocin is synthesized by magnocellular cells in the hypothalamic supraoptic
and paraventricular nuclei. The oxytocin neurons send their axons to the posterior lobe
of the pituitary gland where they secrete oxytocin into the inferior hypophyseal artery.
Oxytocin secretion can be regulated by stimulation of either oxytocin cell bodies in the
hypothalamus or nerve terminals in the posterior pituitary. Several studies indicate that
noradrenergic and serotonergic neurons are involved in the regulation of oxytocin
secretion. Noradrenergic projections from neurons in the Al,A2 and A6 cell groups
stimulate magnocellular cells in the paraventricular nucleus, while C2 noradrenergic
neurons inhibit the magnocellular cells (Saphier, 1993). Stimulation of a 1 receptors
increases the secretion of oxytocin (Levy et al.1994; Saphier, 1993). In contrast with
ACTH, D2 and µ-receptors inhibit the secretion of oxytocin. Injection of the 5-HT
releasers p-chloroamphetamine (PCA) and d-fenfluramine increase the concentration of
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plasma oxytocin (Van de Kar et al.1995c; Saydoff et al.1991). The effect of 5-HT
releasers can be inhibited by the 5-HT uptake inhibitor fluoxetine (Van de Kar et
al.1995c). Neurons in the dorsal rap he nucleus innervate magnocellular cells in the
paraventricular nucleus (Saphier, 1991). Furthermore, lesions in the paraventricular
nucleus, but not in the supraoptic nucleus, by the cell-selective toxin ibotenic acid
inhibits the oxytocin response to the 5-HT releaser p-chloroamphetamine (PCA) (Van
de Kar et al. l 995c). These results suggest that serotonin neurons regulate oxytocin
secretion by stimulating oxytocin neurons in the hypothalamic paraventricular nucleus.
Bagdy (1993) and our laboratory (Li et al.1993b) have found that activation of
5-HT 1A receptors increases the secretion of oxytocin. 5-HT,A agonists, such as 8-0HDPAT and ipsapirone increase the concentration of plasma oxytocin in a dose dependent
manner (Li et al.1993b; Bagdy and Kalogeras, 1993).

Furthermore, the oxytocin

response to 8-0H-DPAT can be inhibited by the 5-HT,A antagonist NAN-190 and
WAY-100635 (Vicentic et al.1996; Bagdy and Kalogeras, 1993).

A lesion in the

hypothalamic paraventricular nucleus decreases the effect of ipsapirone on the secretion
of oxytocin (Bagdy, 1994), suggesting that neurons in the PVN are involved in the
oxytocin response to 5-HT,A agonists. Unlike the 5-HT,A receptor-mediated ACTH
response, only a few studies have reported on the oxytocin responses to 5-HT1A
agonists.

The signal transduction mechanism of the 5-HT 1A receptor-mediated

regulation of oxytocin release is still not clear.
No data regarding receptor reserve for the oxytocin response to 5-HT IA agonists
have been published so far.

An observation by Pinto and Battaglia (unpublished)
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indicates that less receptor reserve exists for the oxytocin response to 5-HT tA agonists
than for ACTH. The oxytocin response to 8-0H-DPAT was examined in rats treated
with different doses of EEDQ, to inactivate receptors in a graded manner. Although
the Emax of oxytocin response to 8-0H-DPAT was not reduced with a low dose (1
mg/kg) of EEDQ, the 10 mg/kg dose of EEDQ completely blunted the oxytocin
response to 8-0H-DPAT. This dose of EEDQ, however, did not completely block the
8-0H-DPAT-induced increase in plasma levels of ACTH.
A 5-HT 1A receptor-mediated increase of oxytocin secretion occurs in both males
and females. The physiologic significance of this response is still unknown. Recently,
an interesting study (Bj6rkstrand et al.1996) found that an antagonist for oxytocin
receptors inhibited the effects of 8-0H-DPAT on insulin, cholecystokinin and
somatostatin, suggesting that 5-HT 1A receptor-mediated regulation of oxytocin secretion
may be related to the regulation of other hormones via oxytocin receptors.
Unlike ACTH and corticosterone, oxytocin is released directly into the
circulation from nerve terminals of oxytocin containing neurons in the hypothalamus.
Therefore, the magnitude of the oxytocin response to 5-HT 1A receptors will more
directly reflect the function of 5-HT 1A receptors in the hypothalamus than that of ACTH
and corticosterone responses.

5-HT tA agonist-induced increase of prolactin secretion may not be mediated by 5HT tA receptors
Prolactin is secreted from the anterior pituitary gland. The secretion of prolactin
is regulated by the hypothalamus. It is believed that the hypothalamus produces a
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releasing hormone to stimulate prolactin release.

However, no prolactin releasing

hormone has been found so far. Prolactin secretion is predominantly controlled by
dopamine. Dopamine is released from the hypothalamus to the pituitary and inhibits
secretion of prolactin.

Therefore, inhibition of dopamine release or blockade of

dopamine D2 receptors results in an increase in prolactin release.
Several 5-HT1A agonists, such as 8-0H-DPAT, ipsapirone and buspirone,
stimulate prolactin secretion (Kellar et al.1992; Gartside et al.1990; Di Sciullo et
al.1990; Aulakh et al.1988). Our preliminary data showed that destruction of 5-HT
neurons using icv injection of 5, 7-DHT potentiated the prolactin response to 8-0HDPAT, suggesting that postsynaptic 5-HT 1A receptors are involved in the 5-HT1A
agonist-induced increase of prolactin release. In addition, injection of pertussis toxin,
which inactivates Gi and G0 proteins, or forskolin, an activator of adenylyl cyclase,
inhibits the prolactin response to 8-0H-DPAT (Van de Kar et al.1995a). These results
suggest that the prolactin response to 8-0H-DPAT is mediated by Gi proteins, which
are negatively coupled to adenylyl cyclase.

However, the time course and dose

response of prolactin to 5-HT1A agonists are different from those of ACTH and
corticosterone (Kellar et al.1992; Gartside et al.1990). The prolactin response to 5HT1A agonists can not be inhibited by the 5-HT1Aantagonists pindolol (Levy et al.1995;
Groenink et al.1995; Park and Cowen, 1995) or WAY -100635 (Vicentic et al.1996).
Furthermore, a surgical lesion in the hypothalamic PVN did not inhibit the prolactin
response to ipsapirone (Bagdy and Makara, 1994).

These results suggest that the

prolactin response to 5-HT1Aagonists may be not mediated by 5-HT1A receptors.
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Neuroendocrine challenge test
In conclusion, 5-HT1A receptors are involved in the regulation of the secretion
of ACTH, corticosterone and oxytocin.

Therefore, the magnitude of the hormone

responses to 5-HT1A agonists can be used as a marker to examine the function of
hypothalamic 5-HT 1A receptor systems.
As will be discussed below, dysfunction of serotonergic systems may play a role
in affective disorders. Therapeutic effects of antidepressants may be related to changes
in the function of 5-HT1A receptors. Since hypothalamic neurons are involved in mood
change, determination of the function of hypothalamic 5-HT1A receptors will help in the
diagnosis and monitoring of the therapeutic effects of antidepressants (Van de Kar,
1989). Hormone responses to 5-HT agonists or releasers can be a useful peripheral tool
to determine the function of central serotonergic systems. In fact, hormone responses
to 5-HT agonists or releasers have been used clinically to assess the function of
serotonergic systems in patients with affective disorders (Cowen et al.1994; Hollander
et al.1991; Murphy et al.1991; Price et al.1991; Muller, 1990; Asnis et al.1988; Curtis
and Glitz, 1988). For example, Lesch et al.(Lesch et al.1992c; Lesch, 1991; Lesch et
al.1991b; Lesch et al.1991c; Lesch et al.1990a; Lesch et al.1990b; Lesch et al.1989)
examined ACTH and cortisol responses to ipsapirone to assess changes in the function
of 5-HT1A receptors in depressed patients and the effect of antidepressants on 5-HT1A
receptors. It is possible that changes in the function of 5-HT receptors occur prior to
signs of clinical improvement during the treatment of affective disorders. Therefore,
monitoring the function of 5-HT receptors using a neuroendocrine challenge test may
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be a valuable tool to give physicians early information, such as whether the patient will
respond to the treatment.
Although a neuroendocrine challenge test is a relatively reliable examination
compared to other peripheral tests, its limitations should be noted. First, most agonists
(e.g. a 5-HT 1A agonist) used as a challenge are not exclusively selective for one type
of 5-HT receptor (e.g 5-HT1A receptors).

These drugs may also influence other

neurotransmitter receptors (e.g. Dopamine D2 receptors).

Therefore, the hormone

responses to the agonists may not only reflect the function of 5-HT receptors (5-HT1A
receptors), but also other receptors (D2 receptors). For example, buspirone is a 5-HT 1A
agonist and an antagonist of dopamine D2 receptors. Since dopamine is a predominant
inhibitory control for prolactin release, the prolactin response to buspirone will mainly
represent the function of D2 receptors.

Secondly, since the pathways for 5-HT

receptors regulating hormone release are still unknown and each hormone can be
regulated by several different systems, it is possible that the steady-state of a hormone
will be changed under different physical conditions, such as illness. In this case, the
hormone challenge test may not represent the function of 5-HT receptors. To overcome
these limitations, it is necessary to examine more than one hormone response. Since
each hormone is regulated by different neurotransmitters, determination of several
hormones will allow ruling out some of the side effects of agonists or abnormal
hormone states.
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5-HTlA Receptors and 5-HT Uptake Inhibitors
5-HT and affective disorders
Dysfunction of serotonergic systems is believed to be involved in several
affective disorders, such as anxiety, depression, obsessive compulsive disorder,
premenstrual syndrome and seasonal affective disorder (Sandyk, 1992; Shapira et
al.1994; Eison, 1990; Mann et al.1990; Lesch et al.1992a). There is growing evidence
regarding the involvement of abnormal serotonergic systems in schizophrenia and
epilepsy (Rao and Moller, 1994; Holden, 1995; Statnick et al.1996). The evidence
regarding the involvement of serotonergic systems in affective disorders includes the
following: 1) Alterations of the concentration of 5-HT induce mood changes.
Delgado and his colleagues found that depletion of tryptophan, a precursor of 5-HT,
by a tryptophan-free diet induced a relapse of depressive symptoms in remitted
depressed patients (Delgado et al.1990).

Also, tryptophan depletion worsened

depressive symptoms in drug-free depressed patients one day after the test (Delgado
et al.1994). In contrast, tryptophan depletion improved aggressive behavior one day
after the test (Salomon et al.1994). These results indicate that abnormal serotonin levels
may trigger mood changes, while the symptoms may be related to adaptive postsynaptic
changes induced by the alteration of 5-HT (Delgado et al.1994). Consistent with the
above results, a low 5-HT turnover (low 5-HIAA) in CSF has been found in impulsive
violence offenders, which may be due to a genetic disorder (Virkkunen et al.1995). To
determine whether the effect of tryptophan depletion on mood changes is due to a
decrease of 5-HT release from nerve terminals, Bel and Artigas (1996) recently
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examined the effect of tryptophan depletion on 5-HT concentration in rat frontal cortex
using microdialysis. They found that tryptophan depletion significantly reduced 5-HT
concentration in the frontal cortex of the rats that received fluvoxamine (a 5-HT uptake
inhibitor) treatment.

This result is consistent with the clinical observations.

2)

Changes in 5-HT receptors have been found in the brain of suicide victims. 5-HT
uptake sites were decreased and 5-HT1A receptors were increased in the ventrolateral
prefrontal cortex of suicide victims (Arango et al.1995). Increased 5-HT2Aizc receptors
in the cortex and amygdala and a low level of 5-HT1 receptors in the hippocampus have
also been observed in suicides (Cheetham et al.1990; Hrdina et al.1993). However, the
results from different studies were not consistent. This may be due to the variation in
populations, sample sources and methods used between the studies.
exposure to antidepressants alters 5-HT transmission.

3) Chronic

The theories on the

implication of dysfunction of serotonergic systems in the pathogenesis of affective
disorders were originally based on the therapeutic effects of antidepressants (Shapira
et al.1994). Most antidepressants alter 5-HT transmission, although the effective sites
may vary between classes of antidepressants (Owens and Nemeroff, 1994).

For

example, tricyclic antidepressants tend to potentiate the function of postsynaptic 5-HT
receptors, while SSRI's desensitize presynaptic 5-HT receptors (Blier et al.1987). 4).
5-HT uptake inhibitors are antidepressants As will be discussed below, 5-HT uptake
inhibitors are widely used to treat affective disorders.
Taken together, these observations support the hypothesis that dysfunction of
serotonergic systems may play a role in the pathophysiology of affective disorders.
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However, since affective disorders are complicated processes, it is still unclear what
the mechanisms of affective disorders are in terms of abnormalities of serotonergic
systems.
5-HT1A receptors may play a role in the pathophysiology and therapeutics of
affective disorders (Shapira et al.1994). A few studies observed abnormal functions of
5-HT1A receptors in patients with affective disorders. However, the observations were
not consistent between studies.

For example, hypothermic, ACTH and cortisol

responses to ipsapirone were reduced in patients with unipolar depression, suggesting
a decrease in the function of 5-HT1Areceptors in both pre- and postsynaptic sites (Lesch
et al.1992c; Lesch, 1991; Lesch et al.1990b). However, the results reported by Cowen
at al. (1994) reveal that hypothermia, but not ACTH and growth hormone responses
to 5-HT1A agonists buspirone were attenuated in patients with major depression. This
inconsistency may be due to the differences in population or type of the depression.
However, it should be noted that a dysfunction of 5-HT IA autoreceptors was consistently
observed in both major and unipolar depressed patients. Although several mutated 5HT1A receptor genes have been found, none of them is correlated with depression
(Erdmann et al.1995; Nakhai et al.1995; Xie et al.1995). In fact, more convincing
evidence for existing dysfunction of 5-HT1Areceptors in affective disorders comes from
the involvement of 5-HT1A receptors in the therapy of affective disorders. Several 5HT1A agonists are anxiolytics and express antidepressive properties (De Vry, 1995;
Handley, 1995; Griebel, 1995). Also, some antidepressants, especially 5-HT uptake
inhibitors (SSRI's), desensitize 5-HT1A receptors (Blier et al.1987; Lesch et al.1991c;
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Lesch et al.1990a), as will be discussed later. Furthermore, it has been found that
administration of the 5-HT1A antagonist pindolol, combined with SSRI's, reduced the
delay in the therapeutic effects of SSRI's (Artigas et al.1994; Blier and Bergeron,
1995).

Effects of 5-HT uptake inhibitors on 5-HT1A receptor systems
Selective serotonin reuptake inhibitors (SSRl's)
5-HT uptake inhibitors include fluoxetine (Prozac®), fluvoxamine (Luvox®),
paroxetine (Paxil®), sertraline (Zoloft®) and citalopram. The 5-HT uptake inhibitors,
especially fluoxetine, are widely used to treat depression, obsessive compulsive
disorders, bulimia nervosa, panic disorder, obesity and premenstrual syndrome (Wong
et al.1995; Goldstein et al.1995; Weltzin et al.1994; Advokat and Kutlesic, 1995;
Eriksson et al.1995; Steiner et al.1995; Woods et al.1993; Goldstein et al.1994a;
Goldstein et al.1994b; Lam et al.1995).

A major advantage of the 5-HT uptake

inhibitors is that they produce fewer side effects than the tricyclic antidepressants
(Wong et al.1995; Richelson, 1994).
5-HT uptake inhibitors do not share common chemical structures, but all have
a high affinity for 5-HT uptake sites. They have a relatively low affinity for other
monoamine transporters and receptors (Richelson, 1994; Wong et al.1995). Since the
chemical structures of the 5-HT uptake inhibitors are different, their pharmacokinetic
profiles are quite different as well. Among the 5-HT uptake inhibitors, fluoxetine has
the lowest affinity, while paroxetine has the highest affinity for 5-HT uptake sites
(Richelson, 1994; Wong et al.1995). In humans, the half-life (t 11i.) values for the 5-HT
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uptake inhibitors range from 15 hours (paroxetine and fluvoxamine) to 1.9 days
(fluoxetine) after a single dose of administration (Table I).

There is no active

metabolite for paroxetine and fluvoxamine. However, the metabolite of fluoxetine,
norfluoxetine, has a similar potency for 5-HT uptake sites and a much longer t 112 (7
days) than fluoxetine. Although sertraline has an active metabolite, its activity is only
10% that of sertraline (Van Harten, 1993). It should be noted that the half-life values
of the 5-HT uptake inhibitors are usually increased with chronic treatment (Van Harten,
1993; Goodnick, 1994).

Very few studies have been reported regarding the

pharmacokinetics of 5-HT uptake inhibitors in animals. Caccia et al. (1990) reported
that the mean elimination half-life (t 11z) of a single dose of fluoxetine in rats is about 5
hours (intravenous) or 7 hours (oral), while the t112 of norfluoxetine is about 15 hours.
These t 112 values are much shorter than those in humans. However, the elimination
half-life may not reflect the duration of effects of 5-HT uptake inhibitors in terms of
ability to occupy 5-HT uptake sites. Scheffel et al. (1994) have shown that the t112
values of the inhibitory effect on

125

1-RTI-55 binding (a in vivo radioactive tracer for

5-HT uptake sites) in the mouse brain are about 35, 7 and 6 hours for fluoxetine,
sertraline and paroxetine, respectively.
The doses of 5-HT uptake inhibitors used in animals are determined as the doses
that prevent 5-HT depletion by the 5-HT releasers PCA or fenfluramine, which enter
nerve terminals through 5-HT uptake sites (Fuller et al.1978; Fuller and Wong, 1987).
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TABLE I
PHARMACOLOGIC PARAMETERS OF 5-HT UPTAKE INHIBITORS
Fluoxetine Paroxetine Fluvoxamine Sertraline Citalopram
Ki (nM) 1

25

1.1

6.2

7.3

2.6

Ki ratio
(NE: 5-HT) 1
tmax (h) 2

20

320

180

190

1500

6-8

5

5

6-8

2-4

parent compound

1.9 days

10-16 h

15 h

26 h

33 h

active metabolite

7 days

NA

NA

62-104 h

t 112 (human) 2'3

t112 (rat)4,s
parent compound

5-7 h

active metabolite

15 h

Dosage
(mg/day) 3 ' 6

20-80

3h

20-30

NA: No active metabolite
-: the data are unknown
1. Nemeroff, 1993; Van Harten, 1993
2. Van Harten, 1993
3. Goodnick, 1994
4. Caccia et al. 1990
5. Moret and Briley, 1990
6. Hollister and Claghorn, 1993

100-300

50-200
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5-HT1A receptors in the therapeutic effects of SSRl's
The pharmacologic effects of 5-HT uptake inhibitors are blockade of 5-HT
reuptake sites, resulting in an increase in the concentration of 5-HT in the synaptic
cleft. However, like other antidepressants, the clinical improvement is usually observed
two to three weeks after the onset of treatment with 5-HT uptake inhibitors. This delay
of the clinical improvement suggests that the therapeutic effects of 5-HT uptake
inhibitors might not be directly mediated by their acute pharmacologic effects, but are
due to an adaptive change triggered by the sustained blockade of 5-HT uptake sites.
It has been hypothesized (Briley and Moret, 1993; Blier and de Montigny, 1994;

Gardier et al.1996) that 5-HT1A receptors are involved in the delayed onset of
therapeutic effects of 5-HT uptake inhibitors. The blockade of 5-HT uptake sites by
5-HT uptake inhibitors leads to an increase in the concentration of 5-HT in the synaptic
cleft both in the raphe and in postsynaptic brain areas (Fuller, 1994; Rutter and
Auerbach, 1993). Since somatodendritic 5-HT1A autoreceptors (in the raphe) are more
sensitive to the alteration of 5-HT concentration in the synaptic cleft than postsynaptic
5-HT 1A receptors (Blier et al.1993a; Hoyer and Boddeke, 1993), the increase in 5-HT
concentration in the synaptic cleft will first stimulate somatodendritic 5-HT1A
autoreceptors. The activation of 5-HT1A autoreceptors results in an inhibition in the
firing rate of 5-HT neurons of the raphe nuclei and consequently, reduces 5-HT release
from nerve terminals in the forebrain. Thus, initially, the net 5-HT concentration in
the synaptic cleft of forebrain may not be increased. The decrease in 5-HT release may
even produce an initial supersensitivity of postsynaptic 5-HT 1A receptors (Ceci et

36
al.1993). With repeated administration of 5-HT uptake inhibitors, it is hypothesized
that the over-stimulation of somatodendritic 5-HT1A autoreceptors by the high
concentration of 5-HT will produce a desensitization of somatodendritic 5-HT1A
autoreceptors in the raphe. The desensitization of somatodendritic 5-HT 1A autoreceptors
reduces the responses of serotonin neurons to 5-HT. Consequently, the 5-HT neurons
will be liberated from the inhibition of firing activity and 5-HT release from 5-HT
nerve terminals will return to normal or even be increased.

Therefore, the

concentration of 5-HT in the postsynaptic clefts will be increased, resulting in a
desensitization of postsynaptic 5-HT 1A receptor systems.

The desensitization of

postsynaptic 5-HT 1A receptors may be implicated in the therapeutic effects of 5-HT
uptake inhibitors.
Evidence to support this hypothesis will be discussed below.

Most of the

evidence is focused on somatodendritic 5-HT1A receptors and very few studies have
investigated the adaptive changes in postsynaptic 5-HT1A receptors.

1)

Inhibition of 5-HT neurons induced by acute injection of 5-HT uptake inhibitors is

mediated by somatodendritic 5-HT1A autoreceptors.

Acute administration of 5-HT

uptake inhibitors decreases the firing rate of 5-HT neurons in the dorsal and median
rap he nuclei (Rigdon and Wang, 1991 ; Rutter and Auerbach, 1993; Chaput et al .1988;
Haj6s et al.1995). This effect can be blocked by the 5-HT 1A antagonists pindolol, (S)UH-301, WAY-100135, spiperone and WAY-100635 (Arborelius et al.1995; Haj6s et
al.1995; Gartside et al.1995; Huang and Harlan, 1994), suggesting that 5-HT uptake
inhibitor-induced reduction in the firing rate of 5-HT neurons is mediated by 5-HT1A
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autoreceptors. Consistent with the electrophysiological results, it is limited that the
influence of acute administration of 5-HT uptake inhibitors on extracellular
concentration of 5-HT in the forebrain, which was measured by microdialysis.
Depending on the doses of 5-HT uptake inhibitors used, the extracellular 5-HT
concentration in forebrain regions can be slightly increased (high doses of SSRI's) or
not changed by systemic injections of 5-HT uptake inhibitors (Fuller, 1994; Gartside
et al.1995; Gardier et al.1996; Rutter et al.1995; Rutter and Auerbach, 1993; Invernizzi
et al.1992). Systemic injections of fluoxetine, paroxetine or sertraline (10 mg/kg, ip)
to rats that received a local perfusion of fluoxetine into the diencephalon to block 5-HT
uptake in the nerve terminals, significantly decreased the extracellular concentration of
5-HT in the diencephalon (Rutter et al.1995). This decrease of 5-HT release could be
reversed by systemic injections of 5-HT1A antagonists, such as WAY-100135 or
spiperone. Invernizzi et al. (1996) also observed that systemic injection of the 5-HT1A
antagonist WAY-100635 potentiated the increase of extracellular 5-HT concentration
in the frontal cortex induced by an acute injection of fluoxetine. Similar results have
also been observed in the hippocampus by Hjorth et al. (1994a; 1995).

Also, the

increase of 5-HT concentration in the diencephalon induced by local infusion of
fluoxetine was twice as high as that induced by systemic injection of fluoxetine (Rutter
and Auerbach, 1993). Together, these data suggest that acute injections of 5-HT uptake
inhibitors indirectly activate 5-HT 1A autoreceptors on the 5-HT neurons, resulting in an
inhibition of activity of 5-HT neurons and a decrease in 5-HT release. Furthermore,
the increase in 5-HT concentration in forebrain regions, induced by 5-HT uptake
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inhibitors, is much less than that in the raphe nucleus (Gartside et al.1995; Gardier et
al.1996; Rutter et al.1995). These results suggest that the stimulation of 5-HT 1A
autoreceptors induced by acute injection of 5-HT uptake inhibitors may not be only due
to the higher sensitivity of 5-HT1A autoreceptors compared with postsynaptic 5-HT 1A
receptors, but also due to a higher 5-HT concentration in the raphe regions than that
in the forebrain regions.

However, it is unknown why activation of 5-HT1A

autoreceptors does not inhibit the release of 5-HT in the raphe nuclei.

2) Long-term treatment with 5-HT uptake inhibitors desensitizes 5-HT1A autoreceptors
in the raphe nuclei. Several studies have demonstrated that chronic treatment with 5HT uptake inhibitors reduces the ability of subsequent injections of 5-HT uptake
inhibitors to decrease 5-HT neuronal activity. Blier et al. (1987; 1988) showed that the
firing rate of 5-HT neurons was significantly decreased after 2 days of injections with
the 5-HT uptake inhibitors indalpine, zimelidine or citalopram. However, the firing
rate of neurons was partially restored after 7 days and returned to normal after 14 days
of injections of indalpine, zimelidine or citalopram. Repeated injections of fluoxetine,
paroxetine or cericlamine, a novel 5-HT uptake inhibitor, significantly shifted to the
right the dose-response curve of 8-0H-DPAT- or ipsapirone-induced inhibition of the
firing rate of 5-HT neurons in brain stem slices (Le Poul et al .1995; J olas et al .1994).
This reduction of the effect of 8-0H-DPAT on the firing of 5-HT neurons occurred
after 3 days of repeated injections (Le Poul et al.1995). These results suggest that
repeated injections of 5-HT uptake inhibitors desensitize 5-HT1A autoreceptors in
serotonin neurons.
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Unlike the electrophysiological data, results from microdialysis studies to
determine the effects of repeated injections of 5-HT uptake inhibitors on 5-HT release
have not been as consistent (Gardier et al.1996). Bel and Artigas (1993) reported that
repeated injections of fluvoxamine increased basal level of 5-HT in the frontal cortex,
but not in the raphe region. The increase in the basal level of 5-HT induced by chronic
fluvoxamine (2 weeks) was higher than acute fluvoxamine-induced increase of 5-HT
concentration in the frontal cortex. Also, extracellular 5-HT levels in the frontal cortex
of chronic fluvoxamine-treated rats were not further increased by a challenge with
fluvoxamine. Several other investigators (Rutter et al.1994; Kreiss and Lucki, 1995;
Invernizzi et al.1996; Invernizzi et al.1994) found that repeated injections of fluoxetine
or citalopram increased baseline concentration of 5-HT in several forebrain regions,
such as frontal cortex, striatum, hippocampus and diencephalon. When a single dose
of a 5-HT uptake inhibitor was used as a challenge, the extracellular concentration of
5-HT in the forebrain increased to a much higher degree in the rats that received
repeated injections of 5-HT inhibitors than in the control rats. Furthermore, repeated
injections of 5-HT uptake inhibitors, such as fluoxetine, abolished 8-0H-DPAT-induced
inhibition of 5-HT release (lnvernizzi et al.1996). Taken together, these results suggest
that repeated administration of 5-HT uptake inhibitors leads to a desensitization of 5HT1A autoreceptors on 5-HT neurons. This desensitization of 5-HT1A autoreceptors
liberates serotonin neurons from the inhibition of firing activity and consequently,
increases the concentration of 5-HT in the postsynaptic cleft. However, several studies
do not support this hypothesis. Hjorth and Auerbach (1994b) reported that chronic
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citalopram did not reduce the inhibitory effect of 8-0H-DPAT on 5-HT release in the
frontal cortex and dorsal hippocampus. Also, an increased baseline of hypothalamic
5-HT in rats chronically treated with citalopram was only observed during
administration, but not after a 24 hours washout (Moret and Briley, 1996). Although
Invernizzi et al. (1995) observed a desensitization of 5-HT1Aautoreceptors induced by
chronic fluoxetine, they did not find that chronic citalopram produced desensitization
of 5-HT1A autoreceptors.

These inconsistent results could be due to the different

experimental procedures, different 5-HT uptake inhibitors used or different brain
regions examined.

3)

5-HT1A antagonists shorten the delay of clinical improvement in the 5-HT uptake

inhibitor therapy. If the hypothesis is correct that activation of 5-HT1A autoreceptors
plays a role in the delay of the onset of clinical improvement after administration of 5HT uptake inhibitors, then, blocking the 5-HT 1Aautoreceptors with 5-HT1Aantagonists
while administering 5-HT uptake inhibitors should speed the therapeutic effects of 5-HT
uptake inhibitors. Artigas (1994; 1995) was the first to give depressed patients the 5HT1A antagonist pindolol with 5-HT reuptake inhibitors. Two-thirds of the patients
remitted completely within 1 week. Some of them had taken 5-HT uptake inhibitors
for at least 6 weeks with no full antidepressant responses before pindolol was added.
A similar result was also observed by Blier et al (1995). Nine patients with unipolar
depression and 19 patients with resistant unipolar depression were treated with 5-HT
uptake inhibitors and pindolol. Most of them achieved clinical improvement within 1
week. All patients, Except one, remitted within 14 days. Furthermore, Koran et al.
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(1996) recently reported that pindolol also short the delay of the therapeutic effect of
5-HT reuptake inhibitors on obsessive compulsive disorder. All of these results support
the hypothesis that 5-HT 1A autoreceptors are involved in the delay of clinical
improvement during treatment with 5-HT uptake inhibitors. However, it should be
noted that pindolol is also a B-adrenergic receptor antagonist. It still cannot be ruled
out that the effect of pindolol in accelerating the therapeutic effect of 5-HT uptake
inhibitors is due to its B antagonist effect. There were some patients that did not gain
benefit from the combined pindolol and 5-HT uptake inhibitor treatment. All data, so
far, have come from clinical trials and the number of cases is still limited. Therefore,
further studies are necessary.

4)

The effects of chronic 5-HT uptake inhibitors on postsynaptic 5-HT1A receptors. Data

regarding the effect of 5-HT uptake inhibitors on the function of postsynaptic 5-HT1A
receptors are limited.

Lesch et al.(199lc) reported that long-term treatment with

fluoxetine reduced the ACTH response to the 5-HT 1A agonist ipsapirone in patients with
obsessive-compulsive disorder. Hensler et al. (1991) showed that repeated injections
of sertraline or citalopram attenuated the hypothermic response to 8-0H-DPAT, which
in rats is mediated by postsynaptic 5-HT1A receptors. These results suggest that chronic
injections of 5-HT uptake inhibitors desensitize postsynaptic 5-HT1A receptors.
In conclusion, evidence supports the hypothesis that the therapeutic effects of
SSRI's may be mediated by desensitization of 5-HT1A receptors. However, most studies
focus on the presynaptic 5-HT 1A autoreceptors.

Less is known about the effect of

chronic administration of SSRI's on postsynaptic 5-HT1A receptors.
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The mechanism of desensitization of 5-HTlA receptors induced by chronic
administration of 5-HT uptake inhibitors
The desensitization of 5-HT 1A receptors is defined as a reduction in the function
of 5-HT 1A receptor systems. It is still unknown what changes in the components of 5HT 1A receptor systems contribute to the desensitization.

5-HT1A receptor systems

include the 5-HT1A receptors, G proteins that are coupled to 5-HT1A receptors, second
messengers and effectors that couple to the second messenger and determine the
function of 5-HT1A receptors in the cells. Most studies have investigated the effects of
chronic 5-HT uptake inhibitors on the 5-HT1A receptors. Recently, some studies on the
effects of 5-HT uptake inhibitors on G proteins, second messengers and the regulation
of 5-HT receptors or G proteins have been reported (Newman et al.1992; Jolas et
al.1994; Lesch and Manji, 1992; Lesch et al.1992b).
Several studies have shown that repeated injections of 5-HT uptake inhibitors do
not change the density of 5-HT1A receptors (either pre- or postsynaptic) (Le Poul et
al.1995; Hensler et al.1991; Jolas et al.1994). Le Poul et al. (1995) reported that
neither 5-HT 1A agonist binding (3H-8-0H-DPAT) nor 5-HT 1A antagonist binding (3HWAY-100635) was altered by repeated injections of fluoxetine or paroxetine. These
results indicate that the total number of 5-HT1A receptors and high affinity state 5-HT1A
receptors are not changed by repeated injections of 5-HT uptake inhibitors. Hensler et
al. (1991) found that although repeated injections of sertraline or citalopram attenuated
the hypothermic response to 8-0H-DPAT, there were no changes in the density of 5HT 1A receptors as measured by autoradiographic analysis of 3H-8-0H-DPAT binding.
In contrast, Welnet et al. (1989) reported that repeated injections of fluoxetine for 21
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days decreased the density of 5-HT1A receptors in the dorsal raphe but not in the
hippocampus. Also, Klimek et al. (1994) reported that citalopram, but not fluoxetine,
enhances the density of 5-HT1A receptors in the hippocampus.
Since repeated injections of 5-HT uptake inhibitors may not change the density
of 5-HT1A receptors or the changes only occur in specific nuclei, it is possible that the
desensitization of 5-HT1A receptors induced by 5-HT uptake inhibitors is mediated by
alterations of the signal transduction systems of 5-HT1A receptors.

Newman, et al.

(1992) have found that chronic exposure to fluoxetine reduces 5-HT-induced inhibition
of forskolin-stimulated adenylyl cyclase in rat hippocampus.

In contrast with the

observation, repeated injections of cericlamine (a new 5-HT uptake inhibitor) for 14
days did not reduce the 8-0H-DPAT-induced inhibition of forskolin-stimulated adenylyl
cyclase, although the forskolin-induced activity of adenylyl cyclase was increased in the
chronic cericlamine treated rats (Jolas et al.1994). No study has examined changes in
the coupling of 5-HT1A receptors to their G proteins, although Le Poul et al. (1995)
indicated that the ratio of 5-HT 1A agonist and antagonist binding is not altered by
repeated injections of 5-HT uptake inhibitors. Their data suggest that repeated injections
of 5-HT uptake inhibitors do not alter the coupling of 5-HT1A receptors to their G
proteins. No data regarding changes in the levels of G proteins induced by repeated
injections of 5-HT uptake inhibitors have been reported, although some investigators
have studied the effects of tricyclic antidepressants on the levels of G proteins in several
brain regions (Lesch et al.1991a; Lesch and Manji, 1992) and in glial cells (Chen and
Rasenick, 1995b). Lesch et al. (1992b; 1992) examined the changes in Gs, Gil• Gi2 , G0 ,
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Gq and G 12 rnRN A expression after repeated administration of a low dose of fluoxetine
for 21 days. Their results indicate that fluoxetine increases G12 rnRNA in the frontal
cortex, Gq rnRNA in the neostriatum and Gi2 and G0 rnRNA in the midbrain.

No

change in the G protein rnRNA was detected in the hypothalamus and hippocampus.
These results suggest that chronic administration of 5-HT uptake inhibitors may change
the level of G proteins. All together, these results suggest that the desensitization of
5-HT 1A receptors, induced by repeated injections of 5-HT uptake inhibitors, may not
be due to changes in the density of 5-HT1A receptors and their coupling to G proteins
in the steady state.

It is possible that the desensitization of 5-HT 1A receptors is

mediated by alterations in the components of the signal transduction system, such as the
level of G proteins and activity of adenylyl cyclase, resulting in dynamic changes in the
signal transduction system of 5-HT 1A receptors in the neurons.

Furthermore, the

regulation of 5-HT1A receptors and/or G proteins, for example by phosphorylation or
palmitoylation (Wedegaertner et al.1995; Ross, 1995; Milligan et al.1995), could play
a role in producing the desensitization of 5-HT 1A receptors.

Several studies have

demonstrated that phosphorylation of 5-HT1A receptors induces their desensitization
(Nebigil et al.1995; Raymond and Olsen, 1994; van Huizen et al.1993; Raymond,
1991). Some of these studies have shown that the phosphorylation of 5-HT1A receptors
may be mediated by protein kinase A and/or protein kinase C (Raymond and Olsen,
1994; Raymond, 1991). Others suggest that the phosphorylation of 5-HT1A receptors
may be mediated by other mechanisms but not by protein kinase C (Nebigil et al.1995;
van Huizen et al.1993; Claustre et al.1991a). Mann et al. (1995) reported that repeated
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injections of fluoxetine (5 mg/kg) for 21 days significantly decreased the activity of
protein kinase C in the cortex and hippocampus. Therefore, it is unlikely that the
desensitization of 5-HT1A receptors, induced by repeated injections of 5-HT uptake
inhibitors, is due to the phosphorylation by protein kinase C. So far, no study has been
reported regarding the effects of 5-HT uptake inhibitors on the palmitoylation of 5-HT1A
receptors, although there are some studies on palmitoylation of G proteins (Milligan et
al.1995; Ross, 1995; Wedegaertner et al.1995; Degtyarev et al.1994). Taken together,
the mechanism of desensitization of 5-HT1A receptors, induced by chronic 5-HT uptake
inhibitors, is still unclear. Specifically, no studies have reported on the time-course of
the effect of 5-HT uptake inhibitors on the 5-HT1A receptor system, including changes
in the 5-HT1A receptors, their signal transduction system, and 5-HT 1A receptor-mediated
physiological functions.

CHAPTER III
MATERIALS AND METHODS
Animals

Male Sprague-Dawley rats (225-275 g) were purchased from Harlan Sprague
Dawley Inc. (Indianapolis, IN). The rats were housed two per cage in a lighting (12
hr light/dark; lights on at 7 A.M), humidity and temperature-controlled room. Food

and water were available ad lib. All procedures were conducted in accordance with the
NIH Guide for the Care and Use of Laboratory Animals as approved by the Loyola
University Institutional Animal Care and Use Committee.

Drugs and Reagents

Fluoxetine was a gift from Eli Lilly and Company (lndianapolis,IN).
Desipramine was purchased from Sigma Chemical Co (St. Louis, MO). Paroxetine was
a gift from Smith-Kline Beecham.

8-0H-DPAT was purchased from Research

Biochemicals Inc (Natick, MA). Ipsapirone was a gift from Miles Laboratories, 'Inc.
(West Haven, Connecticut). All the drugs were dissolved in saline and injected in a
volume of 2 ml/kg for antidepressants and 1 ml/kg for 8-0H-DPAT and ipsapirone.
ACTH antiserum was purchased from lgG Corp (Nashville, TN). ACTH (1-39)
standards were obtained from Calbiochem (San Diego CA). Bovine serum albumin and
aprotinin were purchased from Sigma Chemical Co. (St. Louis, MO). Normal rabbit
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serum and goat anti-rabbit-')'-globulin were purchased from CalBiochem (San Diego,
CA).
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1-ACTH was obtained from INCSTAR (Stillwater, MN).

Corticosterone

antiserum was purchased from ICN Biochemicals (Irvine, CA).

Ultima Gold

scintillation fluid was purchased from Packard Instrument Co., Inc. (Downers Grove,
IL). acetone (Spectranalyzed A-19) and petroleum ether were obtained from Fisher.
H-corticosterone,

3
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1-oxytocin and 3H-8-0H-DP AT were purchased from DuPont-NEN

(Boston, MA) at a specific activity of 129 Ci/mmol for the fluoxetine study and 135
Ci/mmol for the paroxetine study. Gpp(NH)p was purchased from Sigma Chemical
Co. (St. Louis, Mo). Recombinant a-subunits of G protein immunoblot standards were
purchased from Calbiochem (San Diego, CA). Anti Gi 112 (AS/7) and anti G0 (GC/2)
sera were purchased from Du-Pont NEN. Anti Gi3 serum was purchased from Upstate
Biotechnology Inc. (Lake Placid, NY). Rabbit peroxidase-antiperoxidase was purchased
from Organon Teknika Co (Durham, NC). The chemiluminescence substrate solution
LumiGlo was obtained from Kirkegaard & Perry Laboratories, Inc. (Gaithersburg,
MD). NP-40 (Nonidet P-40 or lgepal CA-630) was purchased from Sigma Chemical
Co. (St. Louis, Mo).

Biochemical Determinations
Radioimmunoassays
Plasma ACTH radioimmunoassay

ACTH radioimmunoassay was performed in an un-extracted plasma samples
using an ACTH antiserum. The sequence recognition of the antiserum is the 5-18
segment of ACTH. This antiserum does not significantly recognize a-MSH, /j-MSH,
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,6-endorphin, ,6-lipotropin, ACTH 11-24, or ACTH 1-16-amide. ACTH (1-39) was
used as standards. In this double antibody radioimmunoassay, samples and standards
were incubated with the ACTH antibody (final dilution 1:30,000, 223 total binding)
at 4°c for 24 hr in a 0. 01 M phosphosaline buffer (PBS, pH 7. 6) containing 1 % bovine
serum albumin, 0.025 M EDTA, 0.53 normal rabbit serum and 25 KIU/ml aprotinin.
1251-ACTH

(2000 cpm) was added and incubated for 24 hr at 4°C in a total volume of

0.3 ml. The second antibody (goat anti-rabbit-)'-globulin) was added at a final dilution
of 1:50 and incubated overnight at 4°C. After 1.5 ml of cold PBS was added, the tubes
were then centrifuged at 15,000 x g 4°C for 40 min. The radioactivity of the pellet was
counted for 5 min by a Micromedic 4/200 plus 'Y counter and analyzed from a standard
curve using a RIA-AID computer program (Robert Maciel Associates, Arlington, MA).
The sensitivity of the assay is 0.25 pg/tube and the intra- and inter-assay variations are
4.23 and 14.6% respectively.

Plasma corticosterone radioimmunoassay

Corticosterone radioimmunoassay was performed on un-extracted plasma samples
in which corticosterone-binding proteins had been denatured by boiling, as previously
described (Van de Kar et al.1985). The assay is based on procedures and antiserum
(final dilution 1:11,200, 463 total binding) from ICN Biochemicals (Irvine, CA).
Briefly, plasma (2 or 5 µl) and standard (0-5 ng/tube) were incubated with sodium
phosphate buffer (0.05 M pH 7.0) containing 0.16 M NaCl, 0.015 M sodium azide and
2 3 gelatin at 70° C for 20 min to denature plasma proteins. After the tubes were
cooled to room temperature, 0.1 ml antibody (1 :5600 dilution) and radioactive 3H-
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corticosterone tracer (about 6,000 - 7 ,000 cpm) were added to the tubes. The tubes,
with a total volume of 0. 7 ml, were then incubated at 4° C overnight. To separate the
bound from the free tracer, 0.2 ml of cold Dextran T 70-charcoal suspension was added
to the tubes, mixed and incubated at 4°C for 10 min. The tubes was then centrifuged
at 15,000 x g, 4°C for 20 min. The supernatants were decanted into scintillation vials
and 5 ml of Ultirna Gold scintillation fluid was added to each vial. The radioactivity
of 3H-corticosterone was counted by a Hewlett Packard MINAXY scintillation courter
for 2.5 min. The sensitivity of this assay is 0.02 ng/tube, and the intra- and inter-assay
variabilities are 4. 5 % and 11. 9 % respectively.

Plasma oxytocin radioimmunoassay

Oxytocin assay was performed by a method modified from Keil ( 1984). Plasma
was first extracted before it was used in the radioirnrnunoassay. Briefly, rat plasma (1
ml) was mixed with 2 ml cold acetone (Spectranalyzed) and centrifuged at 2000 rpm,
4°C for 30 min.

The supernatant was then added to 5 ml cold petroleum ether and

mixed immediately. After centrifugation at 2000 rpm, 4°C for 15 min. the top layer
was aspirated and discarded. The remaining solution was dried by blowing air into the
tubes in ice.

The dried extract was then dissolved in 1 ml assay buffer (0.05 M

phosphate buffer pH 7.4, containing 0.125 % bovine serum albumin, 0.01 % sodium
azide, 0.001 M EDTA) and was used for the oxytocin radioirnrnunoassay.

This assay

is a double-antibody assay. The plasma extract (20 or 200 µl) and oxytocin standard
(0-1 ng) were incubated with 0.1 ml rabbit anti-oxytocin serum (1 :50,000 dilution) in
a total volume of 0.4 ml assay buffer for 24 hours at 4°C.
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1-oxytocin (3,000 cpm,
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0.1 ml) was then added to the tubes and incubated for 72 hours at 4°C. To the tubes
was then added 0.1 ml goat anti-rabbit )'-globulin (1: 12.5 dilution), followed by 0.1 ml
normal rabbit serum (1: 120 dilution). After incubation for 24 hours, the tubes were
centrifuged at 15,000 x g, at 4°C for 20 min. The supernatant was decanted and the
radioactivity of the pellet was counted for 5 min by a Micromedic 4/200 plus 'Y counter
and analyzed from the standard curve using the RIA-AID computer program (Robert
Maciel Associates, Arlington, MA).

The concentration of plasma oxytocin was

calculated with a correction factor based on the recovery of the extraction.

Radioligand binding assay
Homoi:enate radiolii:and bindint: assays for 5-HT1A receptors in hypothalamus,
midbrain and frontal cortex
Tissue preparation
Hypothalamic, midbrain and frontal cortical homogenates were prepared
according to the protocol of Leonhardt et al. (1992). Briefly, frozen tissues were
placed in a minimum of 25 volumes of ice cold 50 mM Tris-HCl (pH 7.7, 25°C)
containing 0.5 mM EDTA and 10 mM MgS04 and homogenized using a Tekmar
Tissumizer (2 x 5 sec). The homogenate was centrifuged at 37 ,000 x g for 15 min at
4°C. The pellet was resuspended in 30 volumes of buffer, homogenized, incubated at
37°C for 15 min and then centrifuged at 37 ,000 x g for 10 min. Tissue was then
washed and centrifuged once more. The tissue for 3H-paroxetine binding was washed
for 8 times to remove excess fluoxetine.

Finally, the pellet was resuspended to a

volume of 30 mg wet wt./ml in cold 50 mM Tris-HCl (pH 7.7) containing 0.5 mM
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EDTA and 10 mM MgS04 .

The protein concentration of the homogenate was

measured according to Lowry et al. ( 1951).

3H-8-0H-DPAT binding
The 3H-8-0H-DPAT binding assay was used to determine 5-HT 1A receptors in
the hypothalamus, midbrain and frontal cortex.

Briefly, hypothalamic (1.5 mg wet

tissue/tube), midbrain (3 mg wet tissue/tube) or frontal cortical (3 mg wet tissue/tube)
homogenates were incubated with 1 ml Tris buffer (50 mM, pH 7.7) containing 10 mM
MgS04 , 0.5 mM EDTA, 10 µM pargyline, 0.02% ascorbate acid and 3H-8-0H-DPAT
(159.5 Ci/mmol, 1 mCi/ml, New England Nuclear) in a concentration of 0.75-6.0 nM,
at room temperature for 1 hr. Non-specific binding was defined in the presence of 1

µM 8-0H-DPAT. The reaction was stopped by immediate filtration over Whatman
GF/C filters and washed three times with 5 ml of a 50 mM Tris buffer (pH 7.7). The
radioactivity of the filters was counted in 5 ml scintillation liquid at 56 % efficiency.
Scatchard analysis was applied for calculation of the Kd and Bmax of 3H-8-0H-DPAT
labelled 5-HT 1A receptors.
3H-5-HT binding for 5-HT A receptors
1
3H-5-HT was used to determine 5-HT A receptors in the frontal cortex. Briefly,
1
6 mg (wet wt.) of frontal cortex was incubated with 0.75 - 6.0 nM 3H-5-HT in 2 ml
50 mM Tris buffer (pH 7.7, 25°C), containing 10 mM MgS0 4 , 0.5 mM EDTA, 0.02%
ascorbate and 10 µM pargyline for 60 min at room temperature. Non-specific binding
was defined in the presence of 1µM8-0H-DPAT. The content of the assay tubes was
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filtered, washed and analyzed as described for the 3H-8-0H-DPAT binding assay.

3H-paroxetine binding for 5-HT uptake sites
A 3H-paroxetine saturation assay (Battaglia et al.1987) was used to examine 5HT uptake sites. The tissue homogenate was incubated for 30 minutes at 37°C and
further washed a 8 times in 40 volumes of Tris buffer (pH 7.7, 50 mM Tris, 120 mM
NaCl, 5 mM KCl), followed by centrifugation at 37,000 g at 4°C to wash out fluoxetine
and desipramine from the tissues. Preliminary data from our laboratory have indicated
that inadequate washes of the tissue resulted in an apparent increase in K0 for 3Hparoxetine binding, due to fluoxetine remaining bound to the tissue.

However,

following 8 washes, as described above, no significant differences were observed
between vehicle and fluoxetine pretreated rats.

After a final wash, the pellet was

resuspended to a volume of 30 mg wet wt/ml in 50 mM Tris buffer (pH 7. 7) containing
120 mM NaCl and 5 mM KCI. 3H-paroxetine (20.3 Ci/mmol, 1 mCi/ml, Du Pont
NEN, Boston, MA) in concentrations of 0.01-0.4 nM was incubated at room
temperature with midbrain homogenates (1.5 mg tissue/tube) in 5 ml of 50 mM Tris
buffer (pH 7.7), containing 120 mM NaCl and 5 mM KCl, at room temperature for 2
hrs.

Non-specific binding was defined in the presence of 1 µM citalopram.

The

reaction was stopped by immediate filtration over Whatman GF/C filters and the filters
were washed three times with 5 ml of a 50 mM Tris buffer (pH 7. 7). The radioactivity
of the filters was counted in 5 ml scintillation liquid at 56 % efficiency. The Bmax and
Kd of the 5-HT uptake sites were calculated using Scatchard analysis.
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Autoradiographic analysis of 3H-8-0H-DPAT binding

Procedure
The brains from the rats that received saline-challenge were cut into 15 µm
coronal sections using a cryostat at -21°C.

The sections were thaw-mounted on

chromalum/gelatin coated slides and stored at -20°C. Sections were collected from the
following levels: frontal cortex (Bregma +3.70 mm), medial hypothalamus (Bregma 1.80 mm), caudal hypothalamus (Bregma -3.14 mm) and midbrain (Bregma -7.8 mm)
according to the atlas of Paxinos & Watson (1986). Sections from these levels were
used for autoradiographic analysis.
The autoradiographic assay for 3H-8-0H-DPAT- labeled 5-HT1A receptors was
performed as described by Pazos and Palacios (1985). Briefly, after a preincubation
in the assay buffer (containing 0.17 M Tris, 4 mM CaCl, 10 µM pargyline and 0.01 %
ascorbic acid, pH 7.6), slide mounted sections were incubated with 3H-8-0H-DPAT (2
nM) at room temperature for 1 hour. This concentration of 3H-8-0H-DPAT is equal

to its Kd in hypothalamic homogenates (Li et al.1993b). Non-specific binding was
defined in presence of the 10-6M 5-HT. Gpp(NH)p-induced inhibition of 3H-8-0HDPAT binding was examined by incubating the slides in the presence of 10-5M
Gpp(NH)p. After washing the slides twice with Tris buffer at 4°C for 5 min, the slides
were dipped in cold H20 and then blow-dried immediately. They then were exposed
to tritium-sensitive Hyperfilm-3H for either 2 months or 2 weeks (for sections
containing a high density of the binding sites). A set of 3H microscales (Amersham)
was exposed to each film together with the slides to calibrate the optical density into
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fmol/mg tissue equivalent.
The films were developed by a Kodak developing procedure for X-ray films.
Films were placed in a Kodak Developer D-19 for 5 min, followed by 30 sec in Kodak
Indicator Stop Bath solution. Then, the films were transferred into Kodak Fixer for 5
min and subsequently placed in a running water bath for 10 min followed by 5 min in
a water bath containing Kodak Photo-Flo 200. The films were then air-dried.

Data analysis
Autoradiograms were analyzed densitometrically using the NIH image analysis
program for Macintosh computers. The gray scale density readings were calibrated to
fmol/mg tissue equivalent using the [3H]microscales.

Brain regions were identified

according to the atlas of Paxinos and Watson (1986), as shown in Fig.10. The layers
of the cortex were identified according to the atlas of Zilles ( 1985). The density of 3H8-0H-DPAT binding in each brain region was measured and expressed as fmol/mg
tissue equivalent. An area outside of the section was measured as the background of
the film, which was subtracted from each measurement in the section. Specific 3H-8OH-DPAT binding sites in each brain region were determined by subtracting the nonspecific binding sites from the total binding sites in each region.

The percent of

Gpp(NH)p-induced inhibition was calculated using the equation below:

fmol/mg tissue equivalentsp - fmol/mg tissue equivalentopp(NH)p
3 of inhibition x 100 %
fmol/mg tissue equivalentsp

In this equation, fmol/mg tissue equivalentsp represents the specific 3H-8-0H-DPAT
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binding in the absence of Gpp(NH)p; fmol/mg tissue equivalentapp(NH)p represents the
specific binding in the presence of Gpp(NH)p.
The data for a brain region of each rat represents the mean of four adjacent
brain sections.

Immunoblot analysis of G proteins
Membrane preparation

The membranes of the hypothalami, midbrains and frontal cortices were
prepared as described by Sternweis ( 1984) and Okuhara ( 1996). Briefly, the tissues
were homogenized in 1ml50 mM Tris buffer, pH 7.4 containing 150 mM NaCl, 10%
sucrose and 0.5 mM phenylmethanesulfonyl fluoride (PMSF; added immediately before
homogenization), using a Tekmar tissumizer at a speed of 13,500 rpm for about 10
seconds.

After centrifugation at 20,000 x g, 4°C for 60 minutes, pellets were re-

suspended in 50 µl (for the hypothalamus), or 200 µl (for the midbrain and frontal
cortex) of 20 mM Tris buffer, pH 8 containing 1 mM ethylenediamine tetraacetic acid
(EDTA), 100 mM NaCl, 1 % sodium cholate and 1 mM dithiothreitol to solubilize the
membrane proteins. The re-suspended homogenates were incubated and shaken at 4°C
for 1 hour, followed by centrifugation at 100,000 x g, 4°C for 60 minutes.
supernatants were used for G protein measurements.

The

Protein concentrations in the

supernatant were measured according to Lowry (1951) using bovine serum albumin as
a standard. The protein concentrations in the supernatant were: 1.7-2.2 µglµl for the
hypothalamus; 2.0-3.5 µglµl for the midbrain; and 1.6-2.3 µglµl for the frontal cortex.
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Quantification of G proteins
The solubilized proteins (10-35 µg protein) were resolved by SDSpolyacrylamide gel electrophoresis, using gels containing 0.1 3 sodium dodecyl sulfate
(SDS), 12% acrylamide/bisacrylamide (30:0.2), 4 M urea and 375 mM Tris, pH 8.4
(Mullaney and Miligan, 1990). Two samples from each treatment group (i.e. control,
fluoxetine 3 days, fluoxetine 7 days, etc.) were loaded on each gel. Each sample was
repeatedly

measured on three

independent gels.

The proteins were then

electrophoretically transferred to nitrocellulose membranes.

The membranes were

incubated in a solution containing 5 3 non-fat dry milk, 0.05 3 NP40, 50 mM Tris and
150 mM NaCl, pH7.4, and were then washed. The membranes were incubated with
polyclonal antisera for Gi1 12 (AS/7, 2500 dilution), Gi3 (Anti-GiaJ• 1:2000 dilution) and
G0 (GC/2, 1 :2000 dilution) at 4°C overnight. The membranes were then incubated with
a secondary antibody (goat anti-rabbit serum 1: 10,000) for 60 minutes. Following 4
washes with 0.05% NP40 in 50 mM Tris and 150 mM NaCl, the membranes were
incubated with rabbit peroxidase-antiperoxidase (1: 10,000) for 1 hour. After several
washes, the membranes were incubated with the chemiluminescence substrate solution
(LumiGlo) for 1 minute and then exposed to Kodak x-ray film for 10-40 seconds.

Data analysis
Films were analyzed densitometrically using the NIH image analysis program
for Macintosh computers.

The gray scale density readings were calibrated using

transmission step wedge standard (Stouffer Graphic Arts Equipment Co., South Baend,
IN). The integrated optical density (IOD) of each band was calculated as the sum of
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optical densities of all the pixels within the area of the band outlined. An area adjacent
to the G protein bands was used to calculate the background optical density of the film.
The IOD for the film background was subtracted from the IOD for each band. The
resulting IOD for each G protein band was then divided by the amount of protein
loaded on the corresponding lane. The IOD/ µg protein values obtained from treated
rats were divided by the mean IOD/ µg protein values obtained from control rats in
same gel to determine the relative amounts of the G proteins. The data for each rat
were the means obtained from the three gels. Samples from 6-8 rats were measured
for each treatment group.

Characterization of antisera

Recombinant mouse Gil• Gi2 , Gi3 and G0 standards (obtained from CalBiochem)
were used to identify the G protein bands and characterize the specificity of antisera.
As Fig.1 shows, Gil protein can be separated from Gi2 protein under our electrophoretic
conditions. Therefore, we were able to use an antiserum which recognizes both Gi 1 and
Gi2 proteins (AS/7), to measure these Gi proteins independently. Gi3 and G0 proteins
were not detected with the AS/7 antiserum. Anti Gi3 serum recognizes at least three
bands between 39-45 kd. The Gi3 standard co-migrated with the highest molecular
weight band. Therefore, we measured this band as the Gi3 protein. This Gi3 antibody
did not detect Gi 1 , Gi2 or G0 proteins.

GC/2, an anti G0 serum, was found to be

selective for G0 protein and did not detect Gil, Gi2 and Gi3 proteins (Fig. 1).
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Fi2ure 1. Characterization of antibodies against Gi., Gi2, Gu and G 0 proteins
used in immunoblots. The top panel demonstrates the specificity of AS/7 antibody for
the Gi 1 and Gil proteins : The lanes from left to right contain: recombinant Gi1 protein,
recombinant Gi 2 protein, recombinant Gi 1 plus Gi2 proteins, hypothalamic extract,
recombinant G0 protein, and recombinant Gi3 protein. The bottom panel demonstrates
the specificity of the UBI Gi3 antibody. The lanes from left to right contain:
recombinant Gi3 protein, hypothalamic extract plus recombinant Gi3 protein,
hypothalamic extract, recombinant G0 protein, recombinant Gil , and recombinant Gi2
protein.
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Statistics

The data from the hormone analyses were extrapolated from standard curves
using the RIA-AID computer program (Robert Maciel Associates, Arlington, MA).
The data are presented as group means and the standard errors of the means (S.E.M.).
The data from the hormone assays were analyzed by a two-way analysis of variance
(ANOVA) and the data obtained from radioligand binding for the density and affinity
of 5-HT1A receptors and 5-HT uptake sites or from immunoblots for G proteins were
analyzed by one-way ANOVA. Group means were compared by Newman-Keuls' or
Duncan's multiple range test as indicated in the text (Steel and Torrie, 1960).

A

computer program (NWA STATPAK, Portland,OR) was used for all the statistical
analyses.

CHAPTER IV
LONG-TERM FLUOXETINE, BUT NOT DESIPRAMINE, PRODUCES A
DESENSITIZATION OF HYPOTHALAMIC 5-HTIA RECEPTORS

Summary
The present studies determined whether the hypothalamic 5-HT 1A receptor
systems are modified by chronic exposure to antidepressants. Hormone responses to
the 5-HT 1A agonists 8-0H-DPAT and ipsapirone were used as marker to evaluated the
function of 5-HT1A receptors after long-term exposure to two antidepressants, the 5-HT
uptake inhibitor fluoxetine and the norepinephrine uptake inhibitor desipramine. In
addition, the effects of long-term exposure to fluoxetine and desipramine on the density
and affinity of 5-HT1A receptors in the hypothalamus, midbrain and cerebral cortex
were examined. Male rats received fluoxetine (10 mg/kg ip), desipramine (5 mg/kg
ip) or saline injections once daily for 21 days.

8-0H-DPAT (0-500 µg/kg sc), or

ipsapirone (0-5 mg/kg, ip) were administered 18 hours after the final antidepressant
injection and 15 minutes before sacrifice. 8-0H-DPAT and ipsapirone significantly
increased plasma ACTH, corticosterone and oxytocin concentration in a dose-dependent
manner.

Chronic injections of fluoxetine inhibited the ACTH, corticosterone and

oxytocin responses to 8-0H-DPAT or ipsapirone, suggesting reduced 5-HT1A receptor
function.

In contrast, chronic injections of desipramine did not alter the hormone
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responses to either 8-0H-DPAT or ipsapirone. The density and affinity of 5-HT1A
receptors in the frontal cortex or hypothalamus were not altered by either fluoxetine or
desipramine. However, a decrease in the Bmax of 5-HT1A receptors in the midbrain
was observed after chronic fluoxetine, but not desipramine. No change in the 5-HT
uptake sites was observed after either antidepressant.

To verify that the observed

effects require prolonged exposure to fluoxetine, rats received a single injection of
fluoxetine (10 mg/kg, ip), 3 hours before the injection of 8-0H-DPAT (0-500 µglkg
sc). Acute fluoxetine did not reduce any of the hormone responses to 8-0H-DPAT.
In conclusion, the results suggest that chronic, but not acute exposure to fluoxetine
produces a desensitization of hypothalamic 5-HT 1A receptors. This effect is not seen
in rats chronically exposed to desipramine. The mechanism of the effects of chronic
fluoxetine on 5-HT 1A receptor mediated hormone responses is not likely due to reduced
density of 5-HT1A receptors, because no changes were observed in 3H-8-0H-DPAT
binding in hypothalamus and cortex. It could be due to changes in signal transduction
system of 5-HT 1A receptors.

Furthermore, it can not be ruled out that fluoxetine

injections alter the density of 5-HT1A receptors in specific nuclei of the hypothalamus.
Introduction

The present studies examined hormone responses to two 5-HT1A agonists, 8-0HDPAT and ipsapirone, to assess the effect of two antidepressants, fluoxetine and
desipramine on 5-HT 1A receptor function. Several antidepressants are 5-HT uptake
inhibitors with lower affinity for norepinephrine or dopamine uptake sites (e. g
fluoxetine, sertraline, paroxetine) (Beasley et al.1992; Levy and Van de Kar, 1992;
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Perry and Fuller, 1992; Wong et al .1990; Bolden-Watson and Richelson, 1993; Fuller
et al.1991). Other antidepressants, such as desipramine, are norepinephrine uptake
inhibitors with low affinity for serotonin uptake sites (Richelson, 1991). Regardless of
the acute pharmacologic profiles of these antidepressants, the mechanisms of their
antidepressant effects remain unclear, particularly because they have to be administered
for at least 2-3 weeks before clinical improvement can be observed (Richelson, 1991).
Alterations in 5-HT IA receptors have been suggested to contribute to the clinical
improvement observed after long-term exposure to antidepressants (Lesch et al.1991c;
Meltzer, 1990; Richelson, 1991; Newman et al.1992; Stockmeier et al.1992).

To

determine whether changes in 5-HT1A receptor systems occur commonly after chronic
exposure to two classes of antidepressants, in the present study we compared the effect
of chronic fluoxetine and desipramine on the function of 5-HT1A receptors in the
hypothalamus.
Hormone responses to challenges with selective 5-HT agonists can be used as
indices of the function of serotonin receptors, both in humans and experimental animals
(Van de Kar, 1989). Activation of 5-HT1A receptors increases the secretion of ACTH,
corticosterone and oxytocin (Kelder and Ross, 1992; Van de Kar, 1991; Jorgensen et
al.1992; Van de Kar and Brownfield, 1993; Brownfield et al.1992). 8-0H-DPAT is
a selective 5-HT 1A agonist (Van Wijngaarden et al.1990; Hoyer and Schoeffter, 1991)
that has been shown to increase the secretion of oxytocin, ACTH and corticosterone by
activating 5-HT1A receptors (O'Donnell and Grealy, 1992; Calogero et al.1990; Fuller
and Snoddy, 1990; Bagdy et al. 1989; Calogero et al.1989; Koenig et al.1987; Gilbert
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et al.1988a; Vicentic et al.1996). Ipsapirone is a partial 5-HT IA agonist. Like 8-0HDPAT, ipsapirone increases ACTH, corticosterone and oxytocin secretion by activating
hypothalamic 5-HT,A receptors (Lesch et al.1991c; Cowen et al.1990; Gilbert et
al.1988a; Bagdy, 1995; Bagdy, 1994; Bagdy and Makara, 1994). However, the two
5-HT,A agonists have different chemical structures and thus, they may have different
side effects. Since ipsapirone and 8-0H-DPAT have a common pharmacological effect
on 5-HT 1A receptors, the common neuroendocrine profiles obtained with these two 5HT,A agonists are most likely mediated by activation of 5-HT1A receptors.
In the present studies, we examined the neuroendocrine responses to the 5-HT,A
agonists, 8-0H-DPAT and ipsapirone, after chronic exposure to fluoxetine or
desipramine.

To examine the mechanism of the changes in the 5-HT,A receptor

systems induced by the antidepressants, we also measured the affinity and density of
5-HT1A receptors in the hypothalamus, midbrain and cerebral cortex as well as the
affinity and density of 5-HT uptake sites. Furthermore, we compared the effects of
chronic fluoxetine on the hormone response to 8-0H-DPAT with that of acute treatment
with fluoxetine, to determine whether the effects of fluoxetine on the function of 5-HT,A
receptors require long-term treatment.

Experimental Protocol

The rats for the chronic experiment were pretreated with either fluoxetine ( 10
mg/kg ip), desipramine (5 mg/kg ip) or saline once daily for 21 days. These doses
were observed by de Montigny and Aghajanian (1978) to alter the response of rat
forebrain neurons to 5-HT. Furthermore, treatment with these doses has resulted in up-
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regulation of 5-HT2 receptors in the hypothalamus (Li et al.1993a). 8-0H-DPAT (50,
200, 500 µglkg sc), or ipsapirone ( 1, 2, 5 mg/kg ip) or saline were administered 18
hours after the last injection of the antidepressants.

The rats were sacrificed by

decapitation 15 minutes following injection of the 5-HT1A agonists or saline. Trunk
blood was collected in centrifuge tubes containing 0.5 ml of a 0.3 M EDTA (pH 7.4)
solution. The frontal cortex, hypothalamus and midbrain were dissected immediately
after decapitation and frozen in liquid nitrogen. Tissues were stored at -70°C until the
measurement of 5-HT1A receptors and 5-HT uptake sites. In the acute experiment, the
rats received a single dose of saline or fluoxetine (10 mg/kg ip) 3 hours before injection
of 8-0H-DPAT. The doses of 8-0H-DPAT in the acute experiment were the same as
those in the chronic experiment.
Plasma was stored at -70°C until assayed for plasma hormone levels. Plasma
ACTH,

corticosterone

and

oxytocin

concentrations

were

measured

by

radioimmunoassay (see Chapter III). The affinity and density of 5-HT1A receptors in
the hypothalamus, midbrain and frontal cortex were examined by 3H-8-0H-DPAT
binding or 3H-5-HT binding assays. In addition, affinity and density of 5-HT uptake
sites in the midbrain were determined by 3H-paroxetine binding (see Chapter Ill for
details).

Results
Both 8-0H-DPAT and ipsapirone increased plasma ACTH, corticosterone and
oxytocin concentrations in a dose-dependent manner (Fig. 2, 3, 5). Repeated injections
of fluoxetine, but not desipramine, significantly inhibited the 8-0H-DPAT-induced
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increase of plasma ACTH levels (Fig. 2). This inhibition was observed at the 50 µglkg
dose of 8-0H-DPAT in fluoxetine pretreated rats (Newman Keuls' test P < 0.01).
Consistent with the ACTH response to 8-0H-DPAT, chronic fluoxetine, but not
desipramine, inhibited the ipsapirone-induced increase of plasma ACTH concentration
(Fig. 2). Chronic fluoxetine significantly reduced the ACTH response to the 5 mg/kg
dose of ipsapirone (P < 0.01). A single injection of fluoxetine did not significantly
alter the ACTH response to 8-0H-DPAT (Fig. 4).
Similar to the ACTH response, chronic fluoxetine, but not desipramine, shifted
the corticosterone dose response curve of 8-0H-DPAT to the right, but did not change
the maximal response.

A significant inhibition of the corticosterone response by

chronic fluoxetine was observed at the lowest dose (50 µg/kg) of 8-0H-DPAT (P<
0.05, Newman Keuls' test, Fig. 3). Two-way ANOVA revealed no significant effect
of the antidepressants on the ipsapirone-induced increase of plasma corticosterone
concentration. However, a significant inhibition by fluoxetine was observed at the 2
mg/kg dose of ipsapirone (Duncan's multiple range test, P < 0.01). In contrast, a
single injection of fluoxetine potentiated the corticosterone response to the lowest dose
(50 µg/kg sc) of 8-0H-DPAT (Fig. 4). No significant difference was observed in the
corticosterone responses to any dose of ipsapirone after long-term treatment with
desipramine (Fig. 3).
Chronic fluoxetine, but not desipramine, inhibited the effect of 8-0H-DPAT on
oxytocin secretion as seen by a parallel right-shift in the dose response curves (Fig. 5).
The lower doses of 8-0H-DPAT (50 and 200 µglkg sc) produced significantly lower
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effects on plasma oxytocin in fluoxetine treated rats (Newman Keuls' test, P < 0.05).
Chronic fluoxetine, but not desipramine, also reduced the oxytocin responses to
ipsapirone. Two-way ANOVA showed a significant interaction between the effect of
the antidepressants and ipsapirone on plasma oxytocin concentration (F<6 .79i=3.062, P

< 0.01). Furthermore, Duncan's multiple range test indicated that chronic fluoxetine
significantly inhibited the effect of ipsapirone (5 mg/kg) on plasma oxytocin (P <
0.01). Chronic desipramine did not affect the ipsapirone-induced increase in plasma
oxytocin concentration. As can be seen in Figures 5, acute injection of fluoxetine did
not inhibit the oxytocin responses to the same doses of 8-0H-DPAT.
As can be seen in Table II, repeated injections of fluoxetine and desipramine did
not significantly alter the density of 5-HT1A receptors in the hypothalamus and frontal
cortex. However, chronic fluoxetine, but not desipramine, decreased the density of 3H8-0H-DPAT-labeled 5-HT 1A receptors in the midbrain.

Neither fluoxetine nor

desipramine altered the affinity of 3H-8-0H-DPAT binding in any brain region. Also,
long-term injections of the antidepressants did not change the density and affinity of 3Hparoxetine-labeled 5-HT uptake sites in the midbrain.
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Figure 2 Effect of chronic exposure to fluoxetine or desipramine on ACTH
responses to 8-0H-DPAT (top) or ipsapirone (bottom). The data represent mean±
S.E.M of eight to nine rats per group. Two way ANOVA: Main effect of
antidepressants: F<2 •80>=3.058, P<0.053(top); F<2•82>= 3.8664, P<0.05 (bottom); Main
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F<3 .82>=29.33 P<0.01 (bottom); Interaction between antidepressants and 5-HT agonists:
F<6 •80>=2.597 P<0.05 (top); F<6 .82>=2.6918 P<0.05 (bottom). *Significant difference
from the saline challenged group, P < 0. 01.
significant difference from the saline
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(Duncan's multiple range test).
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TABLE II

CHANGES IN BMAX OF 5-HT1A RECEPTORS INDUCED BY CHRONIC
EXPOSURE TO FLUOXETINE AND DESIPRAMINE

Bmax

(finol/Ing protein)

Saline

Fluoxetine

Desipramine

Hypothalainus

196.8 ± 21.89
(100%)

212.3 ± 29.6
(107.9%)

211.1 ± 21.9
(107.2%)

Midbrain

82.19 ± 3.95
(100%)

64.98 ± 2.71 *
(79.0%)

77.7 ± 3.23
(94.53)

Frontal cortex

160.3 ± 8.5
(100%)

150.7 ± 9.3
(93.7%)

155.1 ± 11.5
(96.7%)

158.0 ± 9.0
(100%)

134.8 ± 11.9
(85.3%)

149.0 ± 16.8
(94.3%)

650.3 ± 26.7
(100%)

640.2 ± 30.3
(98.4%)

615.2 ± 37.1
(94.63)

3ff-8-0H-DPAT binding

3H-5-HT binding

Frontal cortex
3H-naroxetine binding

Midbrain

The data represent Inean ± S.E.M of eight rats per group.
The nuinbers in parentheses indicate percent of the control group.
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TABLE III

CHRONIC FLUOXETINE OR DESIPRAMINE DOES NOT CHANGE THE
AFFINITY OF 5-HT 1A RECEPTORS AND 5-HT UPTAKE SITES

Kd
Saline

Fluoxetine

Desipramine

Hypothalamus

1.88 ± 0.2

2.39 ± 0.3

2.03 ± 0.3

Midbrain

1.32 ± 0.06

1.39 ± 0.12

1.56 ± 0.13

Frontal cortex

0.94 ± 0.1

0.87 ± 0.05

0.91 ± 0.04

2.0 ± 0.2

1.83 ± 0.12

1.73 ± 0.27

60.1± 2.5

72.0 ± 4.8

58.7 ± 4.0

3

H-8-0H-DPAT bindin2 (nM}

3

H-5-HT bindin2 (nM}

Frontal cortex
3

H-naroxetine bindin2 (,UM}

Midbrain

The data represent mean ± S.E.M of eight rats per group.
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Discussion
The present results suggest that chronic exposure to fluoxetine produces a
desensitization of hypothalamic 5-HT1A receptors. In contrast, chronic injections of
desipramine, or an acute injection of fluoxetine do not produce desensitization of the
5-HT1A receptors. These data suggest that the effects of chronic fluoxetine on the 5HT1A receptor systems are adaptive changes induced by chronic inhibition of 5-HT
uptake. Such reduction in the function of 5-HT1A receptors could be due to downregulation of 5-HT1A receptors. However, the inhibitory effects of chronic fluoxetine
on hormone responses to 5-HT iA agonists were not accompanied by a significant
reduction in the affinity or density of 5-HT1A receptors in the hypothalamus or frontal
cortex. These reduced hormone responses are due to unknown mechanisms, possibly
alterations in the signal transduction mechanisms, or in the second messenger systems
of 5-HT1A receptors. On the other hand, it cannot be ruled out that the desensitization
of 5-HT1A receptors induced by chronic fluoxetine is due to changes in the density of
5-HT1A receptors in specific hypothalamic nuclei, which cannot be detected by the
radioligand binding assay in homogenates.
8-0H-DPAT is a selective 5-HT 1A agonist with a high affinity for 5-HT1A
receptors (pKi = 8.7) (Hoyer and Schoeffter, 1991) and low affinity for other 5-HT
receptor subtypes (5-HTrn pKi = 5.75; 5-HT1c pKi = 5.1; 5-HT2 pKi < 5; 5-HT3 pKi

< 5; 5-HT uptake pKi = 6.25) (Van Wijngaarden et al.1990). Several studies have
demonstrated that 8-0H-DPAT increases the secretion of ACTH, corticosterone and
oxytocin by activating 5-HT1Areceptors (Cowen et al.1990; Gilbert et al.1988a; Koenig
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et al.1987; Bagdy and Kalogeras, 1993; Li et al.1993 b; Vicentic et al.1996).
Ipsapirone is a partial 5-HT1Aagonist. Like 8-0H-DPAT, ipsapirone increases ACTH,
corticosterone and oxytocin secretion by activating hypothalamic 5-HT iA receptors
(Lesch et al.1991c; Cowen et al.1990; Gilbert et al.1988a; Bagdy, 1995; Bagdy, 1994;
Bagdy and Makara, 1994). These two 5-HT1A agonists, ipsapirone and 8-0H-DPAT,
have a common pharmacological effect on 5-HT1Areceptors, despite different chemical
structures. Therefore, the common neuroendocrine profiles obtained with these two 5HT1A agonists are most likely mediated by activation of 5-HT1A receptors.

Our

observation that chronic exposure to fluoxetine inhibits the ACTH and corticosterone
responses to the 5-HT lA agonists is consistent with observations by Lesch et al. (Lesch
et al .1991 c). They reported that chronic exposure of humans to fluoxetine inhibited the
ACTH response to ipsapirone (Lesch et al.1991c). These results suggest that chronic
exposure to fluoxetine results in desensitization of 5-HT1Areceptors both in rats and in
humans.
In the present studies, the inhibitory effects of chronic fluoxetine on the oxytocin
and ACTH responses to ipsapirone were only observed at a dose of 5 mg/kg and were
not as clear as those observed with 8-0H-DPAT. This could be due to the relatively
low doses of ipsapirone used in the study. In addition, ipsapirone has a higher efficacy
for autoreceptors on the 5-HT neurons in the midbrain than for postsynaptic 5-HT1A
receptors in the forebrain (Aghajanian et al.1990; Sprouse and Aghajanian, 1988).
Since the regulation of hormones is mainly mediated by hypothalamic postsynaptic 5HT 1A receptors (Gilbert et al.1988b), it is possible that ipsapirone has lower efficacy
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than 8-0H-DPAT in stimulating hormone release.

Bagdy and Kalogeras (1993)

observed that plasma oxytocin concentrations were elevated to a higher level by 8-0HDPAT (0.2 mg/kg, iv) than by ipsapirone (2 mg/kg, iv). However, ipsapirone can be
administered to humans and although is not as useful as 8-0H-DPAT, a challenge with
ipsapirone still has diagnostic value to determine the function of the 5-HT1A receptor
system.
The present studies are the first to examine the influence of 5-HT1A receptors on
oxytocin secretion.

Our results show that 8-0H-DPAT dose-dependently increases

plasma oxytocin concentration. Note the similarities in the dose-response curves for
plasma ACTH and oxytocin concentrations. Considering the selectivity of 8-0H-DPAT
for 5-HT 1A receptors (Van Wijngaarden et al.1990), and the dose-dependent effect, the
data suggest that the 8-0H-DPAT-induced increase in oxytocin secretion is mediated
by 5-HT 1A receptors. Chronic fluoxetine, but not desipramine, produced an inhibition
as observed by a parallel shift to the right in the oxytocin dose-response curve. This
inhibition of the oxytocin response resembles the inhibition of the ACTH response to
8-0H-DPAT, supporting the hypothesis that alterations in 5-HT 1A receptor function
might be responsible for this phenomenon.
Since the 5-HT 1A agonist-induced hormone responses are directly mediated by
activation of cells in the hypothalamus, the lack of change in hypothalamic 5-HT 1A
receptors after chronic fluoxetine suggests that the decrease of hormone responses to
8-0H-DPAT by chronic fluoxetine is not due to a reduction in the density or affinity
of 5-HT 1A receptors. Alternatively, since we have measured receptors in the whole
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hypothalamus, there could be changes in specific nuclei in the hypothalamus or in other
brain regions which could be responsible for the altered hormone responses to 8-0HDPAT. Newman et al. (1992) showed that chronic injections of fluoxetine decreased
the function of 5-HT 1A receptor systems as measured by the 5-HT-induced inhibition
of forskolin-stimulated adenylyl cyclase activity in the hippocampus. Also, 5-HT1A
receptor-mediated hypothermia is decreased after long-term exposure to citalopram and
sertraline (Hensler et al.1991) or after electroconvulsive shocks (Stockmeier et al.1992).
These observations suggest that antidepressants produce functional changes in 5-HT 1A
receptors which are not due to alteration in ligand recognition sites. Thus, it is possible
that the desensitization of 5-HT1A receptors induced by chronic fluoxetine is due to a
dysfunction of the signal transduction system linked to 5-HT1A receptors in the
hypothalamus.
An alternative explanation would be that chronic fluoxetine reduces the content
of corticotropin releasing factor (CRF), ACTH or oxytocin. This is not likely because
chronic exposure to the same doses of fluoxetine and desipramine potentiated the ACTH
and oxytocin responses to DOI, a 5-HT2Aizc agonist (Li et al.1993a).

These data

suggest that the reduced hormone response to the 5-HT1A agonists is due to reduced 5HT tA receptor function rather than due to reduced hypothalamic or pituitary content of
releasing factors or hormones.
Although chronic exposure to fluoxetine did not alter the density of 5-HT1A
receptors in the hypothalamus and frontal cortex,

we observed a reduction of the

density of 5-HT1A receptors in the midbrain after repeated injections of fluoxetine.
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Since 5-HT neurons are located in the dorsal and median raphe nuclei in the midbrain,
the 3H-8-0H-DPAT-labeledreceptors in the midbrainprobably mainly represent 5-HT 1A
autoreceptors. Therefore, this result supports the hypothesis that blockade of 5-HT
uptake sites will desensitize 5-HT1A autoreceptors. These data are consistent with the
autoradiographic observations by Welner et al. (Welner et al.1989). However, several
other investigators did not observe changes in the 5-HT1A receptors in the raphe nuclei
(Le Poul et al.1995; Hensler et al.1991; Jo las et al.1994).

Most evidence suggests that hormone regulation is mediated by hypothalamic
postsynaptic 5-HT 1A receptors (Kelder and Ross, 1992; Gilbert et al.1988b).

For

example, depletion of 5-HT stores with PCPA does not reduce the ACTH response to
8-0H-DPAT (Gilbert et al.1988b). Therefore, the reduction in the density of 5-HT1A
receptors, in the midbrain might not be directly related to the inhibitory effect of
chronic fluoxetine on the hormone responses to 5-HT1A agonists. Neither fluoxetine nor
desipramine could alter the density and affinity 5-HT uptake sites in the midbrain,
suggesting that the 5-HT nerve terminals in the midbrain are intact. Therefore, the
reduction of 5-HT1A receptors in the midbrain, by fluoxetine, is not likely due to
neurotoxic effects of fluoxetine.

The lack of alterations in 5-HT uptake sites is

consistent with other reports (Cheetham et al.1993; Dewar et al.1993).
In conclusion, chronic exposure to fluoxetine resulted in a desensitization of
hypothalamic 5-HT 1A receptors.

This effect was not observed in rats chronically

injected with desipramine or in rats that received a single injection of fluoxetine. Also,
this effect was opposite from the effect that chronic fluoxetine has on 5-HT2A 12c receptor
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function.

The mechanism whereby chronic fluoxetine alters the 5-HT1A receptor-

mediated hormone responses is still unclear and it may result from changes in the signal
transduction or second messenger systems.

CHAPTER V
TIME-COURSE OF FLUOXETINE-INDUCED DESENSITIZATION OF
HYPOTHALAMIC 5-HT1A RECEPTORS

Summary
We examined the time-course of fluoxetine-induced desensitization of 5-HT1A
receptors in the hypothalamus. Our previous studies indicated that daily injections of
the 5-HT uptake inhibitor and antidepressant drug fluoxetine for 21 days produced
desensitization of hypothalamic 5-HT1A receptors, without altering their density or
affinity. This desensitization was evident from a reduced ability of the 5-HT1A agonist
8-0H-DPAT to elevate plasma levels of ACTH, corticosterone and oxytocin. In the
present study, we further studied the time-course of the desensitization of hypothalamic
5-HT 1A receptors induced by repeated injections of fluoxetine. To begin to examine the
mechanism of 5-HT1A receptor desensitization,

the density of 5-HT1A receptors in

specific hypothalamic nuclei was examined using autoradiographic analysis of 3H-8-0HDPAT binding. Furthermore, the coupling of 5-HT1A receptors to their G proteins was
studied by examining Gpp(NH)p-induced inhibition of 3H-8-0H-DPAT binding.
Finally, levels of Gi and G0 proteins in the hypothalamus, midbrain and frontal cortex
were determined using immunoblots. Daily injections of fluoxetine (10 mg/kg/day) for
3, 7, 14 or 22 days gradually shifted to the right the dose-response curve of the effects
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of 8-0H-DPAT on plasma ACTH, corticosterone and oxytocin. This was particularly
evident from the inhibition of the hormone responses to the low (50 µg/kg sc) dose of
8-0H-DPAT. Fluoxetine reduced the maximal elevation in plasma oxytocin but not
ACTH and corticosterone after injection of higher (200 and 500 µg/kg sc) doses of 80H-DPAT.

An examination of the time-course revealed a partial reduction of the

ACTH and oxytocin responses to 8-0H-DPAT (50 µg/kg sc) after 3 days and a
maximal reduction of all hormone responses after 14 days of fluoxetine injections.
After 14 days of fluoxetine, the ACTH and oxytocin responses to the 50 µg/kg dose of
8-0H-DPAT were virtually blocked. Repeated injections of fluoxetine did not alter the
density of 5-HT1A receptors and did not reduce their coupling to G proteins in any brain
region. This result suggests that the desensitization of 5-HT1A receptors induced by
repeated injections of fluoxetine is not due to changes in the density of 5-HT1A receptors
in the hypothalamus. On the other hand, the hypothalamic levels of Gil and Gi3 proteins
were significantly reduced after 7 and 14 days of fluoxetine injections. The levels of
G0 and Gi2 proteins in the midbrain were significantly decreased after 3 days and

remained reduced for the duration of fluoxetine injections. Fluoxetine did not reduce
the concentrations of Gi or G proteins in the frontal cortex at any time. The similarity
0

in time-course between fluoxetine-induced reductions in hormone responses to 8-0HDPAT and the reduction in hypothalamic levels of Gi 1 and Gi3 proteins suggests that the
reduction hypothalamic levels of Gi3 and/or Gi 1 proteins plays a role in the gradual
desensitization of 5-HT1A receptors induced by fluoxetine. Furthermore, the earlier
onset of decreased levels of G0 proteins in the midbrain may be involved in the reported
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desensitization of somatodendritic 5-HT1A autoreceptors in the raphe nuclei, after three
daily injections of fluoxetine (Le Poul et al.1995). In conclusion, repeated injections
of fluoxetine produce a delayed and gradual desensitization of hypothalamic 5-HT 1A
receptors. The mechanism of desensitization of hypothalamic 5-HT 1A receptors may
involve decreased levels of Gil and Gi3 proteins, but not a change in the density of 5HT IA receptors.

Introduction

Our previous studies demonstrated that daily injections of fluoxetine for three
weeks reduce the ACTH and oxytocin responses to two different 5-HT1A agonists, 80H-DPAT and ipsapirone. A single injection of fluoxetine did not inhibit the hormone
responses to 8-0H-DPAT.

These results suggest that adaptive mechanisms are

triggered by fluoxetine which lead to the desensitization of hypothalamic 5-HT1A
receptors. The present study was designed to determine the time-course of fluoxetineinduced desensitization of 5-HT1A receptor systems.

The desensitization of

hypothalamic 5-HT 1A receptors was determined functionally from the reduction in
hormone responses to the 5-HT1A agonist 8-0H-DPAT.
Because no changes were observed in the density and affinity of 3H-8-0HDPAT-labelled 5-HT 1A receptors in the hypothalamic homogenate, we hypothesized that
the desensitization of hypothalamic 5-HT 1A receptors may be due to alterations in their
signal transduction mechanisms, or due to changes in the density of 5-HT1A receptors
in specific hypothalamic nuclei. In the present study, we determined the time-course
of effect of fluoxetine on the G proteins that are coupled to 5-HT1A receptors and on
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the density of 5-HT1A receptors in hypothalamic nuclei and other brain regions. The
signal transduction of 5-HT1A receptors was evaluated by examining the levels of Gi and
G0 proteins which may be coupled to the 5-HT1A receptors. In addition, the degree of
Gpp(NH)p-induced inhibition of 3H-8-0H-DPAT binding was used to determine the
coupling of 5-HT 1A receptors to their G proteins. The density of 5-HT 1A receptors in
hypothalamic nuclei was examined by autoradiographic analysis of 3H-8-0H-DPAT
binding.
5-HT 1A receptors are G protein-coupled receptors.

According to the model

proposed by Lefkowitz et al. (1976), G protein-coupled receptors exist in high
(coupled) and low (uncoupled) affinity states with respect to agonists. In general, the
low affinity of agonists for the uncoupled state of receptors precludes labeling of these
receptors by radiolabeled agonists. The coupled receptor-G protein configuration only
exists while GDP is bound to the a-subunit of the G protein. In the presence of an
agonist, GDP will be exchanged with GTP on the a-subunit of G proteins, resulting in
dissociation of the G proteins from the receptors and a return of the receptors to the
low affinity-state. Gpp(NH)p is a non-hydrolyzable GTP analog, that binds irreversibly
to G proteins and dissociates them from their receptors.

In the case of 5-HT1A

receptors, in the presence of Gpp(NH)p, the high affinity-state 5-HT1A receptors will
be converted into the low-affinity state, resulting in inhibition of the binding of an
agonist, such as 8-0H-DPAT. Therefore, the percent inhibition of 3H-8-0H-DPAT
binding, in the presence of Gpp(NH)p, represents the percent of 5-HT1A receptors that
are coupled to their G proteins. In the present studies, we determined the degree of 5-
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HT IA receptors coupling in nuclei of the hypothalamus and in other brain regions by
examining the inhibition of 3H-8-0H-DPAT binding with Gpp(NH)p.
5-HT1A receptors are subclassified into somatodendritic and postsynaptic
receptors. Somatodendritic 5-HT1A autoreceptors are located on 5-HT neurons in the
raphe nuclei and function as feedback regulators of serotonergic neurotransmission.
Activation of 5-HT1A autoreceptors will inhibit the firing-rate of 5-HT neurons and
consequently, decrease 5-HT release from nerve terminals.

Postsynaptic 5-HT1A

receptors are distributed in most forebrain neurons. The function of postsynaptic 5HT1A receptors depends on the function of the target neurons. Activation of 5-HT1A
receptors in the hypothalamic paraventricular nucleus increases the secretion of
corticotropin releasing hormone (CRH), leading to increased release of ACTH and
corticosterone and also increases the secretion of oxytocin (Fletcher et al.1996;
Critchley et al.1994a; Van de Kar and Brownfield, 1993; Gilbert et al.1988a; Bagdy
and Makara, 1994; Bagdy and Kalogeras, 1993). Other physiological roles for 5-HT1A
receptors in this limbic brain area include food intake, mood changes and sexual
behaviors (Uphouse et al.1994b). Therefore, it is important to know the distribution
of 5-HT1A receptors in the different regions of the hypothalamus.

While

autoradiographic information exists on the distribution of 5-HT1A receptors in several
brain regions, little has been known regarding the distribution of 5-HT1A receptors in
nuclei of the hypothalamus. In the present study, we measured the effect of repeated
injections of fluoxetine on the density of 5-HT1A receptors in hypothalamic nuclei and
other brain regions using an autoradiographic analysis of 3H-8-0H-DP AT binding. This
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study not only investigated whether repeated injections of fluoxetine induce a downregulation of 5-HT1A receptors in specific hypothalamic nuclei, but also provided a map
of the distribution of 5-HT1A receptors in the hypothalamus and in several other brain
regions.
5-HT 1A receptors are coupled to G0 and/or Gi proteins (Raymond et al.1993;
Fargin et al.1991; Sprouse and Aghajanian, 1988; Emerit et al.1990). Somatodendritic
5-HT 1A autoreceptors in the raphe nuclei are coupled to G0 proteins, and lead to an
increase in the opening of K+ channels (Sprouse and Aghajanian, 1988). Activation of
5-HT 1A receptors that are coupled to Gi proteins will inhibit the activity of adenylyl
cyclase and, consequently, decrease the intracellular concentration of cAMP (Varrault
et al.1994). 5-HT 1A receptors have a high affinity for Gi proteins; the rank order of
affinity is Gi3 > Gi 1 > Gi2 > G0 proteins (Raymond et al.1993). In the present study,
the effects of repeated injections of fluoxetine on the levels of Gi 1, Gi2 , Gi3 and G0
proteins in the hypothalamus, midbrain and frontal cortex were examined using
immunoblot analysis.

Experimental Protocol

Rats received daily injections of fluoxetine ( 10 mg/kg, ip) for 3, 7, 14 or 22
days.

A control group received saline for 22 days.

Eighteen hours after the last

injection, the rats received a challenge injection of 8-0H-DPAT (0, 50, 200 or 500
µglkg, sc) and were decapitated 15 minutes after the injection of 8-0H-DPAT. Trunk

blood was collected in centrifuge tubes containing 0.5 ml of 0.3M ethylenediamine
tetraacetic acid (EDTA; pH 7.4). After centrifugation at 2,500 rpm, 4°C for 15 min,
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the plasma aliquots were stored at -70°C for hormone assays.

The brains were

collected for autoradiographic analysis of 3H-8-0H-DPAT binding or were dissected
and the hypothalami, midbrains and frontal cortices were stored at -7CJ'C for
immunoblot analysis of G proteins (see Chapter III for detail).
Plasma ACTH, corticosterone and oxytocin concentrations were measured by
radioimmunoassay as detailed in Chapter III.

Results
Hormone responses to 8-0H-DPAT
8-0H-DPAT increased plasma ACTH concentrations in a dose-dependent manner
(Fig. 6). The ACTH response to the 50 µg/kg dose of 8-0H-DPAT was significantly
decreased by repeated injections of fluoxetine (Top panel of Fig. 6). This reduction
appeared within 3 days (p < 0. 05) and reached a maximal reduction after 14 daily
injections of fluoxetine (p < 0. 01, bottom panel of Fig. 6). Also, fluoxetine injections
for 22 days significantly reduced the ACTH response to the higher dose (200 µg/kg sc)
of 8-0H-DPAT. However, repeated injections of fluoxetine did not alter the maximal
ACTH response to the highest dose of 8-0H-DPAT (500 µg/kg).
Consistent with the ACTH data, 8-0H-DPAT also increased plasma
corticosterone levels in a dose dependent manner (Fig. 7). The corticosterone response
to the 50 µg/kg dose of 8-0H-DPAT was not significantly reduced after 3 daily
injections but started to be significantly reduced after 7 daily injections of fluoxetine
(bottom panel of Fig. 7). The maximal corticosterone response to high doses of 8-0HDPAT was not influenced by repeated injections of fluoxetine.
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8-0H-DPAT significantly increased plasma concentrations of oxytocin in a dosedependent manner (Fig. 8). The dose-response curve of oxytocin was significantly
shifted to the right after 3 days of fluoxetine injections (Fig. 8, top panel).

The

reduction of the oxytocin response to the 50 µg/kg dose of 8-0H-DPAT was maximal
after 14 days of fluoxetine injections (Fig. 8 bottom panel). The oxytocin responses
to all three doses of 8-0H-DPAT were decreased by fluoxetine. However, the degree
of inhibition by fluoxetine was greater in the rats challenged with the 50 µg/kg dose of
8-0H-DPAT than in the rats that received higher doses (200 or 500 µg/kg) of 8-0HDPAT.
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Autoradiographic analysis of 3H-8-0H-DPAT binding

A high density of 5-HT1A receptors was observed in several nuclei of the
hypothalamus and amygdala as well as in the hippocampus, dorsal raphe nucleus and
in several layers of the frontal cortex (Figures 10 and 11). In the hypothalamus, the
density of 5-HT1A receptors was markedly different among several nuclei, with
differences of ten-fold between the highest and lowest densities in the regions measured
(Table IV and Fig. 10). For example, the density of 5-HT1A receptors in the lateral
hypothalamic area was 6.8

± 0.8 (fmol/mg tissue equivalent) while the density in the

central sub-division of the ventromedial nucleus was 62.8

±

4.1 (fmol/mg tissue

equivalent; p < 0.01). In the ventromedial nucleus, the central sub-division contained
the highest density of 5-HT1A receptors while the ventrolateral sub-division of the
ventromedial nucleus contained a significantly higher density of 5-HT 1A receptors than
the dorsomedial subdivision of the ventromedial nucleus (38.0 ± 2.0 vs 29.1 ± 2.7,
fmol/mg tissue equivalent; P<0.05; Table IV). The density of 5-HT 1A receptors in the
parvocellular sub-division of the paraventricular nucleus (14.0 ± 1.8 fmol/mg tissue
equivalent) was not significantly different from that in the magnocellular region (9.1

±

1.4; fmol/mg tissue equivalent; Table IV) but both were significantly higher than the
lateral hypothalamic area (p < 0.05).

The density of 5-HT1A receptors in the

dorsomedial hypothalamic nucleus was significantly higher than the density in the two
sub-divisions of the paraventricular nucleus. The lateral hypothalamic area contained
the lowest density of 5-HT1A receptors in the hypothalamus.
A very high density of 5-HT1A receptors was found in the hippocampal CAl and
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dentate gyms (Fig. 11 and Table IV), in the dorsal raphe nucleus, and layers 5 and 6
of the frontal cortex (Fig. 11 and Table IV). Great differences in density of 5-HT1A
receptors were observed in the amygdala. A low density of 5-HT1A receptors was
observed in the central amygdaloid nucleus (13.3 ± 2.3 fmol/mg tissue equivalent) and
the posterior part of the lateral amygdaloid nucleus (16.9

±

2.5 fmol/mg tissue

equivalent), while a high density was observed in the basomedial amygdaloid nucleus
(65.5

± 4.1

fmol/mg tissue equivalent). In the cortex, the lowest density of 5-HT 1A

receptors was observed in layers 1-3 of the parietal cortex, while high densities were
observed in layers 5 and 6 of the cingulate and frontal cortices (Table IV).
Table IV shows the effects of repeated injections of fluoxetine on specific 3H-80H-DPAT binding in several brain regions. No change was observed in the density
of 3H-8-0H-DPAT-labelled 5-HT 1A receptors binding sites in any brain regions after
daily injections of fluoxetine.
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Medial hypothalamus

Caudal hypothalamus

Fi1rnre 10. Autoradiogram of 3H-8-0H-DPAT binding and Gpp(NH)pinduced inhibition of 3H-8-0H-DPAT binding in the hypothalamus. Medial
hypothalamus (left column) and caudal hypothalamus (right column) were examined.
The top panel represents the total 3H-8-0H-DPAT binding; the middle panel represents
3
H-8-0H-DPAT binding in the presence of Gpp(NH)p (1Q-5M); the bottom panel
represents non-specific binding defined by 3H-8-0H-DPAT binding in the presence of
10-6M of 5-HT. Abbreviations: ABL: Basolateral amygdaloid nucleus; ABM:
Basomedial amygdaloid nucleus; AC: Central amygdaloid nucleus; AHN: Anterior
hypothalamic nucleus; ALP: Lateral amygdaloid nucleus, posterior region; AM: Medial
amygdaloid nucleus; CAl-3: Field CAl, CA2 and CA3 of ammon's horn in the
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hippocampus; DG: Dentate gyrus (hippocampus); DMH: Dorsomedial hypothalamic
nucleus; LH: Lateral hypothalamic area; PAR 1: Parietal cortex, area 1; PVNm:
Paraventricular hypothalamic nucleus, magnocellular region; PVNp: Paraventricular
hypothalamic nucleus, parvocellular region; VMHC: Ventromedial hypothalamic
nucleus, central region; VMHDM: Ventromedial hypothalamic nucleus, dorsomedial
region; VMHVL: Ventromedial hypothalamic nucleus, ventrolateral region
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Midbrain

Frontal cortex

Fi1:ure 11. Autoradiogram of 3H-8-0H-DPAT binding and Gpp(NH)pinduced inhibition of 3H-8-0H-DPAT binding in the midbrain (left column) and
frontal cortex (right column). The top panel represents the total 3H-8-0H-DPAT
binding; the middle panel represents 3H-8-0H-DPAT binding in the presence of
Gpp(NH)p (1Q-5M); the bottom panel represents non-specific binding defined by 3H-80H-DPAT binding in the presence of 10-6M of 5-HT. Abbreviations: CG3:Cingulate
cortex, area 3; DR:Dorsal raphe; Fr2:Frontal cortex, area 2; MR:Medial raphe
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Table IV
REPEATED INJECTIONS OF FLUOXETINE DO NOT ALTER THE
DENSITY OF 5-HT1A RECEPTORS
Density of 3H-8-0H-DPAT - labeled 5-HT1A receptors
(fmol/mg tissue equivalent)
Brain regions
Cortex
Fr2

Nuclei

Saline

3 days

7 days

14 days

22 days

layer 1-3 26.2± 1.3 25.0± 1.5 25.0±2.5 25.2±1.9 26.8±2.5
layer 5

79.3±4.5 78.4±4.7 79.6±4.2 77.9±3.5 84.6±4.0

layer 6

64.1±4.7 61.8±5.4 64.9±4.4 62.3±3.8 68.7±4.4

--------------------------- ~------------------------------------------------------CG3

layer 1-3 44.3 ±5.8 41.1 ±5.4 42.4±5.3 42.2±3.4 48.5±2.5
layer 5
layer 6

--------------------------PARl

65.3±6.7 65.8±8.2 65.9±7.2 65.4±5.1 70.2±3.4
57.4±5.1 57.2±7.0 58.1±5.81 57.4±3.4 61.7±3.7
~----------------------------------------------------

layer 1-3 13.5±2.0 14.7±1.8 13.6± 1.8
layer 4

16.2±1.1 15.0± 1.6

28.8± 1.3 26.9±2.2 28.1±1.8 29.5±3.0 31.0±2.0

layer 5-6 46.5±2.0 42.4±3.1 42.6±3.3 42.9±5.2 46.5±2.9

Hypothalamus

Amygdala

PVNm
PVNp
AHN
LH
VMHDM
VMHC
VMHVL
DMH
AC
APL
ABL
ABM
AM

9.1±1.4

8.0±1.0

10.4± 1.4

14.0± 1.8 14.2±1.1 16.5±1.6

9.6±1.4

10.9±1.3

15.2±1.1 15.8± 1.2

18.5±2.0 18.6±0.9 20.8±1.9 20.5±1.5 21.3±1.3
6.8±0.8

6.1±0.7

6.5±1.1

6.3±0.4

7.2±0.7

29.1±2.7 24.1±1.1 28.7±1.8 28.2±2.1 27.7±1.3
62.8±3.6 54.9±5.3 58.0±3.7 57.3±7.0 54.3±3.6
38.0±2.0 32.3±3.4 33.5±1.7 34.5±3.8 31.1±2.9
22.4±2.6 19.7±2.1 21.1±1.0

18.4±0.8 18.1±1.1

13.3±2.3 13.2±1.9 13.3±2.5

14.7±1.6 14.7±1.9

16.9±2.5 16.8±1.4 16.5±2.3

16.9±1.7 17.8±2.9

32.2±3.2 28.2± 1.1 31.7±1.4 29.1±2.0 31.1±3.1
65.5±4.1 57.3±4.5 65.3 ±3.3

61.1±6.5 62.5±4.3

39.4±2.1 36.0±2.2 41.1±1.9 38.0±4.2 38.3±2.4
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TABLE IV-Continued
Density of 3H-8-0H-DPAT - labeled 5-HTlA receptors
(fmol/mg tissue equivalent)
Brain regions

Nuclei

Hippocampus

CAl

103.6±7.1104.5±6.4 114.6±8.2 114.9±8.4 117.6±5.8

CA2

19.5±1.3 19.0±1.0 19.9±1.3 22.4±2.3 19.5±1.7

CA3

49.0±3.0 44.9±5.5 51.3±3.7 47.9±6.0 48.2±5.2

DG

126.4±9.7 127.0±6.7 135.1±8.2129.2±7.2133.8±4.5

DR

79.2±5.5 59.6±8.3 79.7±4.3 66.0±6.8 80.1±4.9

MR

35.5±3.9 25.9±3.9 35.4±3.4 23.3 ±3.0 24.1±3.8

Mid brain

Saline

3 days

7 days

14 days

22 days

The data represent mean ± S.E.M. of 5-6 rats per group.
ABL:
ABM:

AC:
AHN:
ALP:
AM:
CAl-3:
CG3:
DG:
DMH:
DR:
Fr2:
LH:
MR:
PAR 1:
PVNm:
PVNp:
VMHC:
VMHDM:
VMHVL:

Basolateral amygdaloid nucleus
Basomedial amygdaloid nucleus
Central amygdaloid nucleus
Anterior hypothalamic nucleus
Lateral amygdaloid nucleus, posterior region
Medial amygdaloid nucleus
Field CAl, CA2 and CA3 of ammon's horn in the hippocampus
Cingulate cortex, area 3.
Dentate gyms (hippocampus)
Dorsomedial hypothalamic nucleus
Dorsal raphe
Frontal cortex, area 2
Lateral hypothalamic area
Medial raphe
Parietal cortex, area 1
Paraventricular hypothalamic nucleus, magnocellular region
Paraventricular hypothalamic nucleus, parvocellular region
Ventromedial hypothalamic nucleus, central region
Ventromedial hypothalamic nucleus, dorsomedial region
Ventromedial hypothalamic nucleus, ventrolateral region
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Gpp(NH)p-induced inhibition of 3H-8-0H-DPAT binding

Gpp(NH)p inhibited 3H-8-0H-DPAT binding in all brain regions examined
(Figures 10 and 11). However, the degree of inhibition varied from 143 to 853
between several brain regions (Fig. 12).

For example, Gpp(NH)p produced 853

inhibition of 3H-8-0H-DPAT binding in the central nucleus of the amygdala, but only
173 inhibition in the dorsal raphe nucleus (Fig 12). In the hypothalamus, the greatest
inhibition was observed in the dorsomedial nucleus (61 3), while the lowest degree of
inhibition was observed in the central sub-division of the ventromedial nucleus (143;
see Fig. 12). In the paraventricular nucleus, a greater inhibition was observed in the
parvocellular sub-division (41 %) than in the magnocellular sub-division (20. 7 %)
(Fig.10, 12).
As Table V shows, fluoxetine did not alter the Gpp(NH)p-induced inhibition of
3

H-8-0H-DPAT binding in any brain region after the daily injections.
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Figure 12. Degree of Gpp(NH)p-induced inhibition of 3H-8-0H-DPAT
binding varies between brain regions. The data are represented as mean ± S.E.M.
The abbreviations are the same as listed in Table V.
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TABLE V
REPEATED INJECTIONS OF FLUOXETINE DO NOT ALTER THE PERCENT
OF G PROTEIN - LINKED 5-HT1A RECEPTORS

Brain regions

Nuclei

% Gpp(NH)p-induced inhibition of 3H-8-0H-DPAT

Saline

3 days

7 days

14 days

22 days

Cortex
Fr2

layer 1-3 35.8±3.5 33.7±6.7 34.3±5.8 33.4±7.1 31.8±3.3
layer 5

21.2±2.1 20.8±4.5 15.3±3.8 22.1±2.9 25.4±4.7

24.2±2.2 18.6±3.8 17.3±3.6 24.1±2.2 28.2±5.3
------------------~'!Y-~E-~- ~-------------------------------------------------------CG3

layer 1-3 31.1 ±2.2 25.3±0.7 18.6±5.8 32.5±7.7 35.2±7.0
layer 5

------------------~'!Y-~E-~PAR 1

30.0±2.0 25.6±3.1 21.2±5.0 34.4±3.9 35.7±3.1
21.3±2.6 21.2±3.2 19.4±5.8 27.5±3.0 32.6±3.0

~------------------------------------------------------

layer 1-3 42.9±7.6 50.7±6.7 40.2±6.4 49.0±4.3 46.7±4.9
layer 4

34.7±4.8 35.7±2.0 28.4±2.1

33.5±3.3 38.7±3.5

layer 5-6 34.3±4.5 35.8±2.6 27.9±2.8 29.0±4.8 36.8±3.6
Hypothalamus PVNm

41.0±7.7 32.7±8.3 42.7±8.2 28.4±8.1 33.1 ±8.2

PVNp

20.7±7.7 27.3±5.8 31.0±5.7 30.7±6.5 33.5±4.6

AHN

19.1±7.4 30.4±4.7 29.4±4.8 33.6±4.8 32.6±4.2

LH

22.6±5.6 30.7±7.6 31.3±4.7 36.2±7.4 41.4±5.9

VMHDM 25.0±3.9 26.2±4.1 21.1 ±4.5 26.6±4.8 18.3±1.3
VMHC

14.3±5.5 27.7±5.6 19.0±4.7 17.4±7.3 16.3±4.8

VMHVL 35.6±4.8 40.7±5.5 37.8±5.7 36.7 ±5.8 35.6±5.4
Amygdala

DMH

61.4+5.6 61.0+3.0 57.7+5.2 56.2+2.8 52.4±2.3

AC

85.5±3.5 85.0±1.3 85.4± 1.9 88.2±0.7 85.0±0.9

ALP

54.1±3.5 56.9±1.9 59.2±3.8 66.0±3.8 54.2±2.7

ABL

44.8±3.6 44.4±5.4 46.0±4.7 42.8±2.5 40.1 ±5.4

ABM

28.4±3.1 31.9±4.3 33.7±2.9 27.6±6.1 32.6±2.8

AM

30.0+5.1 36.2+4.9 35.9+4.9 31.3±6.4 33.5+4.4
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TABLE V-continued
Brain regions

Nuclei

% Gpp(NH)p-induced inhibition of 3H-8-0H-DPAT

Saline
Hippocampus

Midb rain

3 days

7 days

14 days

22 days

CAI

20.0±4.0 I2.8±6.0 I7.I ±2.8

CA2

39.6±3.8 39.I±4.I 38.4±4.2 35.4±6.0 41.0±5.6

CA3

23.6±4.7 28.I ±5.I 25.4±6.8 23. I ±6.2 35.8±5.5

DG

21.0±1.7 20.6±3.6 23.5 ±5.3 20.7±4.5 31.0±3.3

DR

I7.4±4.3

MR

43.7+4.9 47.7+4.5 55.4+3.3 34.2+2.3 38.6+5.5

13.8±2.2 22.2±3.6

I2.6±7.4 21.3±4.I 26.9±2.4 25.6±3.8

The data represent mean ± S.E.M. of 5-6 rats per group.
ABL:
ABM:

AC:
AHN:
ALP:
AM:
CAI-3:
CG3:
DG:
DMH:
DR:
Fr2:
LH:
MR:
PAR 1:
PVNm:
PVNp:
VMHC:
VMHDM:
VMHVL:

Basolateral amygdaloid nucleus
Basomedial amygdaloid nucleus
Central amygdaloid nucleus
Anterior hypothalamic nucleus
Lateral amygdaloid nucleus, posterior region
Medial amygdaloid nucleus
Field CAI, CA2 and CA3 of ammon' s horn in the hippocampus
Cingulate cortex, area 3.
Dentate gyms (hippocampus)
Dorsomedial hypothalamic nucleus
Dorsal raphe
Frontal cortex, area 2
Lateral hypothalamic area
Medial raphe
Parietal cortex, area I
Paraventricular hypothalamic nucleus, magnocellular region
Paraventricular hypothalamic nucleus, parvocellular region
Ventromedial hypothalamic nucleus, central region
Ventromedial hypothalamic nucleus, dorsomedial region
Ventromedial hypothalamic nucleus, ventrolateral region
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G,, subunits in hypothalamus, midbrain and frontal cortex

The G protein a-subunits Gil• Gi2 , Gi3 and G0 were examined in the
hypothalamus, midbrain and frontal cortex using immunoblots.

Figure 13 presents

examples of Gi 1 , Gi2 and Gi3 proteins in the hypothalamus and midbrain. The levels of
Gi1 and Gi3 proteins were significantly decreased in the hypothalamus of rats that

received injections of fluoxetine for 7 and 14 days (Fig. 14A, 14C). The level of G0
proteins in hypothalamus was only significantly reduced in rats that received fluoxetine
injections for 7 days (Fig. 14D). The level of Gi2 proteins in the hypothalami of rats
that received injections of fluoxetine was not significantly different from those that
received injections of saline (Fig 14B).

The levels of G0 and Gi2 proteins in the

midbrain were significantly decreased after 3 days of fluoxetine injections and remained
below control levels for the duration of fluoxetine exposure (Fig. 15). The levels of
Gi 1 and Gi3 proteins in the midbrain were not significantly reduced by injections of

fluoxetine (Fig. 15). Gi or G 0 protein levels were not reduced in the frontal cortex of
rats that received injections of fluoxetine (Table VI).
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Hypothalamus

AS/7
Hypothalamus

AntiG; 3
Mid brain

GC/2

- Ga
Veh

3

7

14

22

Days of fluoxetine (10 mg/kg . ip)

Fia=ure 13. Example of immunoblots of G proteins in brain regions from rats
that received daily injections of fluoxetine. Top panel: Gi 1 and Gi2 proteins in the
hypothalamus; middle panel: Gi3 proteins in the hypothalamus; bottom panel: G0
proteins in the midbrain. The lanes from left to right contain membrane extracts from
brain regions of rats that received: vehicle, fluoxetine for 3 days, fluoxetine for 7 days,
fluoxetine for 14 days and fluoxetine for 22 days.
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Figure 14. Fluoxetine reduces the levels of G proteins in the
hypothalamus. The data represent mean ± S.E.M. of 6-8 rats per group. A.
Level ofGi 1 proteins, One way ANOVA: F<4 • 31 >=3.197, P<0.05 B. Level ofGi2
proteins. One way ANOVA: F<4 . 33>=0.4276, NS. C. Level of Gi3 proteins. One
way ANOVA: F<4 • 33> = 2.8079; P < 0.05. D. Level of G0 proteins. One way
ANOVA: F<4 • 35>=5.316, P<0.01.
* Significant difference from the vehicle group, P <0.05 (Duncan's multiple range
test)
NS: No significant difference from the vehicle group.
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Figure 15. Fluoxetine reduces the levels of G proteins in the midbrain.
The data represent mean ± S.E.M. of 6-8 rats per group. A. Level of Gi 1 proteins,
One way ANOVA: Fc4 • 35>=0.9818, NS; B. Level of Gi2 proteins. One way
ANOVA: Fc4 .31)=2.827, P=0.05 . C. Level of Gi3 proteins. One way ANOVA: Fc4 •
> = 1.1669; NS . D. Level of G0 proteins. One way ANOVA: F<4 . 34>=6.56,
35
P<0.01.
*Significant difference from the vehicle group, P<0.05 (Newman Keuls' multiple
range test).
NS: No significant difference from the vehicle group.
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TABLE VI

DAILY INJECTIONS OF FLUOXETINE DO NOT ALTER LEVELS OF GPROTEINS IN THE FRONTAL CORTEX

Saline

3 Days

7 Days

14 Days

22 Days

Gi1

93.1 ± 9.9

117.6±10.0 113.3±10.4 118.1±15.1

113.1±12.7

Gi2

102.4±10.6

99.5±10.5

123.7±21.1

94.7±11.1

128.1±26.3

Gi3

101.8± 5.5

120.8±16.0 157.5±28.1

133.9±22.6

133.9±26.0

Go

99.8± 6.4

99.6±12.0

102.2± 9.4

110.7±18.7

85.9± 9.4

The data represent means ± S.E.M. of the a subunits, expressed as % of the
integrated optical density of the immunoblots/ µg protein. The data were obtained
from 6-8 rats per group.

110

Discussion
The present results indicate that repeated injections of fluoxetine produce a
delayed and gradual desensitization of hypothalamic 5-HT 1A receptors.

This

desensitization is unlikely due to down-regulation of 5-HT 1A receptors in the
hypothalamus or due to changes in the coupling of 5-HT1Areceptors to their G proteins.
The results of the present study demonstrate a similarity in time-course between the
fluoxetine-induced reduction in hypothalamic levels of Gi proteins and the fluoxetineinduced inhibition of neuroendocrine responses to a challenge with the 5-HT,A agonist
8-0H-DPAT. This similarity in time-courses suggests that hypothalamic Gil or Gi3
proteins may play a role in fluoxetine-induced desensitization of hypothalamic 5-HT 1A
receptors.

The delay in desensitization of hypothalamic 5-HT tA receptors might

underlie the delayed onset of therapeutic effects of fluoxetine and other 5-HT uptake
inhibitors.

Hormone responses to 8-0H-DPAT
We used the changes in magnitude of elevation of plasma levels of ACTH,
corticosterone and oxytocin, after injection of several doses of 8-0H-DPAT, as
indicators of desensitization of hypothalamic 5-HT1A receptors. 8-0H-DPAT increases
plasma ACTH, corticosterone and oxytocin concentrations by activating hypothalamic
5-HT 1A receptors.

The ACTH and corticosterone responses to 8-0H-DPAT can be

inhibited by the 5-HT 1A antagonists pindolol, spiperone, or WAY-100635 (Pan and
Gilbert, 1992; Gilbert et al.1988a; Critchley et al.1994a; Koenig et al.1987;
Przegalinski et al.1989) and the oxytocin responses to 8-0H-DPAT also can be
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inhibited by NAN-190 and pindolol (Bagdy and Kalogeras, 1993). We have recently
observed that the 5-HT1A antagonist WAY-100635 (1 mg/kg, sc) blocks the effects of
8-0H-DPAT (50 µg/kg, sc) on plasma levels of ACTH, corticosterone and oxytocin
(Vicentic et al.1996). The location of the 5-HT1A receptors that stimulate the secretion
of ACTH and oxytocin is likely in the hypothalamic paraventricular nucleus because
injection of pindolol into the hypothalamic paraventricular nucleus inhibits the ACTH
response to injection of 8-0H-DPAT into the same site (Pan and Gilbert, 1992).
Mechanical destruction of the hypothalamic paraventricular nucleus also inhibits the
ACTH, corticosterone and oxytocin responses to ipsapirone, a partial 5-HT 1A agonist
(Bagdy and Makara, 1994). These data suggest that the ACTH and oxytocin responses
to 8-0H-DPAT are mediated by hypothalamic 5-HT1A receptors and can be used as
markers for the functional status of hypothalamic 5-HT lA receptor systems.
The present observations of fluoxetine-induced desensitization of hypothalamic
5-HT1A receptors are consistent with our previous observations (Chapter IV), that daily
injections of fluoxetine for 21 days produce a shift to the right in the dose-response
effects of 8-0H-DPAT on plasma ACTH, corticosterone and oxytocin. In the present
study, we further demonstrated that the desensitization of hypothalamic 5-HT IA
receptors require at least 3 days of injections of fluoxetine. This delayed desensitization
of hypothalamic 5-HT 1A receptors resembles the therapeutic delay seen in clinical
studies and is different from the rapid desensitization (less than 24 hours) after a single
injection of 8-0H-DPAT and other 5-HT 1A agonists (Kelder and Ross, 1992). The
difference between the SSRI's and the 5-HT 1A agonists could be due to the fact that 5-
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HT 1A agonists can immediately and directly activate post-synaptic 5-HT 1A receptors.
In contrast, 5-HT uptake inhibitors need to overcome the inhibitory influence of
somatodendritic 5-HT 1A autoreceptors before they can induce an increase in the synaptic
concentration of 5-HT in the hypothalamus, which in tum can activate post-synaptic 5HT 1A receptors.

Therefore, the present results support the hypothesis that

somatodendritic 5-HT 1A receptors play a role in the delayed clinical improvement after
onset of treatment with 5-HT uptake inhibitors.
A difference was observed between the effect of fluoxetine on ACTH and
oxytocin responses to 8-0H-DPAT.

ACTH showed no reduction in the maximal

response to 8-0H-DPAT while oxytocin showed a reduction in the maximal responses
to 8-0H-DPAT. This difference can be explained by the fact that a larger receptor
reserve exists for the 5-HT 1A receptor-mediated ACTH and corticosterone responses,
than for the oxytocin response to 8-0H-DPAT (Meller and Bohmaker, 1994; Pinto et
al.1994).
Autoradiogram of 3H-8-0H-DPAT binding

The present studies provide autoradiographic data on the distribution of 5-HT 1A
receptors in sub-regions of hypothalamic nuclei.

While several studies have used

autoradiographic analyses to examine other regions in the brain (Khawaja, 1995; Le
Poul et al.1995), few studies have examined the hypothalamus in the detail reported
herein. In studies from other laboratories, only a few nuclei were examined (Frankfurt
et al.1994; Hensler et al.1991; Pompeiano et al.1992; Palacios et al.1987). In the
present study, several sub-divisions of hypothalamic nuclei were examined. The highest
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density of 5-HT1A receptors in the hypothalamus was found in the ventromedial nucleus
(VMH). This observation is in agreement with studies using an antibody against the 5HT tA receptor, autoradiography or in situ hybridization for the mRN A coding for this
receptor, (Wright et al.1995; Kia et al.1996; Frankfurt et al.1994; Hensler et al.1991;
Frankfurt et al.1993). Differences in the density of 5-HT1A receptors in the three subdivisions of the VMH (central, dorsomedial and ventrolateral) may be related to the
differences between males and females in the interaction between 5-HT 1A receptors and
gonadal steroids with respect to sexual behavior (Uphouse et al.1994a; Uphouse et
al.1994b; Coirini et al.1992; Mendelson and Gorzalka, 1986). Physiological studies
indicate that activation of 5-HT1A receptors on neurons in the VMH activates their
potassium conductance (Newberry, 1992).
The density of 5-HT 1A receptors in the paraventricular nucleus (PVN) was lower
than that in the surrounding tissue. The PVN can be roughly divided into parvocellular
and magnocellular sub-regions. The parvocellular cells secrete corticotropin releasing
hormone (CRH), which then stimulates the secretion of ACTH from the anterior
pituitary gland. Serotonergic nerve terminals make direct synaptic contact with these
CRH cells (Liposits et al.1987). There are more serotonergic terminals innervating
parvocellular CRH cells than magnocellular cells. Furthermore, oxytocin containing
cells receive a higher innervation than vasopressin containing cells (Sawchenko et
al.1983). Parvocellular cells in the PVN contain a higher density of 5-HT 1A receptors
than magnocellular cells which contain oxytocin and vasopressin. Activation of 5-HT 1A
receptors can stimulate the secretion of ACTH and oxytocin, but not vasopressin
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(Bagdy and Kalogeras, 1993; Li et al.1993b; Van de Kar and Brownfield, 1993;
Vicentic et al.1996). Thus, the observation of a very low density of 5-HT1A receptors
in the magnocellular cells in the lateral wing of the PVN is in agreement with the
neuroendocrine data.
In addition to the hypothalamus, we determined the distribution of 5-HT1A
receptors in nuclei of the amygdala, regions in the hippocampus, raphe nuclei and
several cortical areas and layers.

Neurons in the amygdala are involved in mood

changes (Deakin, 1996; Handley, 1995; Adolphs et al.1994). Also, the central nucleus
of the amygdala and hypothalamic paraventricular nucleus receive collateral projections
from the dorsal raphe nucleus (Petrov et al.1994). It is possible that 5-HT uptake
inhibitors might also influence 5-HT 1A receptors in the amygdala. Therefore, it was
interesting to know whether repeated injections of fluoxetine would alter the density of
5-HT 1A receptors and their coupling to G proteins.

The hippocampus contains a very

high density of 5-HT1A receptors (Khawaja, 1995; Le Poul et al.1995).

Several

investigators studied the effects of long-term administration of 5-HT uptake inhibitors
on the hippocampal 5-HT1A receptors (Klimek et al.1994; Newman et al.1992; Hensler
et al.1991).

With respect to the relative distribution of 5-HT1A receptors in

hippocampal CAI, CA2 and CA3 regions, our results agree with those of other
investigators (Khawaja, 1995). The cortex was also used as a standard for comparison
because it has been studied extensively (Burnet et al.1994; Burnet et al.1995; Fanelli
and Mcmonagle-Strucko, 1992). The cortex receives a different pattern of serotonergic
inputs than the hypothalamus (Van Bockstaele et al.1993; Petrov et al.1992; Reichling
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and Basbaum, 1991). This could mean that fluoxetine might not have the same effects
on the cortex and hypothalamus.

In the present studies, the cortex was used as a

control to test the region-selectivity of the effect of 5-HT uptake inhibitors on 5-HT1A
receptors and for comparison with other studies. The 5-HT 1A receptors in the dorsal
and median raphe nuclei are known as somatodendritic autoreceptors, involved in autoinhibition of the firing of serotonergic neurons. Neurons both in the dorsal and median
raphe nuclei innervate the hypothalamus. Because changes in the release of 5-HT in
the hypothalamus are dependent on somatodendritic 5-HT1A autoreceptors, we included
the dorsal and median raphe in the autoradiographic analysis of the distribution of 5HT tA receptors.
The present data suggest that fluoxetine-induced desensitization of 5-HT1A
receptors is not due to a reduction in the density of 5-HT1A receptors in the PVN. This
is consistent with our previous results indicating that chronic injections of fluoxetine do
not alter the density or affinity of 5-HT1A receptors in whole hypothalamic homogenates
(Li et al.1994). Furthermore, the lack of changes in the density of 5-HT1A receptors
in other brain regions is consistent with several investigations from other laboratories
(Le Poul et al.1995; Hensler et al.1991).

In the present study, we did not observe reductions in 3H-8-0H-DPAT labeled
5-HT 1A receptors in either the dorsal raphe or median raphe nuclei.

This result is

consistent with other autoradiographic results indicating that chronic 5-HT uptake
inhibitors do not change the density of 5-HT1A receptors in the dorsal raphe and median
raphe nuclei (Le Poul et al.1995; Hensler et al. 1991).
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Autoradiographic analysis of Gpp(NH)p-induced inhibition of 3H-8-0H-DPAT
binding
The present studies provide the first autoradiographic data on Gpp(NH)p-induced
inhibition of 3H-8-0H-DPAT binding in the hypothalamus and other limbic brain
regions.

Gpp(NH)p inhibits the binding of 3H-8-0H-DPAT in most brain regions.

However, the degree of inhibition varies between different brain regions.

This

variation in the degree of inhibition suggests that differential coupling of 5-HT1A
receptors occurs in different brain regions.
8-0H-DPAT is a 5-HT 1A agonist. One might expect that 3H-8-0H-DPAT, in
the concentration of 2 nM, would mainly label the high affinity (coupled) state of 5HT 1A receptors. Therefore, Gpp(NH)p should be able to inhibit most of the binding of
3

H-8-0H-DPAT to 5-HT 1A receptors. However, results observed from the present and

other studies indicate that 3H-8-0H-DPAT binding cannot be completely blocked by
micromolar concentrations of Gpp(NH)p (Weinstein et al .1995). Butkerait et al. ( 1995)
found no significant differences between the Bmax of 3H-8-0H-DPAT binding in Sf9
cells that express 5-HT 1A receptors with G proteins and the same cells without G
proteins. However, the Kd of 3H-8-0H-DPAT binding was significantly higher in the
absence of G proteins (Kd

= 7.2±0.9 nM) than in the presence of G proteins

(Kd

=

1.1 ± 0.2 nM). On the other hand, in many brain regions, the binding ratio of the 5HT 1A agonist 3H-8-0H-DPAT to the antagonist 3H-WAY-100635 was more than 0.5,
suggesting more than 50 % coupling of receptors (Gozlan et al.1995; Le Poul et
al.1995; Kulikov et al.1995). This ratio is much higher than the ratio of agonist to
antagonist binding for other receptors. For example, the binding ratio of the 5-HT2A 12c
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agonist DOI to the 5-HT2A antagonist ketanserin is about 0.2 (i.e. 20% of receptors are
coupled) (Teiteler et al.1990; Pinto and Battaglia, 1994). The high ratio of 3H-8-0HDPAT to 3H-WAY-100635 binding could be due to two possibilities: 1) a larger number
of 5-HT1A receptors are coupled to G proteins compared with most other receptors; or
2) 8-0H-DPAT binds to both the high and low affinity states of 5-HT1A receptors. The
present results and other studies support the latter possibility. This is possible because
the affinity of 8-0H-DPAT for G protein-coupled 5-HT1A receptors is close (less than
one logarithm scale) to that for uncoupled 5-HT1A receptors (Chamberlain et al.1993).
Taken together, these results suggest that 8-0H-DPAT may bind to both high and low
affinity states of 5-HT1A receptors. The degree of Gpp(NH)p-induced inhibition of 3H8-0H-DPAT binding might depend on the ratio of 5-HT 1A receptors existing in the high
and low affinity states in each brain region.
Repeated injections of fluoxetine did not change the Gpp(NH)p-induced
inhibition of 3H-8-0H-DPAT binding. The lack of change suggests that no alteration
occurred in the fraction of coupled 5-HT1A receptors. This conclusion is consistent with
the results reported by Le Poul et al. (1995) who observed that repeated injections of
fluoxetine did not change the ratio of 5-HT1A agonist (3H-8-0H-DPAT) to antagonist
(3H-W A Y-100635) binding.

Changes in the levels of Gi and G0 proteins induced by repeated injections of
fluoxetine
The time-course of the effect of fluoxetine on Gi 1 and Gi3 proteins in the
hypothalamus appears to parallel the reductions in ACTH and oxytocin responses to 8-
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OH-DPAT, suggesting that the desensitization of 5-HT1A receptors may be due to
decreased levels of Gil and Gi3 proteins. In vitro, both Gi 1 and Gi3 proteins are known
to be coupled to 5-HT1A receptors (Raymond et al.1993).

However, the hormone

responses to 8-0H-DPAT were partly reduced after 3 days of fluoxetine injections,
while the hypothalamic levels of Gi 1 and Gi3 proteins were not significantly reduced
until 7 days.

One explanation for this difference in time-course is that hormone

responses to 5-HT 1A agonists are amplified through linkage via G proteins to the second
messenger enzymes. Note that the hypothalamic levels of Gi 1 and Gi3 proteins after 3
days of fluoxetine injections were 79.9

± 6.8%

and 82.6

± 6.1 % respectively.

After

7 days, the hormone responses to 8-0H-DPAT were almost maximally inhibited and
the hypothalamic levels of Gil and Gi3 proteins were 58.0

± 7.9%

respectively and statistically different from the control group.

and 71.1

± 10.43

These observations

suggest that a small change in the levels of G proteins might induce a large change in
hormone responses.
The midbrain was examined for changes in G proteins because it contains
serotonergic neurons in the dorsal and median raphe nuclei. The most salient finding
is that the reduction in G proteins in the midbrain precedes the reductions of G proteins
in the hypothalamus and that different G proteins are reduced in the midbrain than in
the hypothalamus. The levels of G0 and Gi2 proteins in the midbrain were reduced by
repeated injections of fluoxetine at 3 days and remained low for the duration of the
injections. Since G0 proteins are coupled to 5-HT 1A autoreceptors and probably play
a role in the feedback inhibition of serotonergic firing (Sprouse and Aghajanian, 1988),
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the decrease in their levels in the midbrain may be related to the desensitization of
somatodendritic 5-HT 1A autoreceptors. This observation agrees with the hypothesis that
desensitization of the 5-HT1A autoreceptors in the raphe occurs before the
desensitization of postsynaptic 5-HT 1A receptors.

However, one cannot dismiss the

possibility that the reduction of G0 and Gi2 levels in the midbrain could also influence
the functions of other neurotransmitter receptors which are known to be coupled to G0
and Gi proteins.
Fluoxetine did not change the levels of Gi or G0 proteins in the frontal cortex
at any time. This is consistent with the results reported by other investigators (Lesch
and Manji, 1992; Lesch et al.1991a) and suggests that the regulation of the expression
of these G proteins is region specific. The reason for the difference between brain
regions is still unclear and deserves further investigation. It may be due to differences
in the origin of serotonergic projections to frontal cortex versus the hypothalamus
(Mamounas et al.1991; Willoughby and Blessing, 1987), or to differences in colocalized peptides in the serotonergic pathways that innervate the cortex and
hypothalamus (Smith et al.1994; Li et al.1991; Francois-Bellan et al.1992), which could
differentially modulate the regulation of G proteins. Other antidepressant drugs also
differentially alter the expression of G proteins. For example, chronic injections of
imipramine decrease the level of Gi proteins in the hypothalamus and the hippocampus
but not in the frontal cortex (Lesch and Manji, 1992; Lesch et al.1991a). It is not clear
if the reduction in Gi and G0 proteins is due to reduced synthesis. Infusion of a lower
dose of fluoxetine (2.5 mg/kg/day) for 21 days did not alter Gi and G0 mRNA levels
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in the hypothalamus and midbrain (Lesch and Manji, 1992; Lesch et al.1992b). This
could mean that fluoxetine does not reduce the synthesis of Gi and G0 proteins and that
the reduction is due to increased degradation or alterations in post-translational
modification, such as reduced levels of palmitoylation of the G proteins (McCallum et
al.1995; Milligan et al.1995; Ross, 1995). On the other hand, this particular study
(Lesch and Manji, 1992; Lesch et al.1992b) used a lower dose of fluoxetine than the
dose used in the present experiment and the lower dose might not have produced the
same reduction in the levels of G proteins observed in the present study.
It is difficult to reconcile the reduction in the levels of Gi 1 and Gi3 in the
hypothalamus with lack of change in the Gpp(NH)p-induced inhibition of 3H-8-0HDPAT binding.

It should be noted that Gpp(NH)p-induced inhibition of 3H-8-0H-

DPAT binding is an indicator of a steady state condition of coupled 5-HT1A receptors.
Therefore, the Gpp(NH)p-induced inhibition of 3H-8-0H-DPAT binding may not
necessarily represent the dynamic status of agonist-induced coupling and signal
transduction of 5-HT 1A receptors in living cells.

In addition, it is possible that a

decrease in the levels of G proteins will influence the coupling of G proteins to adenylyl
cyclase, resulting in an alteration in the level of second messenger.
In summary, the results of the present study suggest that daily injections of
fluoxetine produce a desensitization of 5-HT IA receptors in the hypothalamus. This
desensitization occurs gradually and reaches a maximum after 14 days. The mechanism
of desensitization of hypothalamic 5-HT 1A receptor systems may involve decreased
levels of Gi 1 and/or Gi3 proteins.

Furthermore, the earlier onset of reductions in
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midbrain G0 proteins, compared with the decreases of hypothalamic Gi 1 and Gi3
proteins, supports the hypothesis that sustained inhibition of 5-HT transporters first
desensitizes somatodendritic 5-HT 1A autoreceptors in the raphe nuclei and, subsequently
desensitizes postsynaptic 5-HT 1A receptors.

CHAPTER VI
REPEATED INJECTIONS OF PAROXETINE PRODUCE A GRADUAL
DESENSITIZATION OF 5-HT1A RECEPTORS IN THE HYPOTHALAMUS
Summary
In the previous studies, we demonstrated that repeated injections of fluoxetine
produce a delayed and gradual desensitization of 5-HT 1A receptors in the hypothalamus
of male rats. The desensitization of hypothalamic 5-HT1A receptors was evidenced by
a reduction in hormone responses to 8-0H-DPAT and by reduction in hypothalamic
levels of Gil and Gi3 proteins which may be coupled to 5-HT1A receptors. However,
no changes were observed in the density of 5-HT1A receptors or in the coupling of 5HT IA receptors to their G proteins. The present study examined the time-course effects
of paroxetine on hypothalamic 5-HT 1A receptors, to study whether the desensitization
of 5-HT1A receptors is mediated by the sustained blockade of 5-HT uptake sites. Male
rats were injected with paroxetine (10 mg/kg, ip) once daily for 1, 3, 7 and 14 days.
Control rats received saline injections for 14 days.

Eighteen hours after the last

injection, the rats were challenged with 8-0H-DPAT (50 and 500 µg/kg, sc) and were
decapitated 15 min after the injection of 8-0H-DPAT.

Repeated injections of

paroxetine reduced the 8-0H-DPAT-inducedelevation of plasma ACTH, corticosterone
and oxytocin levels. The ACTH and corticosterone responses to the 50 µg/kg dose of
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8-0H-DPAT, but not the high dose (500 µg/kg) of 8-0H-DPAT were significantly
reduced by repeated injections of paroxetine.

On the other hand, the oxytocin

responses to both low and high doses of 8-0H-DPAT were reduced by the repeated
injections of paroxetine.

ACTH and oxytocin responses to 8-0H-DPAT were

significantly reduced after 3 daily injections of paroxetine. The reduction reached a
maximum after 7 and 14 daily injections of paroxetine. The corticosterone response
to 8-0H-DPAT was not significantly reduced until 7 days of paroxetine injections.
One daily injection of paroxetine did not alter the ACTH and corticosterone responses
to 8-0H-DPAT. These results suggest that repeated injections of paroxetine produce
a delayed and gradual desensitization of 5-HT 1A receptors in the hypothalamus. The
desensitization of hypothalamic 5-HT 1A receptors require injections of paroxetine for
more than one days.
Repeated injections of paroxetine did not alter the density of 5-HT1A receptors
in any brain region.

However, the profile of changes in the levels of Gi and G0

proteins is somewhat different from that induced by fluoxetine. Injections of paroxetine
significantly reduced the levels of all four G proteins in the hypothalamus, although the
reduction in the levels of Gi 1 and Gi3 proteins was greater than in Gi2 and G0 proteins.
The time-course of the reduction in the level of Gi3 proteins in the hypothalamus was
similar to the time-course of reduced hormone responses to 8-0H-DPAT. The
hypothalamic level of Gi1 proteins was significantly reduced after one day of paroxetine
injection and a reduced level of Gil proteins was maintained up to 14 days of injections.
Unlike fluoxetine, paroxetine significantly reduced the level of Gi2 proteins in the
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hypothalamus after seven daily injections. The levels of all four G proteins in the
midbrain were decreased after the injections of paroxetine. Midbrain levels of Gi2 and
Gi3 proteins were significantly reduced after one daily injection of paroxetine and this

reduced level was maintained until 14 days of injections. The level of Gil proteins was
significantly decreased after three daily injections of paroxetine. Similar to fluoxetine,
paroxetine reduced the level of midbrain G0 proteins after three daily injections.
Although paroxetine did not alter the levels of Gi3 and G0 proteins in the frontal cortex,
the levels of Gi 1 and Gi2 proteins were significantly decreased in the frontal cortex after
one day of paroxetine injection.

These results suggest that repeated injections of

paroxetine reduce Gi and G0 proteins in a region-specific manner. Furthermore, the
differential profiles of the effects of paroxetine and fluoxetine on the levels of G
proteins suggest that the reductions in the levels of Gi and G0 proteins are not only
mediated by the blockade of 5-HT uptake sites, but also by side effects of these 5-HT
uptake inhibitors.

In conclusion, these results suggest that repeated injections of

paroxetine produce a delayed and gradual desensitization of 5-HT 1A receptors in the
hypothalamus. This desensitization is not due to changes in the density of hypothalamic
5-HT lA receptors. Since the time-course of the effect of paroxetine on the hypothalamic
level of Gi3 proteins is similar to the time-course of the hormone responses to 8-0HDPAT , the reduced Gi3 proteins may be partly involved in the desensitization of 5HT 1A receptors. In addition, the consistent effect of paroxetine and fluoxetine on the
level of G0 proteins in the midbrain suggests that a reduction of the level of G0 proteins
in the midbrain may play a role in the desensitization of 5-HT1A autoreceptors induced
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by the repeated injection of 5-HT uptake inhibitors.

Introduction

5-HT uptake inhibitors, such as fluoxetine, paroxetine, fluvoxamine and
sertraline are widely used to treat affective disorders (Wong et al.1995; Goldstein et
al.1995; Weltzin et al.1994; Advokat and Kutlesic, 1995; Eriksson et al.1995; Lam et
al.1995). The pharmacologic effect of these drugs is blockade of 5-HT uptake sites.
Because 5-HT uptake sites are responsible for reuptake of 5-HT from the synaptic cleft
back into nerve terminals, blockade of 5-HT uptake sites will prolong the activity of 5HT and consequently increase the concentration of 5-HT in the synaptic cleft. Since
the depletion of 5-HT has been hypothesized to be related to the pathology of
depression, the blockade of 5-HT uptake sites by 5-HT uptake inhibitors should produce
an immediate therapeutic effect on the treatment of depressed patients. However, the
clinical application of these antidepressants suggests that the therapeutic effects of 5-HT
uptake inhibitors may not be exclusively mediated by the blockade of 5-HT uptake sites
because the clinical improvement is usually achieved 2-3 weeks after the onset of
treatment. It is believed that the therapeutic effect of 5-HT uptake inhibitors may be
related to adaptive changes induced by the blockade of 5-HT uptake sites.
Activation of 5-HT 1A autoreceptors may be involved in the delay of the
therapeutic effects of 5-HT uptake inhibitors. Recently, Studies (Artigas et al.1994;
Artigas, 1995; Blier and Bergeron, 1995) found that co-administration of the 5-HT 1A/B
adrenergic antagonist pindolol with 5-HT uptake inhibitors reduces the delay of clinical
improvement in depressed patients. Our studies (Li et al.1996) (See Chapter V) have
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demonstrated that repeated injections of fluoxetine produce a delayed and gradual
desensitization of hypothalamic 5-HT 1A receptors. To determine whether the effect of
fluoxetine on the 5-HT 1A receptors in the hypothalamus is mediated by blockade of 5HT uptake sites, another 5-HT uptake inhibitor paroxetine was used. Paroxetine has
a chemical structure and pharmacokinetic profile that is different from fluoxetine
(Nemeroff, 1993; Van Harten, 1993; Goodnick, 1994). For example, paroxetine has
a 10 fold higher affinity for 5-HT uptake sites than fluoxetine (Bolden-Watson and
Richelson, 1993; Richelson, 1994). Also, paroxetine has a higher ratio of affinity for
serotonin/norepinephrine uptake sites than fluoxetine.

The pharmacokinetics of

paroxetine are quite different from those of fluoxetine (Goodnick, 1994; Van Harten,
1993; Richelson, 1994; Lane et al. 1995). In humans, the half-life of paroxetine (about
1 day) is much shorter than that of fluoxetine (3-5 days). Paroxetine does not have an
active metabolite, while fluoxetine has an active metabolite, norfluoxetine, that has a
long half-life (7-15 days). Also, one can expect that paroxetine will have different side
effect than fluoxetine because of their different chemical structures. In fact, clinical
application has shown that the side effects of paroxetine are different from those of
fluoxetine (Lane et al.1995). However, since both fluoxetine and paroxetine inhibit 5HT uptake sites, a common effect of these two drugs would likely be mediated by
blockade of 5-HT uptake sites. For example, there is no significant difference in their
therapeutic effects for treatment of depression (Tignol, 1993; Lane et al.1995),
suggesting that their therapeutic effect is mediated by blockade of 5-HT uptake sites.
5-HT 1A receptors can be classified into somatodendritic and postsynaptic
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receptors. Somatodendritic 5-HT 1A autoreceptors are located on the 5-HT neurons in
the dorsal and median raphe nuclei in the midbrain.

The function of the 5-HT1A

autoreceptors is feedback regulation of 5-HT release from serotonergic nerve terminals.
Stimulation of 5-HT1A autoreceptors by 5-HT or 5-HT1A agonists will decrease the firing
rate of neurons and subsequently reduce the release of 5-HT from nerve terminals.
Postsynaptic 5-HT 1A receptors are distributed in most forebrain regions, such as the
hippocampus, hypothalamus, amygdala and cortex (Kia et al.1996; Gozlan et al.1995;
Khawaja, 1995).

The postsynaptic 5-HT 1A receptors are activated by serotonergic

inputs from 5-HT neurons and produce physiological responses, which depend on the
function of the target cells.

For example, stimulation of 5-HT1A receptors in the

hypothalamus will increase the secretion of several hormones, such as ACTH,
corticosterone and oxytocin. Since plasma hormone concentrations are easy to measure,
the hormone responses to 5-HT1A agonists can be used as markers of the function of
hypothalamic 5-HT 1A receptors. The magnitude of the hormone response to 5-HT1A
agonists reflects the function of 5-HT1A receptors in the hypothalamus.
5-HT 1A receptors are G protein-coupled membrane proteins.

So far, the

evidence suggests that 5-HT 1A receptors are coupled to Gi or G0 proteins (Butkerait et
al.1995; Mulheron et al.1994; Fargin et al.1991). Somatodendritic 5-HT 1A receptors
may be coupled to G0 proteins, which increase the opening of K+ channels and
consequently suppress the activity of 5-HT neurons (Sprouse and Aghajanian, 1988;
Innis and Aghajanian, 1987; Innis et al.1988). Postsynaptic 5-HT1A receptors have a
higher affinity for Gi3 and Gi 1 proteins than that for Gi2 and G0 proteins (Raymond et
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al.1993; Mulheron et al.1994; Bertin et al.1992). Stimulation of 5-HT 1A receptors that
are coupled to Gi proteins will inhibit the activity of adenylyl cyclase, resulting in a
decrease of cAMP in the cells. In the present study, the effect of daily injections of
paroxetine on the levels of Gi and G0 proteins in the hypothalamus, midbrain and frontal
cortex were determined to assess the effect of sustained inhibition of 5-HT uptake on
the signal transduction system of 5-HT 1A receptors.
We have hypothesized here that repeated injections of paroxetine would produce
a delayed and gradual desensitization of 5-HT tA receptors in the hypothalamus. The
time-course of the effect of paroxetine on the hormone responses to 8-0H-DPAT was
examined to assess the function of 5-HT1A receptors in the hypothalamus. To study
whether the desensitization is mediated by a down-regulation of 5-HT 1A receptors, the
time-course of effect of paroxetine on the density of 5-HT1A receptors in the
hypothalamus and several other brain regions was determined by autoradiographic
analysis of 3H-8-0H-DPAT binding. Furthermore, we examined the levels of Gi and
G0 proteins in the hypothalamus, midbrain and frontal cortex, to determine whether a
reduction in the signal transduction system of 5-HT 1A receptors plays a role in the
desensitization of 5-HT1A receptors.
Experimental Protocol

Male rats were injected with paroxetine (10 mg/kg, ip) once daily for 1, 3, 7
or 14 days. The control rats received saline injections for 14 days. Eighteen hours
after the last injection, the rats were challenged with saline or 8-0H-DPAT (50 or 500
µg/kg, sc) and decapitated 15 min after the injection of 8-0H-DPAT. Trunk blood was
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collected in centrifuge tubes containing 0.5 ml of 0.3M EDTA (pH 7.4) solution. After
centrifugation at 2500 rpm, 4°C for 15 min, plasma aliquots were stored at -7D°C until
they were used for hormone assays.

The brains from saline challenged rats were

quickly and carefully removed and frozen on powdered dry ice until the brains were
completely frozen.

The brains were then wrapped with plastic wrap, parafilm and

aluminum foil and stored at -70°C until they were sectioned for autoradiography. The
brains of the other rats were dissected and the hypothalamus, midbrain and frontal
cortex were stored at -70°C for immunoblots of Gi and G0 proteins.
Plasma

ACTH,

corticosterone

and

oxytocin

were

measured

by

Radioimmunoassay as described in Chapter III. The density of 5-HT1A receptors in the
hypothalamus and several other brain regions was analyzed by autoradiography (See
Chapter III for details). The levels of Gi 1, Gi2 , Gi3 and G0 proteins were analyzed using
immunoblots as described in Chapter III.

Results
Hormone responses to 8-0H-DPAT
8-0H-DPAT significantly increased plasma ACTH concentration.

Repeated

injections of paroxetine significantly reduced the ACTH response to the 50 µglkg dose
of 8-0H-DPAT (top panel of Fig.16). A partial reduction of the ACTH response to
8-0H-DPAT occurred after 3 daily injection of paroxetine and this inhibition was
maximal after 7 and 14 days of injections. One daily injection of paroxetine did not
alter the ACTH response to 8-0H-DPAT (bottom panel of Fig. 16).

Repeated

injections of paroxetine did not decrease the maximal effect of 8-0H-DPAT (500 µg/kg)
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on ACTH secretion. However, the ACTH response to this high dose of 8-0H-DPAT
(500 µglkg) was potentiated by the daily injections of paroxetine for 7 days (top panel
of Fig. 16).
Figure 17 shows the effect of both 8-0H-DPAT doses (top) and a time-course
(bottom) of the effect of repeated injections of paroxetine on the corticosterone response
to

8-0H-DPAT.

concentration.

8-0H-DPAT significantly increased plasma corticosterone
Repeated injections of paroxetine significantly inhibited the

corticosterone response to the 50 µglkg dose of 8-0H-DPAT.

Unlike the ACTH

response, the reduced corticosterone response to 8-0H-DPAT was statistically
significant only after 7 daily injections of paroxetine (bottom panel of Fig.17).
Injections of paroxetine for one or three days did not decrease the corticosterone
response to 8-0H-DPAT. However, the corticosterone response to the high dose (500
µglkg) of 8-0H-DPAT was significantly potentiated by repeated injections of paroxetine

for three days (top panel of Fig. 17).
As is shown in Figure 18, 8-0H-DPAT significantly increased plasma oxytocin
concentration. Paroxetine significantly decreased the oxytocin response to both low and
high doses of 8-0H-DPAT after 3 daily injections.

The reduction of the oxytocin

response to 8-0H-DPAT reached a maximum after 7 and 14 daily paroxetine injections
(bottom panel of Fig. 18). Injection of paroxetine for 1 day did not reduce the effect
of 8-0H-DPAT on oxytocin. However, the oxytocin response to the high dose (500
µglkg) of 8-0H-DPAT was significantly reduced by injection of paroxetine for one day

(top panel of Fig. 18).
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Autoradiographic analysis of 3H-8-0H-DPAT binding
Autoradiographic analysis of 3H-8-0H-DPAT binding was used to examine the
effect of paroxetine on the density of 5-HT1A receptors. The time course of the effect
of repeated injections of paroxetine on the density of 5-HT1A receptors was determined
in several nuclei in the hypothalamus, amygdala, hippocampus and dorsal and median
raphe nuclei as well as several layers of the cortex.

As shown in Table VII, the

distribution of 5-HT1A receptors varies among brain regions, which is consistent with
that seen in the previous study (Chapter V). Like fluoxetine, paroxetine did not alter
the density of 5-HT1A receptors in any brain regions after daily injections (Table VII).

Levels of Gi and G 0 proteins in the hypothalamus, midbrain and frontal cortex
The effects of repeated injections of paroxetine on the levels of Gi 1 , Gi2 , Gi3 and
G0 proteins were determined using immunoblots.

The four G proteins were

differentially influenced in the hypothalamus, midbrain and frontal cortex by repeated
injections of paroxetine.
Repeated injections of paroxetine significantly reduced the levels of all four G
proteins in the hypothalamus, although the reduction in the levels of Gil and Gi3 proteins
was greater than that of Gi2 and G0 proteins (Fig. 19). The level of Gu proteins was
significantly reduced after one day of paroxetine injection and the reduced level of Gi 1
proteins was maintained until 14 days of injections (Fig.19A). Paroxetine significantly
decreased the level of Gi3 and G0 proteins after 3 days of injections (Fig. 19C, D). The
low level of Gi3 proteins was maintained until 14 daily injections of paroxetine (Fig.
19C), while the level of G0 proteins returned to normal levels after 14 days of injections
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(Fig. 19D). The time-course of the effect of paroxetine on the level of Gi3 protein was
similar to the time-course in reducing the hormone responses to 8-0H-DPAT. The
level of Gi2 proteins was significantly decreased only after 7 daily paroxetine injections
(Fig. 19B).
As shown in Fig. 20, the levels of all four G protein were decreased in the
midbrain after daily injections of paroxetine. The levels of Gi2 and Gi3 proteins were
significantly reduced after one day of injection of paroxetine and the reduced level was
maintained until 14 days of injections (Fig. 20B, C). The level of Gn proteins was
significantly decreased after 3 days of injections of paroxetine (Fig. 20A). Paroxetine
reduced the level of G0 proteins in the midbrain after 3 and 7 daily injections (Fig,
20D).
Although paroxetine did not alter the levels of Gi3 and G0 proteins in the frontal
cortex, the levels of Gi1 and Gi2 proteins were significantly decreased in the frontal
cortex after injection of paroxetine for one day (Fig. 21A,B).
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TABLE VII
REPEATED INJECTIONS OF PAROXETINE DO NOT ALTER THE DENSITY
OF 5-HT1A RECEPTORS AT ANY BRAIN REGION
Brain regions

Nuclei

Density of 3H-8-0H-DPAT - labeled 5-HT1A receptors
Saline

1 days

3 days

7 days

14 days

Cortex
Fr2

layer 1-3 26.5±1.5 22.9±1.7 23.2±1.6 23.3±1.1 22.9±2.2
layer 5

72.6±3.6 64.1 ±2.6 64.6±3.4 62.1 ±3.2 64.2±3.9

-----------------~l!X~~-~- §l._l_t_~:.~-.?~·Qt_~:.~_.?.7-:±t_'!:.~_.?_~._Q_;!;.~:.~-~~.:~.;t~..:l_
CG3
layer 1-3 44.9±4.4 40.3±2.2 41.4±4.3 40.4±3.3 37.8±3.8
layer 5

65.5±5.6 54.9±3.5 56.7±4.4 57.9±4.3 56.3±5.1

layer 6

62.5±4.5 51.6±1.8 52.1±3.3 55.0±3.8 54.8±4.6

Hypothalamus PVNm

7.0±0.6

5.8±0.4

5.6±0.3

6.1 ±0.7

6.6±0.7

PVNp

8.3±0.7

7.3±0.4

7.2±0.4

8.0±0.7

8.6±0.6

AHN

12.8±0.6 10.8±0.5 10.6±1.0 10.9±1.2 12.3±0.8

LH

4.7±0.3

4.2±0.3

4.2±0.4

4.3±0.2

4.7±0.2

VMHDM 21.6± 1.6 21.8± 1.4 21.2± 1.1 19.4±1.0 18.9± 1.0
VMHC

32.8±2.6 32.2±2.4 31.2±2.1 27.8±1.9 29.1±1.8

VMHVL 19.8±1.3 19.2±0.9 19.2±1.1 17.7 ±1.0 17.1 ±0.8
Amygdala

Hippocampus

Midbrain

DMH

10.0±0.9

9.8±0.7

10.0±0.4

8.6±0.3

9.1±0.3

AC

6.1 ±0.4

6.5 ±0.5

6.4±0.2

6.1 ±0.3

5.4±0.3

ALP

11.5±0.7 11.1±0.7 13.1±0.4 11.8±0.7 11.2±0.4

ABL

17.2±1.1 16.7±0.8 17.3±0.7 17.2±0.7 16.8±0.6

ABM

26.5±2.1 24.3±2.2 24.5±1.7 23.0±1.1 24.1±1.3

AM

18.7±2.1 18.1±1.0 18.6±0.7 18.0±0.9 17.8±0.6

CAl

62.9±1.7 49.1±5.8 51.9±3.0 43.9±4.7 59.0±4.0

CA2

14.5±0.4 12.2±1.3 11.6±0.5 10.6±0.9 13.6±0.8

CA3

31.6±1.1 26.5±3.2 27.3±2.0 25.2±3.2 31.9±2.3

DG

84.1+3.0 66.5±5.5 70.7±4.4 63.2±6.4 78.3±5.2

DR

30.8±1.8 32.4±1.5 32.0±0.9 32.9±0.4 31.9±0.9

MR

21.7+1.7 23.4+2.2 20.5± 1.2 20.2±1.4 18.5±0.9
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The data represent mean

± S.E.M.

of 5-6 rats per group.

Abbreviations:
ABL:
Basolateral amygdaloid nucleus
ABM:
Basomedial amygdaloid nucleus
Central amygdaloid nucleus
AC:
AHN:
Anterior hypothalamic nucleus
Lateral amygdaloid nucleus, posterior region
ALP:
Medial amygdaloid nucleus
AM:
CAl-3:
Field CAl, CA2 and CA3 of ammon's horn in the hippocampus
Cingulate cortex, area 3.
CG3:
Dentate gyrus (hippocampus)
DG:
DMH:
Dorsomedial hypothalamic nucleus
Dorsal raphe
DR:
Fr2:
Frontal cortex, area 2
Lateral hypothalamic area
LH:
Medial raphe
MR:
PAR 1:
Parietal cortex, area 1
Paraventricular hypothalamic nucleus, magnocellular region
PVNm:
PVNp:
Paraventricular hypothalamic nucleus, parvocellular region
Ventromedial hypothalamic nucleus, central region
VMHC:
Ventromedial hypothalamic nucleus, dorsomedial region
VMHDM:
VMHVL:
Ventromedial hypothalamic nucleus, ventrolateral region
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Fi~ure 19. Paroxetine reduces the levels of G proteins in the hypothalamus.
The data represent mean ± S.E.M. of 6-8 rats per group. A. Level of Gi 1 proteins,
One way ANOVA: F<4 • 24) =3.7267, P<0.05; B. Level of Gi2 proteins. One way
ANOVA: F<4 • 25)= 1.892, NS. C. Level of Gi3 proteins. One way ANOVA: F<4 .
27)=2.8918, P<0.05; D. Level of G0 proteins. One way ANOVA: F<4 • 28) =3.3027,
P<0.05.
* Significant difference from the vehicle group, P < 0.05 ( Newman Keuls' multiple
range test)
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Fi2ure 20. Paroxetine reduces the levels of G proteins in the midbrain. The
data represent mean ± S.E.M. of 6-8 rats per group. A. Level of Gi 1 proteins, One
way ANOVA: F<4• 24l =19.55, P<0.01 B. Level of Gi2 proteins. One way ANOVA:
F<4• 24l =12.6; P<0.01 . C. Level of Gi3 proteins. One way ANOVA: F<4• 24l=8.809,
P<0.01. D. Level of G0 proteins. One way ANOVA: F<4 • 27l=4.449; P<0.01
* Significant difference from the vehicle group, P < 0.05 (Newman Keuls' multiple
range test)
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Fi2Ure 21. Paroxetine reduces the levels of G proteins in the frontal cortex.
The data represent mean ± S.E.M. of 6-8 rats per group. A. Level of Gi 1 proteins,
One way ANOVA: F<4 . 30)=12.045; P<0.01 B. Level of Gi2 proteins. One way
ANOVA: F<4 • 3l=5.189, P=0.01 . C. Level of Gi3 proteins. One way ANOVA: F<4 •
32l=0.9768, NS. D. Level of G0 proteins. One way ANOVA: Fc4 . 28l=0.289, NS.
* Significant difference from the vehicle group, P<0.05 (Newman Keuls' multiple
range test)
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Discussion
The results of the present study agree with the data obtained with fluoxetine and
suggest that sustained blockade of 5-HT uptake produces a delayed and gradual
desensitization of 5-HT1A receptors in the hypothalamus. This desensitization of 5-HT 1A
receptors is unlikely due to a down-regulation of hypothalamic 5-HT IA receptors. Since
the time-course of paroxetine-induced reduction in the level of Gi3 proteins in the
hypothalamus is similar to the time-course of reduction in the hormone responses to 80H-D PAT, it is possible that the reduction in the level of Gi3 proteins is involved in
the desensitization of hypothalamic 5-HT 1A receptors.
In the present study, we examined changes in 5-HT1A receptors after 1, 3, 7 and
14 daily injections of paroxetine. In contrast, the study on the effects of fluoxetine had
a time-course of 0, 3, 7, 14 and 22 days. The reason for adding a one day paroxetine
group was to determine when the desensitization of the hypothalamic 5-HT1A receptors
would starts. We have observed that 3 daily injections of fluoxetine partially reduce
the hormone responses to 8-0H-DPAT. In the present study, we determined whether
the desensitization of hypothalamic 5-HT 1A receptors occurs after one daily injection of
paroxetine. We deleted the group of 22 daily injections in the present study because
the maximal effects of fluoxetine on the 5-HT1A receptors were observed after 14 daily
injections.

Comparing the time-course of fluoxetine with that of paroxetine, these

results suggest that the desensitization of 5-HT1A receptors in the hypothalamus requires
more than one day of sustained inhibition of 5-HT uptake.

However, one daily

injection of paroxetine significantly decreases the levels of Gi1 proteins in the
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hypothalamus, the levels of Gi2 and Gi3 proteins in the midbrain and the levels of Gil
and Gi2 proteins in the frontal cortex. These results suggest that paroxetine induces
some changes after one daily injection.

These changes may not be related to the

function of hypothalamic 5-HT 1A receptors, because the neuroendocrine response is an
amplified response to activation of the hypothalamic 5-HT1A receptors and it was not
reduced after one daily injection of paroxetine.
In the present study, ACTH, corticosterone and oxytocin responses to 8-0HDPAT were used to assess the function of hypothalamic 5-HT1A receptors. Several
studies have demonstrated that 8-0H-DPAT-induced increases of plasma ACTH,
corticosterone and oxytocin are dose-dependent.

The ACTH and corticosterone

responses to 8-0H-DPAT can be abolished by the 5-HTIA antagonists, pindolol,
spiperone, NAN-190, UH-301, WAY-100135 and WAY-100635 (Cowen et al.1990;
Lejeune et al.1993; Pan and Gilbert, 1992; Critchley et al.1994b; Przegalinski et
al.1989; Kelder and Ross, 1992; Vicentic et al.1996). The oxytocin response to 8-0HDPAT can be inhibited by WAY-100635 and NAN-190 (Vicentic et al.1996; Bagdy and
Kalogeras, 1993). A lesion in the hypothalamic paraventricular nucleus blunted the
ACTH, corticosterone and oxytocin responses to ipsapirone (Bagdy and Makara, 1994;
Bagdy, 1995). These data suggest that the hormone responses to 8-0H-DPAT are
mediated by activation of 5-HT1A receptors in the hypothalamus, likely in the
paraventricular nucleus. Therefore, the magnitude of hormone responses to 8-0HDPAT can be used as a tool to assess the function of hypothalamic 5-HT 1A receptors
(Van de Kar, 1991; Van de Kar, 1989; Van de Kar and Brownfield, 1993). The results
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of the present study show that repeated injections of paroxetine significantly decrease
the hormone response to 8-0H-DPAT, suggesting that paroxetine produces a
desensitization of 5-HT1A receptors in the hypothalamus.

The desensitization of

hypothalamic 5-HT 1A receptors appears after 3 daily injections and reaches a maximum
effect after 7 and 14 days.

These results are consistent with those observed with

repeated injections of fluoxetine, suggesting that the desensitization of 5-HT1A receptors
is mediated by the blockade of 5-HT uptake sites.
It was unexpected that the ACTH and corticosterone responses to the 500 µg/kg

dose of 8-0H-DPAT were significantly potentiated by 3 or 7 daily injections of
paroxetine. However, at the same time points, the ACTH and corticosterone responses
to the low dose (50 µg/kg) of 8-0H-DPAT were decreased by daily injections of
paroxetine. The 50 µg/kg dose of 8-0H-DPAT is close to the ED50 dose for ACTH
and corticosterone and is more sensitive to changes in the function of 5-HT1A receptors.
On the other hand, the 500 µg/kg dose of 8-0H-DPAT is a maximal dose for ACTH
and corticosterone. At this high dose, 8-0H-DPAT may stimulate some other receptors
for which 8-0H-DPAT has a relative high affinity. For example, the affinity of 8-0HDPAT for 5-HT7 receptors is about 10-fold lower than that for 5-HT 1A receptors (Hoyer
et al.1994). In addition, no potentiation of the effects of 8-0H-DPAT was observed
in the oxytocin response. All together, the potentiation of the AC TH and corticosterone
responses to the high dose of 8-0H-DPAT may not be mediated by hypothalamic 5HT IA receptors.
Similar to our previous observations with fluoxetine, daily injections of
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paroxetine decreased the ACTH and corticosterone responses to a low dose, but not a
high dose of 8-0H-DPAT, while the decrease in the oxytocin response was observed
at both low and high doses of 8-0H-DPAT. There is a higher 5-HT 1A receptor reserve
for ACTH and corticosterone responses than for the oxytocin response to 5-HT 1A
agonists (1994; 1994), unpublished data from Pinto and Battaglia). This difference in
receptor reserve might explain the difference between ACTH and oxytocin. However,
it is also possible that the lack of change in the ACTH and corticosterone responses to
a high dose of 8-0H-DPAT is due to activation of other receptors, which increase
ACTH and corticosterone secretion and may be sensitized by repeated injections of
paroxetine.
Repeated injections of paroxetine did not alter the density of 5-HT1A receptors
in any brain regions. This observation is in agreement with our observations with
fluoxetine and also in agreement with the data reported by other investigators (Le Poul
et al.1995; Hensler et al.1991). Le Poul et al. (1995) showed that neither fluoxetine
nor paroxetine altered the density of 5-HT1A receptors in the dorsal raphe nucleus and
in the dentate gyms of the hippocampus. Hensler et al. ( 1991) found that repeated
injections of sertraline or citalopram did not influence the density of 5-HT1A receptors
in several brain regions.
There are similarities but also differences between paroxetine and fluoxetine with
respect to their effects on the levels of G proteins.

Overall. paroxetine seems to

produce a greater and earlier reduction in the levels of Gi and G() proteins, especially
the levels of Gi 1 and Gi2 proteins. For example, paroxetine reduced the level of Gi1

148
proteins in the hypothalamus after one daily injection, while fluoxetine did not
significantly reduce the level of Gi 1 proteins until 7 daily injections.

Similarly,

fluoxetine did not significantly alter the hypothalamic level of Gi2 proteins, but
paroxetine decreased the level of Gi2 proteins after 7 daily injections. So far, there is
no good explanation for the differential influence on the levels of Gi and G0 proteins by
fluoxetine and paroxetine, since little is known regarding the mechanism though which
they decrease G protein levels.
Beside the differential effect of fluoxetine and paroxetine on levels of G
proteins, there are some similarities which may be more important for the
desensitization of 5-HT1A receptors. For example, the time-course of reduction in the
hypothalamic level of Gi3 proteins is similar to the time-course of hormone responses
to 8-0H-DPAT after repeated injections of paroxetine. This observation is consistent
with the results observed with repeated injections of fluoxetine. Since 5-HT1A receptors
have a high affinity for Gi3 proteins, this similarity in time-courses for reduction in the
hypothalamic level of Gi3 proteins and the neuroendocrine resporu;es to 8-0H-DPAT
suggests that the reduction in the level of Gi3 may be involved in the desensitization of
hypothalamic 5-HT 1A receptors.
Repeated injections of paroxetine significantly decreased the level of Gi2 proteins
in the midbrain. The reduction in the level of Gi2 proteins appeared after one daily
injection and remained for 14 daily injections. Paroxetine reduced the level of G0
proteins after 3 daily injections. These changes are similar to the results observed with
fluoxetine injections.

The level of G0 proteins returned to normal after 14 daily
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injections of paroxetine, which is in contrast with fluoxetine-induced reduction of G0
proteins which remained reduced during the 22 daily injections. Desensitization of 5HT1A autoreceptors in the dorsal raphe nucleus has been detected after 3 to 14 daily
injections of fluoxetine or paroxetine (Le Poul et al.1995). However, no data are
available on the effect of one daily injection of 5-HT uptake inhibitors on 5-HT1A
autoreceptors. Therefore, it is difficult to determine which G proteins are involved in
the desensitization of 5-HT1A autoreceptors.
In conclusion, the results of the present of study suggest that repeated injections
of paroxetine produce a delayed and gradual desensitization of hypothalamic 5-HT 1A
receptors. This desensitization is similar to that induced by fiuoxetine, suggesting that
sustained blockade of 5-HT uptake sites mediates this effect. Since no change was
detected in the density of 5-HT1Areceptors in the hypothalamic nuclei, it is unlikely that
the desensitization of hypothalamic 5-HT1Areceptors is due to a down-regulation of 5HT1A receptors. The similarity of the time-course of the leYel of Gi3 proteins to the
time-course of the hormone responses to 8-0H-DPAT, after repeated injections of
paroxetine, suggests that the reduction of the level of Gll proteins may be partly
involved in the desensitization of 5-HT1A receptors.

CHAPTER VII
GENERAL DISCUSSION

The present studies demonstrate that prolonged blockade of 5-HT uptake sites
by 5-HT uptake inhibitors produces a delayed and gradual desensitization of
hypothalamic 5-HT 1A receptors.

This desensitization is not induced by blockade of

norepinephrine uptake sites following long-term administration of desipramine. Because
neither fluoxetine nor paroxetine changes the density and affinity of 5-HT 1A receptors
in the hypothalamus, the desensitization of hypothalamic 5-HT1A receptors is unlikely
due to receptor down-regulation. A reduction in the level of Gi3 proteins may play a
role in the desensitization of hypothalamic 5-HT1A receptors, because the time-course
of the reduction in the level of Gi3 proteins is similar to the time-course of the reduction
of the hormone responses to 8-0H-DPAT. Therefore, the results of the present studies
support our hypothesis that repeated injections of 5-HT uptake inhibitors produce a
delayed and gradual desensitization of hypothalamic 5-HT1A receptors that may be due
to changes in their signal transduction mechanisms.

The Neuroendocrine Challen1:e Test --- A Tool to Examine the Function of
Hypothalamic 5-HT1A Receptors
In the present studies, ACTH, corticosterone and oxytocin responses to the 5HT 1A agonists 8-0H-DPAT and ipsapirone were used to eyaluate the function of
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hypothalamic 5-HT 1A receptors.

Several studies have demonstrated that ACTH,

corticosterone and oxytocin responses to 5-HT 1A agonists are mediated by 5-HT1A
receptors (Van de Kar, 1991; Van de Kar and Brownfield, 1993). First, several 5-HT1A
agonists, such as 8-0H-DPAT, ipsapirone, buspirone and gepirone stimulate the
secretion of ACTH, corticosterone and oxytocin in a dose-dependent manner (Cowen
et al.1990; Fuller, 1992; Gilbert et al.1988a; Koenig et al.1988; Bagdy and Kalogeras,
1993). Second, the hormone responses to 5-HT1A agonists can be inhibited by 5-HT 1A
antagonists, such as pindolol, spiperone, NAN-190, UH-301, WAY-100135 and WAY100635 (Cowen et al.1990; Lejeune et al.1993; Pan and Gilbert, 1992; Critchley et
al.1994b; Przegalinski et al.1989; Kelder and Ross, 1992; Bagdy and Kalogeras, 1993;
Vicentic et al.1996), but not by 5-HTrn, 5-HT2 , 5-HT3 and adrenoceptor antagonists
(Przegalinski et al.1989). Third, the hormone responses to 5-HT1A agonists may be
mediated by postsynaptic 5-HT1A receptors.

A lesion in 5-HT neurons by

intracerebroventricular injection of 5,7-DHT or depletion of 5-HT with PCPA did not
decrease the effects of 5-HT1A agonists on the secretion of ACTH and corticosterone
(Przegalinski et al.1989; Gilbert et al.1988b and our unpublished data). Furthermore,
a lesion in the paraventricular nucleus of the hypothalamus blunted the corticosterone
and oxytocin responses to ipsapirone (Bagdy and Makara, 1994; Bagdy, 1994).
Together, these results suggest that 5-HT 1A agonists increase the section of ACTH,
corticosterone and oxytocin by activating postsynaptic 5-HT tA receptors in the
hypothalamus. Therefore, the magnitude of the hormone responses to 5-HT1A agonists
can be used as an index for the function of hypothalamic 5-HT 1A receptors.
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Although it is clear that stimulation of 5-HT1A receptors in the hypothalamus
increases the secretion of ACTH, corticosterone and oxytocin, the intracellular pathway
of the 5-HT1A receptor-mediated regulation of hormone secretion is still unknown. For
example, no data are available regarding which G proteins and second messengers
mediate the increase in the secretion of hormones, and how the second messengers
trigger the release of these hormones.

Therefore, one should be aware of these

limitation when interpreting the data in neuroendocrine challenge test.

Also, it is

possible that a change in production of a specific hormone will alter its response to a
5-HT 1A agonist.

Most 5-HT 1A agonists have side effects to interact with other

receptors, which can also increase the secretion of these hormones.

Therefore, a

hormone response to a 5-HT 1A agonist may not only reflect the function of 5-HT1A
receptor systems but also of other receptors.

For example, buspirone is a 5-HT1A

agonist and a dopamine D2 antagonist. Since dopamine is a predominant controller of
prolactin secretion, the increase in prolactin induced by buspirone may mainly represent
the D2 antagonist effect but not the activity of 5-HT1A receptors.
A number of approaches can be used to overcome these limitations of
neuroendocrine challenge tests.

First, it is necessary to test multiple hormone

responses. Each hormone is differentially regulated in terms of their synthesis, their
location and stimulation of their secretion by neurotransmitters. Therefore, the side
effect of 5-HT1A agonists may not influence all the hormones in a same manner. For
example, in the present studies, repeated injections of paroxetine potentiated the ACTH
and corticosterone responses to a high dose of 8-0H-DPAT. Since potentiation was not
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observed in the oxytocin response, it is unlikely that the paroxetine-induced potentiation
of ACTH and corticosterone responses to 8-0H-DPAT is mediated by 5-HT1A
receptors. Secondly, using more than one 5-HT 1A agonist for the hormone challenge
test also helps to distinguish between hormone responses mediated by 5-HT1A receptors
and responses mediated by other receptors.

Different 5-HT1A agonists may have

different side effects which may influence the secretion of hormones. These side effects
of 5-HT1A agonists on the hormone responses may be different between 5-HT1A
agonists, while they share the same effects on 5-HT 1A receptor-mediated hormone
responses.

Thirdly, comparing the hormone responses to 5-HT 1A agonists with the

response to other receptor agonists, such as 5-HT2Anc agonists, can rule out the
possibility that changes in the hormone responses to 5-HT1A agonists are due to an
alteration in the production of the hormone.

For example, long-term injections of

fluoxetine decrease the hormone responses to 5-HT1A agonists but potentiate the
hormone responses to a 5-HT2Aizc agonist (Li et al.1993a). suggesting that the decrease
in hormone responses to 5-HT1A agonists is not due to a reduction in the synthesis of
these hormones.
An advantage of hormone challenge test is that the hormone responses to 5-HT1A
agonists amplify the changes in the 5-HT1A receptor systems. For example, activation
of 5-HT1A receptors on parvocellular cells of the PVN increases the secretion of CRF.
CRF further increase the secretion of ACTH from corticotrophs in the pituitary.
ACTH will further increase corticosterone release from the adrenal cortex. Along the
HPA axis, the signal of any change in the 5-HT1A receptors is enlarged in the each step.
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This amplification is beneficial to monitor changes in 5-HT1A receptors.
As we hypothesized, desensitization of hypothalamic 5-HT 1A receptors may play
a role in the therapeutic effects of SSRI's. It is possible that the changes in the 5-HT1A
receptors occur prior to the improvement of clinical symptoms in patients receiving
SSRI's. Therefore, neuroendocrine challenge tests can proYide early information for
physicians to monitor and predict the therapeutic effects of SSRI's.

Comparison of Desipramine with Fluoxetine in Neuroendocrine Challen1:e tests
In the present studies, we compared the effect of desipramine and fluoxetine on
the function of hypothalamic 5-HT 1A receptors. Desipramine is a norepinephrine uptake
inhibitor and a tricyclic antidepressant, while fluoxetine is a 5-HT uptake inhibitor and
an atypical antidepressant (DeVane, 1994). The results of the present studies indicate
that repeated injections of fluoxetine, but not desipramine, produce a desensitization of
hypothalamic 5-HT 1A receptors.

These results suggest that the desensitization of

hypothalamic 5-HT 1A receptors is selectively induced by inhibition of 5-HT uptake but
not by inhibition of norepinephrine uptake. Other studies agree with these observations.
For example, Lesch and co-investigators (1991; 199lc) observed that long-term
treatment with fluoxetine decreases the ACTH response to ipsapirone in patients with
obsessive-compulsive disorder, while a tricyclic antidepressant, amitriptyline, did not
change the ACTH response to ipsapirone in depressed patients.
In contrast with the differential effect of fluoxetine and desipramine on the
hypothalamic 5-HT 1A receptors, both fluoxetine and desipramine potentiated the
hormone responses to the 5-HT2 agonists DOI and MK-212 (Li et al.1993a).
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Fluoxetine increased the density of the high affinity state 5-HT2A12c receptors in the
hypothalamus (Li et al.1993a and our unpublished data).

These observations are

consistent with results from other studies (Li et al.1993a; Hulihan-Giblin et al.1994;
Cadogan et al.1993; Hrdina and Vu, 1993) and suggest that both 5-HT uptake inhibitors
and tricyclic antidepressants increase the function of 5-HT 2A 12c receptors in the
hypothalamus, although the mechanism of the supersensitivity of 5-HT2A;2c receptors
may be different between the two classes of antidepressants. The fact that both 5-HT
uptake inhibitors and tricyclic antidepressants have similar therapeutic effects on
depression suggests that the sensitization of 5-HT2A12c receptors may play a role in
therapeutic effects of the antidepressants in the treatment of depression.

Comparison of the Effects of Fluoxetine with Paroxetine on Hypothalamic 5HT lA Receptors
To study whether the desensitization of hypothalamic 5-HT1A receptors, induced
by repeated injections of fluoxetine, is due to blockade of 5-HT uptake sites, we
compared the effects of fluoxetine with another 5-HT uptake inhibitor, paroxetine.
Paroxetine has a chemical structure and pharmacokinetic profile that is different from
fluoxetine.

For example, fluoxetine has a long t 112 and an active metabolite

(norfluoxetine) which has a similar potency for 5-HT uptake sites and a longer half-life
than fluoxetine. Paroxetine has more than 10-fold higher affinity for 5-HT uptake sites,
a shorter half-life and no active metabolites.

Also, due to difference in chemical

structure, paroxetine and fluoxetine may have different side effects.

For example,

fluoxetine has about 20-fold higher affinity for 5-HT2A 12c receptors than paroxetine,
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while paroxetine has a much higher affinity for muscarinic receptors than fluoxetine
(Stanford, 1996).

On the other hand, both fluoxetine and paroxetine share similar

effects in inhibiting 5-HT uptake sites. Therefore, if both fluoxetine and paroxetine
produce a desensitization of 5-HT 1A receptors, then this desensitization most likely is
mediated by the blockade of 5-HT uptake sites. As was shown in Chapter V and VI,
both fluoxetine and paroxetine reduced the neuroendocrine responses to 8-0H-DPAT
and the level of Gi3 proteins in the hypothalamus, but did not alter the density of 5-HT1A
receptors.

These results suggest that the desensitization of hypothalamic 5-HT lA

receptors is mediated by the blockade of 5-HT uptake sites.

Furthermore, the

desensitization of hypothalamic 5-HT 1A receptors is not due to receptor downregulation, but may partly be mediated by a reduction in the hypothalamic level of Gi3
proteins.
The effects of fluoxetine and paroxetine on the levels of Gi and G0 proteins are
not similar. Overall, repeated injections of paroxetine produce a greater and earlier
reduction in the hypothalamic levels of Gi proteins, especially the levels of Gil and Gi2
proteins, than that seen with fluoxetine.

So far, there is no explanation for the

differential effects on the levels of Gi and G 0 proteins between fluoxetine and
paroxetine. It is possible that paroxetine reduces the levels of Gi and G 0 proteins not
only because of blockade of 5-HT uptake sites, but also via stimulation of other
receptors, such as muscarinic receptors, for which paroxetine has a higher affinity than
fluoxetine (Stanford, 1996). 5-HT1A agonists induce a faster desensitization of 5-HT1A
receptors than 5-HT uptake inhibitors (De V ry, 1995). If this is the case for muscarinic
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agonists and if paroxetine acts as an agonist, then the stimulation of muscarinic
receptors may explain the earlier effects of paroxetine on the levels of some G proteins.
However, too little information is available on the regulation of the level of G proteins,
and future studies are needed to clear this issue.
Fluoxetine and paroxetine are used to treat depressed patients. The efficacy of
the antidepressants is similar. However, paroxetine appears to have an earlier onset of
therapeutic effect on depression than fluoxetine (Lane et al.1995; Nemeroff, 1993;
Schone and Ludwig, 1993). This earlier onset of therapeutic effect is consistent with
our observation that paroxetine induces an earlier reduction in the levels of G proteins.
On the other hand, the side effects induced by fluoxetine or paroxetine are somewhat
different. Sedation and nausea are common with paroxetine, while anxiety, agitation
and insomnia are common with fluoxetine. Since paroxetine does not induce anxiety
and agitation, fewer patients will drop out from the treatment. Although the mechanism
for the difference between paroxetine and fluoxetine is still unknown, it is possible that
the earlier onset of therapeutic effect and the fewer side effects of paroxetine are due
to its higher selectivity for 5-HT uptake sites.

Possible Mechanism for the Desensitization of Hypothalamic 5-HT tA Receptors

In the present studies, we observed that repeated injections of 5-HT uptake
inhibitors produce a delayed and gradual desensitization of hypothalamic 5-HT 1A
receptors as evidenced by a reduction in the neuroendocrine responses to 8-0H-DPAT.
The mechanism for the desensitization is still unknown. Most evidence has shown that
5-HT 1A receptors are coupled to Gi or G0 proteins, which inhibit adenylyl cyclase, close
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ca++ channels and open K+ channels. Therefore, any changes in the 5-HT1A receptors,
Gi proteins and adenylyl cyclase could alter the overall function of 5-HT 1A receptors.
Few studies have investigated the regulation of hypothalamic 5-HT1A receptors.
Newman et al. (1992) observed that repeated injections of fluoxetine for 3 weeks reduce
the inhibitory effect of 5-HT on forskolin-stimulated adenylyl cyclase in the
hippocampus, suggesting that chronic fluoxetine-induced desensitization could be
mediated by changes at the receptor level, signal transduction system of 5-HT1A
receptors, or the second messenger, adenylyl cyclase. It can be ruled out that a downregulation of the hypothalamic 5-HT1A receptors is involved in their desensitization,
because the density of 5-HT 1A receptors in the hypothalamus and other brain regions
was not altered by repeated injections of either fluoxetine or paroxetine. Also, a lack
of change in the Gpp(NH)p-induced inhibition of 3H-8-0H-DPAT binding suggests that
the desensitization of 5-HT1A receptors is not due to a decrease in the ability of 5-HT1A
receptors to couple to their G proteins. However, it is still possible that the coupling
of 5-HT1A receptors to the G proteins that link to the release of hormones is decreased
in living cells. There is differential affinity of 5-HT1A receptor coupling to G proteins
(Gi3

> Gi1 > Gi2 > G proteins) (Mulheron et al.1994; Raymond et al.1993).
0

Therefore, a reduction in the level of Gi3 proteins could alter the proportion of G
proteins that are coupled to 5-HT1A receptors. This change can not be determined by
Gpp(NH)p-induced inhibition of 3H-8-0H-DPAT binding, while it can result in a
reduction of the function of 5-HT1A receptors. Few studies have reported on the effect
of 5-HT uptake inhibitors on levels of G proteins that are coupled to 5-HT1A receptors.
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Results of the present studies suggest that the decrease in the level of Gi3 proteins may
play a role in the desensitization of the hypothalamic 5-HT 1A receptors. However, since
it is still unknown whether Gi3 proteins mediate 5-HT1A receptor-induced secretions of
ACTH, corticosterone and oxytocin, it seems too early to conclude that the reduction
in the level of Gi3 proteins mediates the desensitization of 5-HT 1A receptors.
Another possible mechanism for the desensitization of the hypothalamic 5-HT1A
receptors is their phosphorylation. Supersensitivity of 5-HT2A receptors induced by
repeated injections of 5-HT uptake inhibitors could be a cause of desensitization of 5HT1A receptors. Increasing of the activity of 5-HT2A receptors will stimulate protein
kinase C, which in tum can phosphorylate 5-HT1Areceptors. 5-HT 1A receptors contain
at least three potential sites for phosphorylation by protein kinase C (Raymond et
al.1992). Phosphorylation of 5-HT1Areceptors induces a desensitization of the 5-HT 1A
receptors (Harrington et al.1994; Nebigil et al.1995; Raymond and Olsen, 1994; van
Huizen et al.1993; Raymond, 1991). It has been reported that 5-HT1Aagonist-induced
desensitization of 5-HT1Areceptors in HeLa cells can be mimicked by a protein kinase
C activator and by forskolin, which activates adenyly 1 cyclase and consequently
activates protein kinase A. The desensitization of 5-HT 1A receptors induced by 8-0HDPAT can be blocked by inhibitors of protein kinase C, suggesting that protein kinase
C can be involved in the desensitization of 5-HT1A receptors (Harrington et al.1994).
This result is consistent with some studies (Raymond and Olsen, 1994; Raymond,
1991), while yet other studies suggest that the phosphorylation of 5-HT1A receptors
might be mediated by another G-protein-activated protein kinase, but not by protein
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kinase C (Nebigil et al.1995; van Huizen et al.1993). All these data suggest that 5HT IA receptors can be phosphorylated and consequently be desensitized, although it is
still unknown whether phosphorylation of 5-HT1A receptors alters their binding of
agonists or their coupling to G proteins. However, it should be noted that most of
these studies were performed in cells expressing cloned 5-HT IA receptors. To date, no
data are available regarding the effect of 5-HT uptake inhibitors on the phosphorylation
of 5-HT1A receptors.
G proteins function as a linkage between receptors and second messengers.
Activation of receptors by agonists induces an exchange of GDP by GTP on the a
subunits of G proteins, resulting in a dissociation of the ex subunits from the B'Y
complex of the G proteins and the receptors.

The a subunits of G proteins then

activate or inhibit second messenger systems. On the other hand, the dissociation of
a subunits from their B'Y complex activates the GTPase activity of a subunits of G

proteins and hydrolyzes the GTP to GDP, resulting in a reduced ability of G" proteins
to interact with adenylyl cyclase and recombination of a subunits with fi)' subunits.
Therefore, if the GTPase activity were increased, the a subunits of G proteins would
be inactivated faster and reduce the signal transduction of receptors. An in vitro study
has recently reported that three regulators of G protein signaling (RGS), GAIP (G
Alpha Interacting Protein), RGS4 and RGSlO, activate the GTPase activity of a
subunits of Gi proteins, especially of Gi3 proteins (Berman et al.1996; Watson et
al.1996; Koelle and Horvitz, 1996; Hunt et al.1996; De Vries et al.1995). RGS4 has
been found in the rat brain (Watson et al. 1996). If the effect of RGS proteins on the

161
GTPase activity also occurs in vivo, it can be hypothesized that desensitization of
hypothalamic 5-HT 1A receptors, induced by repeated injections of 5-HT uptake
inhibitors, may be due to an increase of RGS4, GRSlO or GAIP in the hypothalamus.
The increase of RGS4 and/or GAIP results in an increase in the GTPase activity of a
subunits of Gi proteins, and consequently, increases in hydrolysis of GTP and
inactivation of Gai proteins. This rapid inactivation of a subunits of Gi proteins will
decrease the function of the second messenger related to 5 -HT IA receptors.

This

hypothesis can account for the results of the present studies, i.e. that repeated injections
of 5-HT uptake inhibitors decrease the function of the hypothalamic 5-HT1A receptors
without changing the density of 5-HT1A receptors and the coupling of 5-HT 1A receptors
to their G proteins. However, it is still unknown whether repeated exposure to 5-HT
uptake inhibitors alters the levels of RGS4, RGSlO and/or GAJP in the hypothalamus.
This hypothesis is currently being investigated.
It is also possible that the desensitization of 5-HT1A receptors results from an

interaction between 5-HT 1A receptors and other receptors. 5-HT1A receptors share Gi
proteins with several other receptors, such as D2 dopamine receptors, GABAs receptors,
M2 muscarinic receptors and µ opiate receptors (Odagaki and Fuxe, 1995; Innis and
Aghajanian, 1987; Innis et al.1988). However, no evidence, so far, has shown that 5HT uptake inhibitors influence these receptors.
Beside the mechanisms discussed above, other regulations of the G proteins and
second messenger systems can also induce the desensitization of 5-HT 1A receptors. For
example, alterations in the linkage between G proteins that are coupled to 5-HT1A
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receptors and adenylyl cyclase may change the function of 5-HT1A receptors. Since Gi
proteins are negatively coupled to adenylyl cyclase, increases in the concentration of
cAMP may eventually decrease the function of 5-HT1A receptors. So far, no study on
the effect of 5-HT uptake inhibitors on palmitoylation of 5-HT1A receptors has been
reported.

Si1mificance of the Present Studies

Results of the present studies indicate that repeated injections of 5-HT uptake
inhibitors produce a delayed and gradual desensitization of the hypothalamic 5-HT 1A
receptors as examined by reduction in the hormone responses to S-HT1A agonists. This
result is consistent with report by Lesch et al. (1991c), who found that long-term
administration of fluoxetine reduces the ACTH response to ipsa.pirone in patients with
obsessive compulsive disorder.

These results support the hypothesis that repeated

injections of 5-HT uptake inhibitors induce an adaptive change in postsynaptic 5-HT1A
receptors, which may play a role in the therapeutic effects of 5-HT uptake inhibitors.
Most 5-HT uptake inhibitors produce a desensitization of 5-HT 1A receptors,
while most tricyclic antidepressants desensitize B adrenergic receptors (Bourin and
Baker, 1996). It is still unknown what is the significance of the desensitization of
hypothalamic 5-HT 1A receptors in terms of their therapeutic effects. One possibility is
that the desensitization of hypothalamic 5-HT1A receptors could be related to the
treatment of a subgroup of depressed patients, whose symptoms are due to impaired
serotonergic neurotransmission. According to the "amine hypothesis" , depression can
be initiated by impaired adrenergic and/or serotonergic systems. It is not surprising
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that a subgroup of depressed patients who suffer from impaired serotonergic systems
will be more responsive to 5-HT uptake inhibitors than those who have impaired
adrenergic systems (Leonard,

1993; Asberg and Martensson,

1993).

The

desensitization of hypothalamic 5-HT 1A receptors may be a benefit for this group of
patients. In fact, fluoxetine has been used to treat melancholia, which does not respond
to tricyclic antidepressants (Asberg and Martensson, 1993). File and her colleagues
(1996; 1994) reported that 5-HT1A autoreceptors in the median raphe are involved in
the anxiolytic effect of 5-HT1A agonists, while stimulation of postsynaptic 5-HT1A
receptors in the dorsal hippocampus produces an anxiogenic effect. So far, no clinical
evidence supports their observation. However, if these observations are also correct
in human, then the desensitization of postsynaptic 5-HT 1A receptors by 5-HT uptake
inhibitors may be related to the antianxiety effects of SSRI's.
Although SSRI' s and tricyclic antidepressants have similar efficacy for
depression, SSRI's are also used to treat other affective disorders, such as obsessive
compulsive disorder, premenstrual syndrome, and eating disorders.

Tricyclic

antidepressants are ineffective for these disorders. The desensit1zation of hypothalamic
5-HT 1A receptors may play a role in these specific applications. Recent evidence has
suggested that SSRI's can be used to treat schizophrenia (Breier, 1995; Costall and
Naylor, 1992). Since D2 dopamine receptors share Gi proteins with 5-HT 1A receptors,
the decrease in the Gi proteins induced by SSRI' s may be beneficial for the treatment
of schizophrenia.
Another possible beneficial effect of the desensitization of 5-HTIA receptors is
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the development of tolerance for the side effects of SSRI's (De Vry, 1995). In general,
both tricyclic antidepressants and SSRI's have similar therapeutic effects for depression
(Owens, 1994; Harrison, 1994; Blier and de Montigny, 1994; Montgomery, 1994;
Wong et al.1995). However, tricyclic antidepressants have severe side effects, such
as tachycardia, hypertension and impairment of motor and cognitive functions. An
overdose of tricyclic antidepressants can result in cardiovascular disorders and even
death (Blier and de Montigny, 1994; Montgomery, 1994; Wong et al.1995; Leonard,
1993). On the other hand, SSRI's have much fewer severe side effects and are better
tolerated.

This benefit makes SSRI's have a lower dropout rate than tricyclic

antidepressants (Lane et al.1995; Gram, 1994).

One could expect that the different

effect of SSRI's and tricyclic antidepressants on hypothalamic 5-HT 1A receptors may be
involved in the differential side effects of these two classes of antidepressants (De Vry,
1995).
Although both 5-HT 1A agonists and 5-HT uptake inhibitors induce a
desensitization of 5-HT1A receptors, neither group of drugs decreases the density of 5HT1A receptors (De Vry, 1995; Chen et al.1995; Hensler et al.1991). This suggests
that the regulation of 5-HT1A receptor systems is usually not at the receptor level.
Tricyclic antidepressants increase G protein activation of adenylyl cyclase (Ozawa and
Rasenick, 1989; Chen and Rasenick, 1995a; Ozawa et al. 1994), while repeated
injections of 5-HT uptake inhibitors reduce the levels of Gi and G0 proteins in a regionspecific manner, suggesting that G proteins and signal transduction systems may be the
target of antidepressants.

Therefore, understanding the role of signal transduction
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systems in the treatment of affective disorders will be beneficial for the development
of new antidepressants (Broekkamp et al .1995).

Limitation of the Present Studies
Several limitations should be noted when interpreting the data in the present
studies. First, the present studies were performed with normal male rats, in which
neurotransmission may be different from that in depressed patients. Therefore, it is
possible that desensitization of hypothalamic 5-HT 1A receptors does not occur in
depressed patients. However, Lesch et al (1991c) observed that long-term treatment
of obsessive compulsive disorder patients with fluoxetine reduced the ACTH response
to ipsapirone. Furthermore, the time-course of the desensitization of hypothalamic 5HT IA receptors may be different from the time-course of therapeutic effect in humans,
especially since the pharmacokinetics of 5-HT uptake inhibitors in rats are different
from those in humans. For example, the dose of fluoxetine used in rats was much
higher than the dose used in humans, but the half-life of f111oxetine in rats is much
shorter than the half-life in humans (1 day vs. 5 hours) (1990).
In the present studies, hormone responses to 5-HTM agonists were used to
examine the function of 5-HT IA receptors. The hormone challenge test has been used
in both experimental animals and humans to study the function of 5-HT1A receptors.
However, these hormone responses reflect mainly 5-HT1A receptors which control
neurons in the parvocellular and magnocellular regions of the paraventricular nucleus
of the hypothalamus. It is still unknown whether the changes in 5-HT1A receptors in
the neuroendocrine cells can reflect changes in other neurons in the hypothalamus or
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even in other brain regions. So far, only a few studies have reported on the effects of
repeated exposure to 5-HT uptake inhibitors on the function of postsynaptic 5-HT1A
receptors (Newman et al.1992; Hensler et al.1991). Since our data suggest that the
effects of 5-HT uptake inhibitors on the levels of G proteins are region-specific, it is
possible that the effects of 5-HT uptake inhibitors on the 5-HT1A receptor systems are
also region-specific.
Signal transduction of 5-HT 1A receptors was evaluated in these studies by
examining the levels of Gi and G0 proteins. The limitations of thjs approach are, first,
that little is known about the specific Ga proteins that are involved in 5-HT 1A receptorinduced increases in the secretion of ACTH and oxytocin. Secondly, the reduction of
the levels of G proteins is not necessarily related to the function of 5-HT1A receptors,
since several receptors are coupled to the same G proteins. Therefore, better methods
should be used to determine the signal transduction of 5-HT1A receptors, such as
agonist-stimulated [35S]-GTP')"S [35S-guanosine-5 '-0-(thiotriphosphate)] binding and
agonist-dependent photolabeling of G protein a subunits with [32P]GTP azidoanilide.
Gpp(NH)p-induced inhibition of 3H-8-0H-DPAT binding was used to examine
the coupling of 5-HT 1A receptors to the G proteins in the present studies. Gpp(NH)p
is a non-hydrolyzable GTP analog, which exchanges with GDP a.nd binds to a subunits
of G proteins when agonists bind to the receptors. The binding of Gpp(NH)p to the a
subunits of G proteins will dissociate the G proteins from the receptors and tum the
receptors from their high affinity state to the low affinity state.
presence of Gpp(NH)p, agonist-binding will be inhibited.

Therefore, in the

In the case of 5-HT1A
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receptors, Gpp(NH)p will inhibit 3H-8-0H-DPAT binding.

The percent of the

inhibition was used to represent the degree of 5-HT1A receptors which are coupled to
G proteins. However, it should be noted that the assay was performed in vitro in a
frozen brain slice and only 3H-8-0H-DPATwas incubated with the brain sections. This
is different from the normal environment surrounding 5-HT IA receptors in living cells.
Therefore, the degree of Gpp(NH)p-induced inhibition of 3H-8-0H-DP AT binding can
only reflect the steady-state coupling of 5-HT 1A receptors to G proteins.

In other

words, Gpp(NH)p-induced inhibition of 3H-8-0H-DPAT binding is more dependent on
the ability of 5-HT 1A receptors to couple to their G proteins than on the condition of
these G proteins. For example, the degree of Gpp(NH)p-induced inhibition of 3H-80H-DPAT binding may not reflect changes in the levels of Gprote:ins, but may indicate
the ability of 5-HT 1A receptors to couple to their G proteins.

Therefore, a lack of

change in the percentage of Gpp(NH)p-induced inhibition of 3H-8-0H-DPAT binding
suggests that fluoxetine does not alter the ability of 5-HT 1A receptors to couple to their
G proteins.

Conclusions
The present results suggest that prolonged blockade of 5-HT uptake sites
produces a delayed and gradual desensitization of the hypothalamic 5-HT IA receptors.
This desensitization is not due to a decrease in the density of S-HT1A receptors in the
hypothalamus because no change in the density of 5-HT1A receptors has been detected
after repeated injections of either fluoxetine or paroxetine.

Farthermore, a lack of

changes in the Gpp(NH)p-induced inhibition of 3H-8-0H-DPAT bjnding suggests that
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the coupling of 5-HT lA receptors to G proteins is not altered by repeated injections of
the 5-HT uptake inhibitors. However, it is possible that blockade of 5-HT uptake sites
changes the proportion of different types of G proteins that are coupled to 5-HT1A
receptors due to a reduction in the levels of one or two of the G proteins, resulting in
changes in the function of 5-HT1A receptors. It has been shown that one receptor can
couple to several types of G proteins with various affinities (Mons and Cooper, 1995;
Rudolph et al.1996; Yung et al.1995; Kozasa and Gilman, 1995; Chan et al.1995).
The differential coupling to G proteins can alter the efficacy of the receptor in terms
of its function. This could be due to a different linkage between G proteins and second
messengers.

For example, Gz proteins produce more potent inhibition of type V

adenylyl cyclase than Gi 1 proteins (Kozasa and Gilman, 1995). Another possible reason
for the alteration of efficacy is that the rate of dissociation of G proteins and receptors
is different between the G protein subtypes (Kozasa and Gilman, 1995). In the present
studies, we demonstrated that blockade of 5-HT uptake sites reduces the hypothalamic
levels of Gil and Gi3 proteins, but not Gi2 proteins. Since Gi1 and Gi3 proteins have a
higher affinity for 5-HT 1A receptors than Gi2 and G0 proteins (Raymond et al.1993), one
can expect that Gi 1 and Gi3 proteins are the majority of G pmteins coupled to the 5HT 1A receptors in the normal condition. When the levels of Gi1 and Gi3 proteins are
reduced, the ratio of Gi 1 , Gi2, Gi3 and G0 proteins coupled to j-HT 1A receptors may be
changed. This would result in an alteration in the linkage 10 second messengers or a
reduction in the efficacy, and subsequently a decrease in the function of 5-HT1A
receptors.

The results in the present studies suggest that a reduction in the
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hypothalamic level of Gi3 proteins may be involved in the desensitization of 5-HT 1A
receptors, because there is a similarity of the time courses in reducing the hypothalamic
level of Gi3 proteins and the hormone responses to

5-HT 11~.

agonists after repeated

injections of fluoxetine and paroxetine.
In conclusion, the results of the present studies support our hypothesis that
repeated injections of 5-HT uptake inhibitors produce a delayed and gradual
desensitization of hypothalamic 5-HT lA receptors. The mechanism of the desensitization
of hypothalamic 5-HT 1A receptors may be related to a reduction in the hypothalamic
level of Gi3 proteins.
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